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Abstract 
Head and neck squamous cell carcinoma (HNSCC) is a frequently fatal and increasingly 
common epithelial malignancy.  Significant morbidity and mortality frequently results from the 
invasion of tumours into surrounding structures and local metastasis to lymph nodes. The 
invasion and migration of HNSCC cells is increasingly recognised to be influenced by factors 
derived from adjacent tumour-associated stroma.  The contextual signals regulating stromal-
tumour interactions, however, remain poorly understood.  Here, a role for endothelin-1 (ET-1) 
and angiotensin II (Ang II), in promoting pro-metastatic cross-talk between head and neck 
cancer cells and adjacent fibroblasts is investigated.   
The results of this study indicate that treatment of normal oral fibroblasts (NOFs) with ET-1 
activates ADAM17 mediated release of epidermal growth factor receptor (EGFR) ligands, 
triggering EGFR signalling and increased migration and invasion in neighbouring HNSCC cells.  
ET-1 mediated paracrine transactivation of EGFR also increases cyclooxygenase-2 (COX-2) 
levels in the head and neck cancer cells, providing a molecular insight into the mechanisms by 
which the elevated levels of ET-1 observed in HNSCC may contribute to disease progression.   
Evidence is also provided that Ang II stimulates migration and invasion of HNSCC via AT1R using 
a similar paracrine mechanism to that employed by ET-1, and also via an autocrine mechanism, 
acting on HNSCC cells alone.  AT1R is expressed by both HNSCC cells and NOFs, but not normal 
oral keratinocytes (NOKs).  Angiotensin 1-7 (Ang 1-7), a proteolytic product of the degradation 
of Ang II, is able to inhibit the stimulation of HNSCC migration by Ang II and other peptides 
implicated in HNSCC progression including ET-1 and bradykinin (BK).  Together, these results 
demonstrate a novel role for the RAS in head and neck carcinogenesis and implicate Ang 1-7 as 
a possible novel therapeutic agent in the treatment of HNSCC.  
In addition, it is shown herein that ET-1 and Ang II increase the proliferation and migration of 
NOFs, and induce a more contractile phenotype, key features of myofibroblast 
transdifferentiation, a strong indicator of poor prognosis in HNSCC.  Interestingly Ang II, but 
not ET-1, stimulates changes in gene expression indicative of myofibroblast 
transdifferentiation, despite both inducing similar levels of pro-invasive paracrine signalling 
between oral fibroblasts and HNSCC. 
The findings in this thesis provide important novel information regarding the role that the ET-
axis and renin angiotensin system (RAS) play in contributing to HNSCC progression and the 
results collected identify potential novel targets and agents for drug therapies in the treatment 
of the disease. 
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1.1 Cancer 
A cancer is a complex of tissues that contains multiple and distinct cell types that interact with 
one another.  Normal cells are recruited to the tumour microenvironment and form the 
reactive stroma.  These recruited cells are nearly always active participants in cancer 
progression and play important roles in tumourigenesis (Hanahan and Weinberg, 2011).  
Cancer is a multi-component process and six biological capabilities have been described as 
being paramount within this process (Hanahan and Weinberg, 2011).  Both the tumour cells 
and those found within the surrounding tumour microenvironment can contribute to the 
acquirement of some of these hallmark characteristics (Hanahan and Weinberg, 2011).  The six 
hallmarks of cancer include sustaining proliferative signalling, resisting cell death, inducing 
angiogenesis, evading tumour suppressors, activating invasion and metastasis and enabling 
replicative immortality (Hanahan and Weinberg, 2000).  Genomic instability is an important 
factor that allows some of these characteristics to be achieved (Hanahan and Weinberg, 2011). 
1.2 Head and neck cancer 
Head and neck cancers originate within the tissues and organs located within the head and 
neck.  The term head and neck cancer is used to describe a number of different cancer types 
including eye cancer, nasal and paranasal sinus cancer, nasopharyngeal cancer, mouth and 
oropharyngeal cancer, laryngeal cancer and oesophageal cancer.  This project focuses on 
mouth and oropharyngeal cancer which describes any cancers found located within the oral 
cavity including those identified on the front two-thirds of the tongue, gums, cheeks, lip, floor 
and roof, described as the palate, of the mouth and behind the wisdom teeth.  The pharynx is 
the clinical name used to describe the throat.  The throat is divided into three areas and the 
area found directly at the back of the mouth is called the oropharynx (Figure 1.1A).  Cancers 
that originate within this area are described as oropharyngeal cancers (Cancer Research UK, 
2012).  The term head and neck cancer will be used in this thesis to describe mouth and 
oropharyngeal cancer. 
Head and neck cancer is a complex disease made even more difficult to treat because of its 
prominent and distinguishable location associated with the anatomy of the patient.  The main 
treatment methods for head and neck cancer have remained unchanged for years and there 
has been little improvement in survival rates over the past three decades, which have 
remained stubbornly low at 50% (Cancer Research UK, 2012).  Treatments include surgery 
which can result in severe disfigurement and emotional trauma for the patient and courses of 
radiotherapy and chemotherapy (Scully and Porter, 2000).  Early diagnosis is the major factor 
in achieving a good prognosis from head and neck cancer (Shah and Gill, 2009;    
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Figure 1.1  Mouth and oropharyngeal cancer:  A schematic diagram highlighting the organs 
and tissues in which head and neck cancers can originate.  The term head and neck cancer is 
used to describe a number of different cancer types including eye cancer, nasal and paranasal 
sinus cancer, nasopharyngeal cancer, mouth and oropharyngeal cancer, laryngeal cancer and 
oesophageal cancer (A).  Photographs of a head and neck carcinoma located on the floor of 
the mouth (B) and a local node metastasis (C) (Photographs courtesy of Dr. K. Hunter).   
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Nagpal and Das, 2003).  Many patients suffering from head and neck cancer show no 
symptoms in the early stages of the disease therefore making it much more difficult to 
diagnose it at an early stage (Cancer Research UK, 2012).  Symptoms can include a sore or 
ulcer within the mouth, a lump or thickening of the mouth, throat or tongue, or the 
observation of patches of red or red and white within the patient’s mouth that do not 
disappear (Scully and Porter, 2000a).  The patient can also experience difficulty when chewing 
or swallowing and they may begin to experience persistent pain.  The symptoms experienced 
by the patient can vary depending on the position and size of the malignancy (Scully and 
Porter, 2000b). 
The TNM system is used as a clinical staging system in the diagnosis and prognosis of head and 
neck cancer.  It was first devised by Pierre Denoix between 1943 and 1952 in order to stage 
and grade all solid tumours.  The system is made up of three parameters; T represents the size 
of the lesion and whether it has invaded into nearby tissue, N describes the regional lymph 
nodes that are involved and it represents the extent and the distribution of metastases within 
the regional lymph nodes and M represents the presence or absence of further distant 
metastases (Figure 1.2A) (La Vecchia et al, 1997).  Clinical staging of HNSCC is determined by 
the TNM system.  The prognosis of a patient decreases as the clinical staging of the tumour 
increases (Figure 1.2B). 
The majority of mouth and oropharyngeal cancers are squamous cell carcinomas.  The oral 
mucosa is the term used to describe the tissue that lines the inside of the mouth, nose, throat 
and larynx.  The oral mucosa is divided into three main layers which include the epithelium, 
the basement membrane and connective tissue (Figure 1.3).  The epithelium consists of tightly 
packed epithelial cells which form a dense, wall like structure.  The epithelium creates a 
somewhat permeable barrier and aids to protect the tissue underneath.  The oral epithelium is 
defined as a stratified, squamous epithelium which is further divided into three more layers. 
The top lay of the epithelium is described as the superficial layer which consists of a single 
layer of cuboidal epithelial cells.  Spinous or prickle cell layers are found beneath the 
superficial layer and the final layer of the epithelium is called the basal layer.  Melanocytes and 
merkel cells can be found within this layer.  These layers can also display a variability of 
keratinisation which is the term used to describe the deposition of keratohyalin granules 
within the cells resulting in the formation of an impermeable layer (Moss-Salentijn and 
Hendricks-Klyvert, 1990).  The basement membrane is located beneath the epithelium and 
provides support for the epithelial cells.  It also helps to connect the epithelium to the 
connective tissue.  The connective tissue found beneath the basement membrane also helps to 
provide structural support.  The connective tissue is composed of various cell types including  
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Figure 1.2  The TNM system and clinical staging associated with head and neck cancer:  The TMN system is made up of three parameters.  T represents the size of 
the lesion, N represents the extent and the distribution of the metastases within the regional lymph nodes and M represents the presence or absence of further 
metastases (A).  Clinical staging of HNSCC is determined by the TNM system (B).  The prognosis of a patient decreases as the clinical staging of the tumour 
increases (Figure adapted from La Vecchia et al, 1997). 
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immune cells, fibroblasts and endothelial cells which form blood vessels.  These cellular 
components are all held together by the extra cellular matrix (ECM).   
Head and neck squamous cell carcinoma (HNSCC) can arise from clinically normal oral mucosa 
but normally the disease is often preceded by a precancerous or potentially malignant lesion.  
Leukoplakia is the most common form of precancerous lesion but eryhroplakia also exists 
(Scully and Porter, 2000a).  Leukoplakia is defined by the World Health Organisation as ‘a white 
patch on the oral mucosa which cannot be rubbed off and cannot be ascribed clinically or 
histologically, to any other diagnosis’.  Leukoplakia typically occurs on the buccal mucosa, 
lateral border of the tongue or on the floor of the mouth.  Areas of the lesion can be well 
defined or can diffuse and cover large areas of the mucosa.  The colour of the lesion can vary 
from ‘pearly’ white to yellowish or greyish-white.  The outline of the lesion can also vary as can 
the texture.  The lesion can be slightly raised, flat or smooth or it can be a thick, verrous, 
fissured lesion that is firm on palpation.  Leukoplakia can be classified as homogenous or non-
homogenous.  The majority of leukoplakias are benign and are a result of the thickening of 
keratin layers.  The remaining examples are described as epithelial dysplasias and are 
characterised by atypical cytological features.  The term dysplasia is used to describe areas of 
the epithelium which exhibit cellular and architectural changes.  These can include an 
abnormal change in cell size and shape, nuclear size and shape, an increased 
nuclear/cytoplasmic ratio, increased or abnormal mitotic figures within the nucleus or an 
increase in the size and number of nucleoli.  Architectural changes include loss of polarity, 
increased cell density, basal cell hyperplasia and a disordered maturation from basal cells to 
squamous cells.  Dysplasias do not invade the basement membrane.  They can be described as 
mild through to severe which represents the depth of epithelium into which it effects.  Mild 
dysplasia effects the lower third of the epithelium, moderate the middle and sever describes 
the involvement of the upper third.  When the dysplasia becomes so severe that it affects all of 
the epithelium, from the bottom through to the top, the lesion is described as a carcinoma in 
situ.  Only around 5% of leukoplakias become malignant (Rodrigues et al, 1998).  The presence 
and severity of dysplasia within the oral mucosa of a patient cannot be used as a reliable guide 
for the treatment of individual cases; however its possible link to the development of 
malignancy makes it a necessary protocol (Fleskens and Slootweg, 2009).  At present there are 
no consistent markers or indicators to determine malignant progression.  Erythroplakia is 
another pre cancerous legion and is defined by the World Health Organisation as ‘a red patch 
on the oral mucosa which cannot be rubbed off and cannot be ascribed clinically or 
histologically, to any other diagnosis’.  Erythroplakias are extremely rare and are nearly always 
dysplastic (Porter and Scully, 2000a;  Scheifele and Reichart, 2003;  Rodrigues et al, 1998).     
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Figure 1.3  Structure of the oral mucosa:  A schematic diagram of the oral mucosa indicating the major structures including the epithelium, basement membrane 
and connective tissue.  The epithelium is made up of stratified squamous epithelial cells that form a well defined, organised, wall like structure.  The phenotype of 
the epithelium can vary depending on its location within the oral cavity.  The epithelium can be differentiated or non-differentiated, keratinised or non-
keratinised.  The basement membrane provides support for the epithelium and connects to the connective tissue found beneath.  The connective tissue is made 
up of a number of different cell types including fibroblasts, endothelial cells and various immune cells.  The ECM holds the components of the connective tissue 
together. 
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1.2.1 Metastasis in head and neck cancer 
In patients presenting with HNSCC, local metastasis to the lymph node and invasion into 
surrounding bone are both common factors associated with the disease.  Metastatic spread is 
also common in patients who present with locally advanced stage HNSCC and is often common 
when HNSCC is diagnosed at a late stage.  There are very few treatment options for patients 
presenting with metastatic disease.  Only a third of patients who present with metastatic 
disease will respond to palliative chemotherapy.  The majority will not and their survival may 
be as short as five to nine months (Bhave et al, 2011). 
The metastatic spread of any cancer is a complex and multi component process.  The tumour 
cells responsible for metastatic spread from the primary tumour must possess the ability to 
intravasate from the primary tumour into the circulatory system, be able to survive within it 
and have the capability to extravasate at a distant site and be able to proliferate within this 
foreign environment.  The cell must undergo and escape a number of cellular processes in 
order to be able to metastasise successfully.  These include the ability to be able to increase 
their migratory and invasion potential and to be able to avoid apoptosis (Bhave et al, 2011).   
The invasion and metastasis of cancer cells is achieved by a number of different mechanisms 
which include the presence and action of certain tumour-associated proteases that have the 
ability to destroy the surrounding matrix and basement membranes of the cancerous cells 
(Noel et al, 1997;  Johnson et al, 1998).  An example of this is the matrix metalloproteinase 
(MMP) family which contains 18 members.  The members that have been associated with 
ovarian cancer include MMPs 2, 3, 7, 9 and 13 and all of these when present have correlated 
with the ovarian carcinoma cells having high invasive and metastatic potential (Rosanò et al, 
2001). 
The conversion of epithelial cells to mesenchymal cells is an important transition and also plays 
a vital role in tumour progression by promoting cellular migration and invasion.  Epithelial to 
mesenchymal transition (EMT) can include a number of characteristic changes to occur within 
a cancer cell resulting in the cell obtaining a fibroblastic invasive phenotype.  With this 
transition the cell begins to down regulate epithelial-specific proteins including tight junction 
(TJ) proteins and adherens.  This is accompanied with a reduction in the expression of E-
cadherin (Cano et al, 2000;  Batlle et al, 2000).  The intracellular domain of E-cadherin can bind 
to and interact with a number of catenin proteins including α-, β-, γ- and p-120 catenin.  The 
catenins can connect the adhesion complex to the actin cytoskeleton (Thiery, 2002).  To create 
a functional and complete adherens junction the catenins that are joined to the actin 
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cytoskeleton must bind to the cytoplasmic tail of cadherins.  If the junction is not completed 
correctly or is disrupted then β-catenin may be released from the adherens junction pool.  β-
catenin, if not degraded correctly, has the ability to translocate to the nucleus and trigger the 
transcription of a variety of genes that can contribute to cancer progression including c-myc 
and cyclin D1.  The loss of E-cadherin therefore results in the increased abundance of β-
catenin; it may be this increase that contributes to the induction of genes that contribute to 
and promote cell migration, invasion, proliferation and EMT (Savagner, 2001). Zonula 
occludens-1 (ZO-1) is a 220 kDa scaffold protein that can interact with specific sites on the 
plasma membrane and also with other proteins (Tsukita et al, 2001).  It has been suggested 
that ZO-1 may play a part in connecting E-cadherin to the actin cytoskeleton (Itoh et al, 2001).  
In has been experimentally shown in nude mice that the phenotypic alterations that arise are 
associated with EMT and increased tumour progression and that this in turn may be caused by 
the cytosolic localization of ZO-1.   
In contrast to the loss of specific markers which are associated with an epithelial phenotype 
the cell can begin to produce mesenchymal markers including vimentin and N-cadherin.  The 
increase in N-cadherin is deemed to be responsible for the increase in invasion and metastatic 
ability of the cancerous cell therefore highlighting its possibility as a therapeutic target in the 
treatment of cancer (Cavallaro and Christofori, 2004;  Huber et al, 2005).   
1.2.2 Incidence and epidemiology 
In 2009, statistics showed that in the United Kingdom (UK) 6,236 people were diagnosed with 
head and neck cancer (Cancer Research UK, 2012) and during 2010 the cancer accounted for 
around 1,985 deaths (Cancer Research UK, 2012).  Head and neck cancer contributes to 3% of 
all cancers diagnosed in the UK (Cancer Research UK, 2012) and is the 12th most common 
cancer  in men and the 16th most common cancer in women (Cancer Research UK, 2012). 
Each year approximately 600,000 people are diagnosed worldwide with head and neck cancer 
(Parkin et al, 2005).  In some parts of the world HNSCC can contribute up to 25% of all cancers 
diagnosed.  The common incidence of HNSCC in these countries is often due to the indulgence 
of the population in high risk factors including tobacco smoking and betal quid chewing.  Two 
thirds of all head and neck cancer cases are diagnosed in people living in developing countries.  
These countries include Sri Lanka, which has the greatest number of males presenting with 
head and neck cancer per 100,000 people in the population, Botswana, Bangladesh and India 
(Cancer Research UK, 2012).  Within the European Union 66,650 new cases of the disease are 
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diagnosed each year (Cancer Research UK, 2012), with the most cases occurring in France and 
closely followed by Spain. 
Head and neck cancer is more common in males compared to females; however this sex 
incidence ratio has decreased in the past 50 years from 5:1 to 2:1 (Cancer Research UK, 2010).  
In the UK the risk of developing oral cancer increases with age.  86% of all oral cancer cases 
occur within people over the age of 50 (Cancer Research UK, 2010).  In developing countries 
head and neck cancer can be common within younger generations too and many European 
countries and in the US there has been an increase in the number of young and middle-aged 
men being diagnosed with cancer of the tongue (Annertz et al, 2002;  Schantz and Yu, 2002;  
Llewellyn et al, 2001). 
Since 1975 there has been a reduction in the number of men above the age of 80 being 
diagnosed with head and neck cancer (Cancer Research UK, 2010).  The number has decreased 
from 70 per 100,000 people in 1975 to around 35 per 100,000 people in 2006.  This 
observation however has not been observed in men over the age of 70 and within this age 
group the incident rate has remained stable (Cancer Research UK, 2010).  There has been an 
alarmingly large increase in the number of head and neck cancer diagnoses observed in men 
who fall between the ages of 40-50 (Cancer Research UK, 2010).  This statistic highlights that 
HNSCC is an arising problem in younger people and therefore there is a pressing need to 
understand the molecular mechanism involved in its development and progression in order to 
define new therapeutic targets that could be used in the treatment of the disease.   
1.2.3 Risk factors 
There are several predisposing risk factors associated with head and neck cancer: tobacco 
usage, alcohol consumption, diet, oral health, exposure to ultraviolet light and exposure to 
viruses. 
1.2.3.1 Tobacco usage 
Tobacco usage is a major risk factor of head and neck cancer.  The main carcinogenic agents 
present and active in all methods of tobacco consumption are thought to be nitrosamines 
which are derived from nicotine (Johnson, 2001).  The production of tobacco smoke from all 
consumption methods including cigarette, pipe and cigar smoking, has been linked to HNSCC.  
The risk of developing the disease increases with the number of cigarettes and cigars smoked 
per day along with the amount of tobacco smoked through a pipe and the length of time a 
person smokes for during their lifetime (Johnson, 2001). 
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Reverse smoking, a habit associated with many communities in India, is the practice in which 
the lit end of a cigarette is placed within a person’s mouth.  This type of inhalation is 
associated with the risk of developing cancer of the palate which is one of the rarest forms of 
head and neck cancer (Gupta et al, 1984). 
Snuff is a type of tobacco that can be inhaled and placed within the oral mucosa in the buccal 
and labial sulci.  The practice is known as snuff dipping.  The habit is common within the south 
eastern states of the US and Sweden and is thought to be one of the reasons why head and 
neck cancer cases have increased within young people (Johnson, 2001). 
The habit of paan chewing is practiced by 200 million people around the world and is most 
common in communities within South-East Asia and India, and in ethnic groups from these 
regions who now live in the UK (Johnson, 2001).  The paan, also described as betal quid, is 
made up of a betal leaf which is wrapped around a betel nut and slaked lime with the addition 
of tobacco and various spices.  The practice of paan chewing involves placing the quid within 
the buccal sulcus and leaving it there for long periods of time.  The area in which the quid is 
held within the mouth often develops leukoplakia.   
1.2.3.2 Alcohol consumption 
The role that alcohol plays in the development of head and neck cancer is controversial (Ogden 
and Wight, 1998).  It has been suggested that the presence of carcinogenic contaminants and 
congeners in alcoholic drinks may be responsible for the enhanced ability of the carcinogens to 
cross the oral mucosal barrier within the mouth (Ogden and Wight, 2008).  The barrier’s 
function may also be impaired by the lifestyle habits associated with heavy drinkers including a 
poor diet and an impaired metabolism.  The consumption of large quantities of alcohol is also 
thought to affect the liver’s ability to detoxify possible carcinogens correctly and to suppress 
the natural immune response of the body.  Both factors can contribute to the risk of 
developing cancer.   Mouthwash usage has also been linked to head and neck cancer and those 
that contain a high alcohol content of 25% or over are thought to be the most dangerous 
(Ogden and Wight, 2008). 
1.2.3.3 Diet and nutrition 
Iron is a vital element needed for the production and maintenance of a correctly functioning 
oral epithelium.  Iron-deficiency anaemia has been recognized as a risk factor for the 
development of head and neck cancer and is thought to be responsible for making the oral 
mucosa more susceptible to damage from carcinogens (Winn, 1995).  Vitamin A is a fatty acid 
that is required for the maintenance of the stratified squamous epithelium of the oral mucosa, 
and a diet high in antioxidant vitamins A, C and E is thought to lead to a reduced risk of 
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developing head and neck cancer (Winn, 1995).  This risk in greatly reduced by consuming a 
diet high in fresh fruit and vegetables. 
1.2.3.4 Oral health 
It has been difficult to fully understand the extent of the risk that poor oral hygiene has on the 
development of head and neck cancer.  Many patients suffering with the disease have poor 
dentitions but they are also heavy smokers and drinkers and therefore it is difficult to link the 
extent of the damage caused by the poor state of the mouth alone (Shah and Gil, 2009).  
People with poor oral health also visit the dentist less regularly and therefore have a slightly 
increased risk of developing head and neck cancer (Cancer Research UK, 2012).  
1.2.3.5 Ultraviolet light 
Squamous cell carcinoma of the lip is the only cancer of the mouth in which ultraviolet (UV) 
light plays a part in its development.  It shows a different geographical distribution from other 
head and neck cancers and is most commonly found within the white population living in 
Australia and Canada (Gorsky and Epstein, 1998;  Hicks and Flaitz, 2000).  These countries 
experience high levels of sunshine throughout the year and lip cancer alone can contribute up 
to 50% of all head and neck cancer diagnosed (Gorsky and Epstein, 1998;  Hicks and Flaitz, 
2000).    The cancer is much more likely to occur on the lower lip and is more common in men 
compared to women (Gorsky and Epstein, 1998;  Hicks and Flaitz, 2000).    Higher levels of the 
melanin pigment in the skin of dark-skinned people act as a barrier against the damage caused 
by UV light and therefore the number of cases of lip cancer that occurs within this group of 
people is relatively rare.  
1.2.3.6 Viruses 
1.2.3.6.1 Human papillomavirus  
The human papillomavirus virus (HPV) has been recognised as a risk factor in the aetiology of 
cancer of the cervix, another form of squamous cell carcinoma (Woods et al, 1993;  Miller and 
White, 1996).  The two types of virus associated with the disease, type 16 and 18, have been 
shown to increase in frequency in the transition of the oral mucosa from its normal form to a 
dysplastic form and on to a carcinoma.  It has been suggested that the virus affects the normal 
mucosa, by triggering its differentiation to a dysplastic phenotype.  The proteins that the virus 
codes for are thought to be able to bind to the tumour-suppressor genes, p53 and 
retinoblastoma (Rb) gene causing their inactivation or mutation and ultimately affecting their 
natural role within the mucosa (Woods et al, 1993;  Miller and White, 1996).  HPV is an 
independent risk factor for oropharyngeal cancer (Ang et al, 2010).  Patients with HPV-positive 
HNSCC have an improved prognosis in comparison to patients with HPV-negative HNSCC (Ang 
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et al, 2010;  Weinberger et al, 2006), in part due to their ability to respond better to radiology 
and chemotherapy (Fakhry et al, 2008).  
1.2.3.6.2 Herpes simplex virus  
It has been observed that the herpes simple virus (HSV) can be carcinogenic and 
cocarcinogenic (Scully, 1993) and elevated levels of the virus have been associated with HNSCC 
(Larssen et al, 1991;  Shillitoe et al, 1982;  Kumari et al, 1982).  This evidence therefore 
suggests that the virus could play a role in the aetiology of head and neck cancer. 
1.2.3.7 Genetic alterations 
There are a number of genetic alterations that have been identified in the development and 
progression of HNSCC.  These alterations can vary among patient cases and ultimately lead to 
the uncontrolled and irregular proliferation of epithelial cells and clonal expansion.   
Genetic alterations can include the loss of chromosomal material from specific areas on 
specific chromosomes, a process known as loss of heterozygosity (LOH) (Field, 1992;  Scully, 
1993).  Different LOH are associated with different stages of histological progression as the 
oral epithelium changes from its normal, stratified, well defined and organised formation 
through to a dysplastic form and finally a carcinoma which can include local and distant 
metastatic properties and invasion into the surrounding bone.  The LOH associated with a 
predysplastic lesion occurs at 9p (Field, 1992;  Scully, 1993).  A LOH at 3p or 17p can cause a 
transition from the predysplastic lesion to a dysplastic lesion (Field, 1992;  Scully, 1993).  An 
additional LOH at 11q, 13q or 14q can lead to the formation of a carcinoma and the addition of 
LOH at 6p, 8 or 4q can cause invasion (Field, 1992;  Scully, 1993).  The areas of LOH identified 
have also been identified as areas of chromosomes containing known and presumed tumour 
suppressor genes including the p53 gene at 17q and the Rb gene at 13q (Field, 1992;  Scully, 
1993). 
Tumour-suppressor genes are important in controlling the growth of a cell.  The genes encode 
for growth inhibitory proteins and in normal circumstances they work in balance with 
oncogenes, which encode growth-promoting genes, to ensure controlled cell proliferation and 
growth.  During carcinogenesis however, a tumour-suppressor gene could be mutated or its 
products could be inactivated.  A proto-oncogene could under the same circumstances also be 
mutated causing the activation of an oncogene or the enhanced activity of an already 
activated oncogene.  In both circumstances the control of correct cellular proliferation could 
be lost and enhanced tumour growth and tumour formation could be triggered.  
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The p53 tumour suppressor gene is located on chromosome 17q13 and is frequently mutated 
in many cancer cases including head and neck cancer and has been detected in over 50% of all 
cases diagnosed (Field et al, 1993;  Brachman et al, 1992;  Hoffmann et al, 2008).  The normal 
function of the p53 protein, the product of the p53 gene, is to detect DNA damage within the 
cell and to arrest the cell cycle and allow correct repair or destruction, via apoptosis, of the 
damaged DNA.  Inactivation of the gene results in cells being unable to respond to DNA 
damage and stress, resulting in uncontrolled cellular growth due to a loss of cell cycle 
inhibition and a lack of apoptosis (Vogelstein et al, 2000).   
The c-myc and ras families are both examples of oncogenes which have been implicated in the 
progression of head and neck cancer.  The families are responsible for the production of many 
growth-promoting proteins which include stimulatory cell-cycle regulating proteins, growth 
factor receptors and signal-transmitters.  Many of these are involved in the activation and 
maintenance of the cell cycle particularly through the G1 phase and into the S phase, the phase 
in which DNA synthesis takes place.  During carcinogenesis the over production or mutation of 
these oncogene products can lead to uncontrolled cell growth and proliferation (Scully, 1992).  
It is common to observe a truncated form of the epidermal growth factor receptor (EGFR); 
EGFR variant III (EGFRvIII).  This truncated form of the receptor has an in-frame deletion of 
exons two to seven which results in a shorter extracellular domain (Sugawa et al, 1990;  Bigner 
et al, 1990).  This mutation results in the receptor being constitutively active in a ligand-
independent manner.  This mutation occurs in approximately 40% of all HNSCC cases (Sok et 
al, 2006) and is known to result in increased cell proliferation, migration invasion and in vivo 
tumour growth (Wheeler et al, 2006).  The mutation is associated with increased levels of 
signal transducer and activator of transcription (STAT) 3 (Wheeler et al, 2010) and is known to 
be able to transform and enhance the motility of normal mouse fibroblasts in vivo (Pedersen et 
al, 2004).  STAT3 is a transcription factor and is found downstream of EGFR and EGFRvIII.  It 
plays a role in mediating EGFR signalling and can regulate MMP-2 and MMP-9 gene expression.  
Constitutive activation of STAT3 is associated with HNSCC (Leeman et al, 2006) and results in 
activation of genes including B-cell lymphoma (BCL)-XL, vascular endothelial growth factor 
receptor (VEGF) and cyclin D1 which promote cell processes including apoptosis, angiogenesis 
and cell cycle progression (Klein and Grandis, 2010).   
1.2.4 Classification and pathology 
HNSCC pathiogenesis is a multistep process which is a result of the accumulation of genetic  
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Figure 1.4  Haematoxylin and eosin stained sections of taken from a normal oral mucosa, 
dysplastic mucosa and a carcinoma of the oral mucosa:  The sections highlight the changes in 
the structure of the oral mucosa associated with the progression of HNSCC.  The loss of 
organisation is clear from that of the normal mucosa, original magnification x200 (A), through 
to a dysplastic mucosa, original magnification x200 (B) and nests of squamous epithelium 
invading the underlying tissues, original magnification x40 (C).  A number of histological 
features are recorded which may impact on the patient’s treatment options and prognosis 
(Photographs courtesy of Dr. K. Hunter). 
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mutations and histological changes within the oral mucosa.  These changes result in the 
alteration of the oral mucosa resulting in the gradual disappearance of its organised, well 
defined, stratified epithelial layer and the accumulation of the disorganisation and loss of 
cellular structures associated with dysplasia and carcinoma (Figure 1.4). 
There are three general clinical classifications for head and neck cancer.  Stage I/II is described 
as early-stage disease.  This classification of cancer is often treated with surgery and/or 
radiation.  Stages III/IV is described as locally advanced disease and two-thirds of all patients 
that present with HNSCC will present at this stage (Grandis et al, 2004).  In order to treat this 
stage of the disease it is often common practice to combine surgery with radiation and/or 
chemotherapy.  The final classification is recurrent/metastatic disease and palliative 
chemotherapy is the most common form of treatment offered to patients.  
HNSCCs can be graded according to their degree of differentiation.  The cancer can be well 
differentiated, where the neoplastic epithelium is clearly of squamous type and masses of 
prickle cells are present and there is still a limiting layer of basal cells which are situated 
around the periphery (Nagpal and Das, 2003).  A tumour can be described as being moderately 
differentiated.  In this example the cells within the tumour show less keratinisation compared 
to the extent seen in the well differentiated tumour and there is more mitotic activity and 
nuclear and cellular pleomorphism.  The cells however are still identified as squamous in type 
(Nagpal and Das, 2003).  A poorly differentiated tumour shows hardly any keratinisation and in 
some examples it is even absent completely.  There is prominent nuclear and cellular 
pleomorphism.  Immunohistochemistry can be used to detect cytokeratins if the epithelial cells 
are so distorted that they have become unrecognizable (Nagpal and Das, 2003).  The 
importance of the non-epithelial components of the area which immediately surrounds the 
tumour cells is paramount when determining the differentiation stage of a HNSCC.  This area is 
described as the tumour microenvironment.  
1.3 Tumour microenvironment 
Tumour cells do not exist alone. The development and progression of epithelial tumours is 
profoundly influenced by the surrounding tumour microenvironment (the reactive stroma).  
The tumour microenvironment is an intricate system of many cell types including endothelial 
cells, smooth-muscle cells, macrophages, dendritic cells and fibroblasts.  The tumour 
microenvironment does not only play a benign, supportive role in cancer progression but 
studies have identified that a reactive, transformed stroma can initiate and promote malignant 
changes in the epithelial cells found adjacent to it (Stover et al, 2006).  In addition to this 
phenomenon malignant epithelial cells can stimulate non-transformed stroma resulting in its  
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Figure 1.5  The tumour microenvironment:  The development and progression of epithelial tumours is profoundly influenced by the surrounding 
microenvironment (the reactive stroma), composed of fibroblasts, blood vessels and lymphatics,  extracellular matrix components  and immune cells.  Any or all of 
these can interact with the cancer cells and influence their behaviour (illustrated by purple arrows). 
Introduction   Chapter 1 
18 
 
activation.  This process creates a supportive tumour microenvironment for the carcinoma, 
contributing and promoting its progression (Stover et al, 2006).  Normal stroma can however 
also play a limiting role in the progression of malignant cells, halting their growth as a result 
(Stover et al, 2006;  Shekhar et al, 2001).   
The processes of acute inflammation and repair consist of a strict pattern and course of events 
and when this ordering is altered during pathological conditions, including chronic unresolved 
inflammation and carcinogenesis, a disorganised microenvironment can be formed (Kumar et 
al, 2005).  The formation and development of tumours has been described as ‘wounds that do 
not heal’ (Dvorak et al, 1986).  In a normal scenario when epithelial cells proliferative at an 
unusually high rate, they trigger a chronic inflammatory reaction in order to re-establish 
homeostasis and repair the damaged tissue by remodelling it (Albini et al, 2005).  Epithelial 
cells, fibroblasts, granulocytes and macrophages are all involved in recreating the correct 
homeostatic balance but they can in fact react in a contradictory manner and begin to 
promote the survival and increase the replication of the dysfunctional epithelial cells (Albini et 
al, 2005).  Inflammatory angiogenesis can occur during this process and has been shown to 
play a role in cancer progression (Sparmann and Bar-Sagi, 2004;  Albini et al, 2005). 
In order for cancer cells to survive and thrive they generate their own supportive 
microenvironment.  They release growth factors including basic growth factor (BGF), factors 
from the VEGF family, platelet derived growth factor (PDGF), EGFR ligands, interleukins, 
cytokines including tumour derived growth factor-β (TGF-β) and colony-stimulating factors.  
The growth factors that they release can act in a paracrine fashion to induce tumour-stromal 
interactions that can result in the promotion of angiogenesis and trigger inflammatory 
responses.  The growth factors also activate surrounding cell types including fibroblasts, 
smooth-muscle cells and adipocytes.  This activation can result in the additional release of 
additional growth factors and proteases, all of which are released into the surrounding 
microenvironment.   
Cancer cells can signal via a paracrine mechanism, they can also act in an autocrine manner, 
acting on themselves to release proteolytic enzymes.  The release of these enzymes can lead 
to the remodelling of the ECM and the basement membrane, promoting a pro-invasive and 
pro-migratory environment.  The newly remodelled ECM can release MMPs which can result in 
the activation of cell surface receptors and ECM-bound growth factors.  This process promotes 
the crosstalk that occurs within the tumour microenvironment including that between cancer 
cells and fibroblasts.   
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The communication network that exists within the tumour microenvironment is complex.  
Autocrine and paracrine signalling not only exists between tumour cells but also between cells 
found within the stroma.  The communication network can also exist in reverse.   In recent 
years studies have suggested that the microenvironment may not be caused by dysfunctional 
epithelial cells but may act as a factor in promoting their further dysfunction by promoting 
their invasive nature and their growth (Albini and Sporn, 2007).  The paracrine control that the 
tumour microenvironment exerts on the epithelial cells that it surrounds can be altered 
depending on the cell types present (Albini and Sporn, 2007).  Fibroblasts form the largest 
component of the tumour microenvironment and there are a number of different types of 
fibroblasts that have been identified in promoting tumourigenesis (Kalluri and Zeisberg, 2006). 
1.3.1 Fibroblasts 
Fibroblasts are the most numerous cell type found within the stroma.  They are non-vascular, 
non-epithelial and non-inflammatory cells (Tarin and Croft, 1969).  Fibroblasts play important 
roles in regulating the differentiation of epithelial cells, ECM deposition, inflammation and 
wound healing (Tomasek et al, 2002;  Parsonage et al, 2005).  Fibroblasts synthesise type I, 
type III and type V collagen and fibronectin (Rodemann and Muller, 1991;  Tomasek et al, 
2002), they secret type IV collagen and laminin, both of which are involved in the formation of 
the basement membrane and fibroblasts secret MMPs which highlight the importance of the 
cell type in maintaining ECM homeostasis (Wiseman and Werb, 2002).  Fibroblasts also secrete 
growth factors and help to control direct mesenchymal-epithelial cell interactions between 
epithelial cells (Wiseman and Werb, 2002).   
1.3.1.1 Cancer associated fibroblasts 
Orimo et al (2005) have observed clear differences between normal fibroblasts and fibroblasts 
located in the stoma surrounding invasive human mammary carcinoma masses.  The 
fibroblasts located within the tumour microenvironment enhanced the growth of the tumour, 
promoted increased vascularisation within the tumour, expressed more α-smooth muscle actin 
(α-SMA), produced increased levels of stomal cell-derived factor 1 (SDF-1) which recruited 
endothelial progenitor cells (EPCs) into the tumour and therefore caused an increase in 
angiogenic promotion (Orimo et al, 2005).  The SDF-1 released from the fibroblasts can work 
via a paracrine mechanism and can act directly on the breast carcinoma cells by binding to the 
CXC chemokine receptor 4 (CXCR4) triggering its stimulation and activation (Orimo et al, 2005).  
It is not known if the altered fibroblasts are a result of the carcinoma cells altering the 
phenotype of the normal fibroblasts or if the myofibroblasts are recruited to the area from 
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outside the tumour microenvironment (Ishii et al, 2003).  There is increasing evidence that the 
former suggestion is the most likely.   
All fibroblasts found within the tumour stroma can be described as cancer associated 
fibroblasts (CAFs) (Anderberg and Pietras, 2009).  This title is used to describe any fibroblasts 
found within the given area regardless of the biomarkers that they possess (Anderberg and 
Pietras, 2009).  In a morphological sense CAFs are described as large cells that have an 
elongated spindle shape.  There are different types of CAFs that vary in their phenotypic 
marker expression profiles.  It is not clear if the differences between CAF types reflect in their 
function and ability to promote tumour progression. Due to their distinct characteristics and 
differences in comparison to normal fibroblasts, CAFs are thought to contribute to tumour 
growth and carcinogenesis.  The term protomyofibroblasts has been used to describe the 
phenotypic spectrum of changes associated with CAFs (Desmouliere et al, 2003).  The 
morphological changes associated with fibroblasts located in the tumour microenvironment 
can range from those that are found within the defined area and show no obvious phenotypic 
changes, through to those that express increased levels of specific markers including α-SMA.  
These CAFs are termed myofibroblasts.  
1.3.1.2 Myofibroblasts 
Myofibroblasts have been identified in the stroma surrounding invasive breast cancers 
(Sappino et al, 1988). Myofibroblasts are characterised by a high expression level of α-SMA 
and have distinct gene-expression profiles (Allinen et al, 2004).  The increased expression of 
vimentin, desmin, fibroblast activation protein and MMPs including MMP-2 are all markers of 
myofibroblasts.  Myofibroblasts found within the tumour microenvironment of a number of 
epithelial carcinomas are similar to that found at sites of wound healing (Serini and Gabbiani, 
1999;  Mueller and Fusenig, 2004).  At the site of injury myofibroblasts are responsible for the 
production of SDF-1 and the subsequent recruitment of EPCs which lead to tissue regeneration 
and repair.  Therefore their recruitment and activation in the tumour microenvironment may 
be as a result of their natural characteristics and could promote tumour progression as a 
consequence of their normal function.  Cancer cells could utilize the body’s normal stromal 
response to tissue injury and in the process create a tumour microenvironment with similar 
characteristics which includes increased levels of SDF-1, EPC recruitment and promote an 
inflammatory response which can in turn promote tumourigenesis (Orimo et al, 2005).  
Expression of CXCR4 on carcinoma cells correlates with poor prognosis and is also known to 
promote primary tumour growth (Staller et al, 2003;  Balkwill, 2004).  Increased SDF-1 
production by myofibroblasts within the tumour microenvironment could increase CXCR4 
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expression via paracrine stimulation.  The targeting of this pathway could be a possible 
therapeutic target in cancer treatment (Orimo et al, 2005). 
The number of myofibroblasts is known to be elevated in many cancer types including skin, 
prostate and breast.  Myofibroblasts are thought to contribute to tumour progression via a 
number of methods.  They can release pro-migratory factors including ECM components, 
MMPs and serine proteases.  They also release growth factors and cytokines including insulin-
like growth factor-1 (IGF-1) and hepatocyte growth factor (HGF) which can both contribute to 
cell survival (Allen and Jones, 2009).  IGF-1 can also stimulate tumour-cell migration and HGF 
can stimulate tumour-cell invasion.  Factors including VEGF and monocyte chemotactic protein 
1 (MCP1) which are also secreted by myofibroblasts can also contribute to the tumour 
microenvironment and stimulate further stromal-epithelial interactions and promote 
angiogenesis and the recruitment of inflammatory cells, all of which are processes that 
contribute to tumour progression (Allen and Jones, 2009).   
Myofibroblasts promote angiogenesis via the release of SDF-1.  SDF-1 is responsible for the 
recruitment of EPCs into the tumour.  This recruitment increases angiogenesis and directly 
contributes to an increase in tumour mass as a result of interactions with the CXCR4 tumour 
cell (Allen and Jones, 2009).  Myofibroblasts have the ability to promote angiogenesis and 
increase tumour mass in the absence of cancer cells suggesting that the function and 
characteristics of myofibroblasts are not solely reliant and in response to tumour-derived 
signals and growth factors (Allen and Jones, 2009).  Other growth factors and signals found 
within the stroma that surrounds the myofibroblasts also contribute to their phenotype.  
Connective tissue growth factor (CTGF) is found in greater levels within myofibroblasts and is 
commonly potently stimulated by TGF-β.  CTGF is found to promote angiogenesis and tumour 
growth. 
1.3.1.2.1 Origin 
The precise origin of ‘CAFs’ remains debateable.  Myofibroblasts found within the tumour 
microenvironment can originate from different sites of origins and display common and site-
specific properties depending on the environmental niche that they have originated from. 
1.3.1.2.1.1 Stromal fibroblasts 
The majority of myofibroblasts are thought to originate from the activation of stormal 
fibroblasts within their local environment.  It is well known that the multifunctional TGF-β 
cytokine can trigger the transdifferentiation and chemotaxis of fibroblasts into myofibroblasts 
(Anderberg and Pietras, 2009).  There are three TGF-β isoforms; TGF-β1, TGF-β2 and TGF-β3.  
The isoforms are initially present within a complex which contains latent TGF-β binding 
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proteins.  These proteins are proteolytically removed in order to activate and release TGF-β.  
TGF-β exerts its effects by binding to the TGFβ2 receptor (TGFβ2R) resulting in its activation 
and the recruitment of the TGFβ1R and subsequent downstream cytoplasmic signalling 
through many different signalling cascades including the intracellular Smad proteins -2 and -3 
and serine-threonine receptors (Border and Noble, 1994;  Attisano and Wrana, 2002).  The 
Smad proteins bind to Smad4 and translocate into the nucleus resulting in the activated 
transcription of target genes.  TGF-β can also activate other signalling pathways including the 
ras/mitogen activated extracellular signal regulated kinase (MEK)/extracellular signal regulated 
kinase (ERK) pathway (Leask, 2010). 
Early studies on fibroblasts identified that they were responsible not only for the mesenchymal 
regulation of germ layers that took place during organogenesis but were also able to regulate 
the proliferation and differentiation of epithelial tumours (Ronnov-Jessen et al, 1996;  Cunha 
et al, 1985).  Stroma that was identified as being transformed could induce malignancy in lung 
and mammary epithelial cells (Nakamura et al, 1997).  Normal fibroblasts are also known to be 
capable of inducing a malignant phenotype in skin and prostate epithelium (Hayashi and 
Cunha, 1991;  Cooper and Pinkus, 1977).  Bhowmick et al (2004) identified that loss of TGF-β 
signalling in fibroblasts resulted in increased fibroblast and luminal epithelial proliferation.  The 
reduction in signalling also resulted in an increase in the development of preneoplastic lesions 
within the prostate epithelial.  In TGFβ2R knockout mice levels of c-Myc were increased and 
the expression of cyclin dependent kinase (CDK) inhibitors, p21 and p27 were reduced.  
Phosphorylation of HGF receptor was also increased in the knockout mice and was suggested 
to be the cause for increased stimulation of epithelial proliferation observed.  TGF-β signalling 
in fibroblasts has the ability to modulate the growth and oncogenic potential of adjacent 
epithelial cells in the surrounding environment. 
1.3.1.2.1.2 Tumour cells 
It has also been suggested that myofibroblasts could also originate from epithelial and 
endothelial tumour cells and develop into myofibroblasts through EMT.  This may be the 
reason why similar genetic alterations have been observed within the tumour epithelium and 
its surrounding stroma (Anderberg and Pietras, 2009).  Other mesenchymal cells including 
vascular smooth muscle cells, pericytes or adipocytes have also been suggested as possible cell 
types which myofibroblasts could originate from.  Experimental evidence for this theory 
however is largely lacking (Anderberg and Pietras, 2009).  
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1.3.1.2.1.3 Bone marrow-derived cells 
Bone marrow-derived cells that were genetically marked have shown that they too can 
contribute to myofibroblasts populations found within tumour-associated stroma (Anderberg 
and Pietras, 2009).  This is also true for mesenchymal stem cells. 
1.3.1.2.1.4 Genetic alterations 
Fibroblasts surrounding breast cancer cells showed altered genetic characteristics including 
somatic mutations and a LOH (Moinfar et al, 2000;  Kurose et al, 2002;  Fukino et al, 2004).  
The genetic alterations could be responsible for the change in fibroblast phenotype resulting in 
the enhancement of their tumourgenetic qualities.  Fibroblasts may exhibit epigenetic 
alterations which could promote an activated autocrine TGF-β feedback loop (Ronnov-Jessen 
et al, 1996;  Serini and Gabiani, 1999), which may result in normal fibroblasts differentiating 
into myofibroblasts.  The stroma that surrounds tumours may be genetically unstable and may 
undergo changes including LOH that results in changes in cell types and the stimulation and 
production of myofibroblasts.  Somatic TP54 genetic mutations have been observed in breast 
tumour epithelium and stroma and have been linked to lymph node metastases (Moinfar et al, 
2000;  Kurose et al, 2002;  Fukino et al, 2004).  Questions relating to the preparations of tissue 
within this study suggest that the results might not be conclusive (Anderberg and Pietras, 
2009).  Another study that is more extensive has suggested that genetic mutations within 
myofibroblasts is a very rare event and can therefore not be used to explain the origin of all 
myofibroblasts (Anderberg and Pietras, 2009).  These studies highlight the controversial beliefs 
surrounding this area of research.  
In the absence of tumour cells, the phenotype of myofibroblasts could be created and 
maintained by epigenetic modulation of the cell’s DNA.  Genetic alterations have frequently 
been associated with cancer progression, in particular the role that genetic mutation in 
oncogenes and tumour suppressor genes, and chromosomal abnormalities and instabilities 
play in tumour initiation and development (Baylin and Ohm, 2006;  Hahn et al, 1999;  Hanahan 
and Weinberg, 2000;  Kinzler and Vogelstein, 1997).  Research conducted however has also 
identified a role for epigenetic mutations in tumour progression.  Epigenetics is a term used to 
describe the alterations in gene expression which are mediated by mechanisms that do not 
affect or alter the primary DNA sequence.  This line of research has been associated with not 
only determining and altering cancer cell phenotype but also that of cells found within the 
tumour microenvironment including fibroblasts and may therefore provide a possible 
explaination for the origin of myofibroblasts.  Epigenetic changes can include the loss or gain of 
DNA methylation and histone modification (Baylin and Ohm, 2006;  Jones and Laird, 1999;  
Hermann and Baylin, 2003;  Jones and Baylin, 2002). 
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In breast cancer and colorectal cancer DNA methylation has been identified in fibroblasts that 
have been isolated from the tumours.  The patterns of epigenetic mutations have also been 
partnered with changes in mRNA levels (Allen and Jones, 2009).  The genetic variability of the 
host has also been suggested as another potential source of origin for myofibroblasts (Allen 
and Jones, 2009).  Non-tumour fibroblasts isolated from women who have been diagnosed 
with breast cancer have been identified as differing from fibroblasts isolated from women who 
don’t have breast cancer. This identification could be a result of single nucleotide 
polymorphisms (SNPs) which are genetic mutations that occur within many genes including 
MMP enzymes which are responsible for modifying the extracellular matrix (Allen and Jones, 
2009). 
1.3.1.3 Fibrocytes 
Fibrocytes are another cell type found within the tumour microenvironment.  They are a 
unique population of CD45+ cells that are distinct from endothelial cells, epithelial cells, 
fibroblasts, monocytes, dendritic cells, T lymphocytes and Langerhans cells that were originally 
identified in the wound chamber of an experimental wound healing model (Keeley et al, 2010).  
They are spindle-shaped and are morphologically distinct from leukocytes in that they display 
prominent cell surface projections which can be seen when the cells are scanned with an 
electron microscope. Fibrocytes can be identified by their distinct set of characteristics which 
change during their development.  They account for 0.1-1% of all nucleated cells found within 
the peripheral blood found with the body of a healthy individual (Keeley et al, 2010).  
Fibrocytes can express collagen, procollagen and CD34 at a site of injury.  They respond to the 
injury and appear at the site of injury much more quickly than fibroblasts do, usually within 
one day of the injury occurring.  Their ability to appear so quickly at the site has led to 
suggestions that they must originate from within circulation (Keeley et al, 2010).  They help to 
promote angiogenesis and release chemokines, cytokines and growth factors that induce 
fibroblast hyperplasia.  They can also contribute and release secretion factors of the 
extracellular matrix.  TGF-β and endothelin-1 (ET-1) can stimulate fibrocytes to differentiate 
into myofibroblasts (Keeley et al, 2010).  When fibrocytes are cultured for lengthy periods of 
time they can acquire an increase in α-SMA expression and can begin to lose the expression of 
CD34 and CD45 (Keeley et al, 2010).  These processes are dependent on the physical 
environment that surrounds the fibrocyte.  Their similarities to myofibroblasts make them an 
important target to study when investigating the role the tumour microenvironment plays in 
cancer progression. 
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1.3.1.4 Cancer stem cells 
Stem cells are another cell type associated and found within the tumour microenvironment 
(Clarke et al, 2006).  They have been identified as being fundamental in the development and 
maintenance of several forms of human cancer (Jordan et al, 2006;  Wang and Dick, 2005;  
Singh et al, 2004;  Reya et al, 2001).  A cancer stem cell can be described as a cell found within 
a tumour that possess the ability to self-renew and to cause the heterogeneous lineages of 
cancer cells that comprise the tumour (Clare et al, 2006). 
There are a number of theories regarding the role that cancer stem cells play in initiating 
tumour development and progression.  It has been suggested that tumours can derive from 
organ stem cells that retain self-renewal properties and that over time these cells can obtain 
epigenetic and genetic changes that are required for tumorigenicity (Clarke et al, 2006).  It has 
also been hypothesised that tumour stem cells are proliferative progenitors that acquire self-
renewal capacity (Clarke et al, 2006). 
The ability of stem cells to enter the cell cycle infrequently is a characteristic which may allow 
cancer stem cells to form a small population of cells that are intrinsically resistant to many 
therapeutic agents which target and kill proliferating cells (Clarke et al, 2006).  
1.3.2 Contributions of cancer associated fibroblasts to tumour progression 
CAFs contribute to cancer progression via a number of different mechanisms:  
1.3.2.1 Growth signals  
Myofibroblasts release many growth factors and hormones including HGF, EGFR, fibroblast 
growth factor (FGF) and Wnt families and cytokines including stromal derived factor-1α (SDF-
1α) and interleukin (IL)-6.  These factors can act via an autocrine mechanism on the 
myofibroblasts themselves to further promote their growth and development and the factors 
can also act on the surrounding epithelial and endothelial cells resulting in the stimulation of 
phenotype transformation; an example of the tumour-stromal interactions that happen within 
the tumour microenvironment (Pietra and Ostman, 2010). 
1.3.2.2 Evasion of apoptosis 
Myofibroblasts produce IGF -1 and -2 and increase the expression of survival signals within the 
tumour cells.  This allows them to avoid cellular apoptosis and stimulates their growth.  
Myofibroblasts also produce lots of ECM components including large quantities of collagen 
used to enhance cross linking and increase the invasive nature of tumours and aid malignant 
growth.  The phosphoinositide 3 (PI3)-kinase and Akt survival pathways are also triggered by 
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myofibroblasts in response to increased integrin ligation by collagen fibres which promote 
downstream signalling. 
1.3.2.3 Sustained angiogenesis 
Myofibroblasts trigger the release of pro-angiogenic factors into the tumour 
microenvironment.  Many pro-angiogenic factors including members of the VEGF family are 
produced at greater levels in tumours in comparison to normal tissue counterparts.  A greater 
induction in the activity of the VEGF promoter is also observed.  Myofibroblasts can also 
increase VEGF production by the activation of the bradykinin (BK) 2 receptor (B2R) resulting in 
an increase in prostaglandin E2 (PGE2) release.  Via a paracrine signalling mechanism 
myofibroblasts can stimulate PDGF receptor signalling.  Using an autocrine signalling 
mechanism they can also cause cytokine CXCL14 to induce the expression of basic fibroblast 
growth factor (BFGF)-2.  The cells can also secret SDF-1 which increases the recruitment of 
endothelial progenitor cells into the tumour neo-vasculature, promoting angiogenesis. 
1.3.2.4 Tissue invasion and metastasis 
In order for tumours to become more invasive and be able to metastasise myofibroblasts 
promote the EMT of tumour cells.  They achieve this by secreting TGF-β and HGF.  
Myofibroblasts also act as a source of increased protease activity including increased MMP 
production, cathespins and plasminogen activators, all of which help to remodel the ECM.  The 
proteases weaken the connections between the tumour cells and adjacent cells and the 
underlying basement membrane.  The proteases degrade the ECM and provide the 
environment with additional growth factors and ECM-adhering properties.  Epithelial cells can 
undergo pro-invasive changes when exposed to stromal cells. 
1.3.3 Signalling networks within the tumour microenvironment 
Complex signalling pathways and networks occur within the microenvironment in order for 
cells to be able to perform basic activities and actions.  The ability of cells to control and 
govern these communication systems allows them to perceive and correctly respond to their 
microenvironment.  This is vital and allows control of basic processes including development, 
tissue repair, and immunity as well as normal tissue homeostasis.  Errors that occur within this 
communication network can result in the formation of diseases including autoimmunity, 
diabetes and cancer.  This thesis focuses on trying to determine the signalling networks 
associated with head and neck cancer pathogenesis.   
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1.3.3.1 Intracellular signalling and extracellular signalling 
Cellular signalling can be classified as intracellular and extracellular.  Cross over between the 
two mechanisms and the cellular components involved in the processes exist.  Intracellular 
signalling is used to describe pathways which are responsible for transmitting information 
within a cell.  This information is usually received via an external stimulus or from signals that 
are generated from within the cell.  Extracellular signalling is used to describe the process in 
which a cell synthesises and releases a signalling molecule into the surrounding 
microenvironment.  This signal molecule can then be transported to another cell onto which it 
is detected by a specific receptor protein.  This event results in the formation of a receptor-
signal complex on the surface of the cell which ultimately promotes a signal that can alter the 
cells metabolism, function, or development.  The removal of the signal from the receptor-
signal complex usually terminates the cellular response.  There are a number of different 
factors and cellular machinery that can be involved in this series of events.   
The EGFR is a receptor tyrosine kinase and is upregulated in a number of malignancies 
including HNSCC (Rubin et al, 1998).  It is 175 kDa in size and an increase in the expression of 
this receptor in HNSCC correlates with a poor prognosis (Rubin et al, 1998).  Activation of the 
receptor via ligand induced autophosphorylation, can lead to downstream signalling including 
that of the mutagenic Raps/Raff/ERK 1/2, p38 MAPK and PI3-K/AKT pathways, all of which are 
involved in regulating cell proliferation, growth and differentiation (Cai et al, 2010;  Ciardiello 
and Tortora, 2008;  Avraham and Yarden, 2011).  Grandis et al (1998) have demonstrated that 
by targeting the EGFR, the proliferation and invasion of HNSCC can be reduced.  The EGFR has 
been blocked as a possible drug therapy target in the treatment of HNSCC and antitumour 
effects have been observed when EGFR blockade has been combined with radiation treatment 
(Bonner et al, 2006).  
The EGFR pathway can be triggered by a number of G protein-coupled receptor (GPCR) ligands 
including lysophosphatidic acid (LPA), gastrin-releasing peptide (GRP), thrombin, ET-1, BK and 
angiotensin II (Ang II) (Lui et al, 2003;  Gschwind et al, 2003), an example of extracellular 
signalling.  The process via which GPCRs activates the EGFR with an increase in activation of 
protein kinase C (PKC), an elevation in intracellular Ca2+ and the generation of reactive oxygen 
species (ROS) (Liebmann, 2011;  Higuchi et al, 2007).  GPCRs are known to promote tumour 
cell growth upon their activation in a number of different cancer types, including HNSCC.  
Therefore a number of drug therapies have targeted GPCRs as a possible treatment method 
for a number of cancers (Li et al, 2005).  GPCRs make good, possible targets because they allow 
specific inhibition and are often over expressed in a number of different tumours.   
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It is widely believed that upstream kinases including src, a tyrosine-specific protein kinase 
encoded by the v-src oncogene of RSV, and metalloproteases and/or ADAM-dependent 
shedding of cell-surface bound EGF-like ligands can also transactivate the EGFR (Higuchi et al, 
2007).  This explains how GPCR ligands can activate the EGFR via an autocrine mechanism 
which involves the release of EGFR ligands including transforming growth factor-α (TGF-α), 
amphiregulin and heparin bound-EGF (HB-EGF) (Lui et al, 2003;  Pai et al, 2002), another 
example of extracellular signalling stimulation.  This result in GPCR activation triggers 
intracellular signalling via ADAM metalloproteinase-dependent transactivation of the EGFR.  In 
breast cancer, BK is known to act as an inflammatory molecule that has the ability to activate 
EGFR leading to an increase in proliferation of breast cancer cells (Greco et al, 2005).  PGE2 has 
also been identified as another inflammatory molecule that can activate EGFR leading to the 
activation of Src and a number of MMPs (Pai et al, 2002;  Buchanan et al, 2003).  This activity 
has been observed in colon cancer and is an example of how the intracellular and extracellular 
signalling pathways can overlap.  Both BK and PGE2 are GPCR ligands and targeting both these 
receptors along with the EGFR could be a possible future target therapy in the treatment of 
cancer and could create enhanced antitumour effects in comparison to just targeting the EGFR 
alone (Thomas et al, 2006). 
Prostaglandins and thromboxanes are important in the regulation of cellular growth and under 
pathological conditions, including inflammation and tumour growth, their expression levels 
can be altered and therefore the pathways that they regulate can be modified.  
Cyclooxygenases (COXs) are responsible for the conversion of arachidonic acid into PGEs and 
thromboxanes.  Cyclooxygenase-2 (COX-2) is mitogen induced.  Its expression is elevated in 
lung cancer in comparison to non-malignant tissues (Castelao et al, 2003;  Hida et al, 1998).  An 
increase in the expression levels of COX-2 leads to an increase in the production of PGE2.  PGE2 
and thromboxane A2 are procarcinogenic and can both promote new vessel formation, 
angiogenesis and increased tumour growth (Ermert et al, 2003).  Prostacyclin has the opposite 
effects and can act as a potent vasodilator and has the ability to inhibit cellular growth.  These 
components are all involved in the processes associated with intracellular signalling.  It has 
been demonstrated that inhibition of COX-2 using inhibitors that target it results in reduced 
proliferation of malignant cells in vitro (Hida et al, 1998) and a reduction in the growth of 
tumours and their metastatic potential (Grubbs et al, 2000). 
The array of proteins found within the ECM provide both physical support to the structure of 
the cell and also stimulate other biological functions including promoting interactions between 
a range of factors including adhesion molecules, growth factors, signal receptors and 
themselves.  The ECM can act as a reservoir for growth factors including VEGF and BFGF (Kim 
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et al, 2011).  Signalling within the ECM can involve integrins.  Integrins are heterodimeric 
transmembrane receptors and consist of 18 α subunits and 8 β subunits which can form 24 
different non-covalent assemblies.  This allows them to interact with a number of components 
of the ECM which results in the production of both mechanical and chemical signals between 
themselves and the actin cytoskeleton.   They can stimulate signalling independently or can 
bind with other growth factor receptors including IGF-1, VEGF receptor, EGFR, PDGF receptor 
and the TGF-β receptor and synergistically they can activate signalling which can affect 
proliferation, migration, differentiation and apoptosis (Kim et al, 2011;  Nelson and Bissell, 
2005).  Other ECM proteins including tenascin-C and fibronectin are consistently upregulated 
in cancer and can promote extracellular signalling within the tumour microenvironment (Allen 
and Jones, 2011).   
MMPs have been implicated in the remodelling of the ECM.  The microenvironment provides a 
large source of MMPs which are all catalytically activated from a latent pro-MMP form.  This 
activation is achieved by the removal of the propeptide domain by proteolytic cleavage.  
Membrane type-1 (MTI)-MMP is responsible for the activation of other MMPs including pro-
MMP-2 and -13.  MMPs are capable of degrading proteins within the ECM and have therefore 
been implicated in the promotion of tumour invasion and metastasis.  MMPs can however also 
process a number of bioactive molecules and are responsible for their release into the 
surrounding microenvironment.  MMPs can cleave cell surface receptors, apoptotic ligands  
including the FAS ligand, chemokines and cytokines (Nelson and Bissell, 2005). 
MMPs are inhibited by tissue inhibitors of metalloproteinases (TIMPs) which play a vital role in 
balancing the proteolytic activity associated with tumours, therefore reducing their invasive 
and metastatic ability.  This is an example of a process which is in place to control extracellular 
signalling mechanisms.  The TIMPs bind to the zinc binding catalytic site on the MMPs in a 1:1 
ratio.  There are four types of TIMPs, TIMPs-1 -2, -3 and -4.  TIMP-1 can inhibit nearly all MMPs 
and TIMPs-2, -3 and -4 can inhibit all MMP activities.  TIMP-3 is an extracellular matrix protein 
and has the potential ability to inhibit a number of ADAMs enzymes.   MMP-dependent 
proteolysis is responsible for the control of activated levels of MMPs and TIMPs (Baker et al, 
2002). 
Urokinase plasminogen activator (uPA) is a 54 kDa serine protease (Andreasen et al, 1997).  
Tumour cells secrete the proteinase in a pro form.  The pro form of uPA, pro-uPA, binds to its 
specific receptor on the surface of the tumour cell and is activated by cathepsin B.  After the 
proteinase has been activated it can convert the proenzyme plasminogen into the catalytically 
active plasmin.  Plasmin has the ability to degrade components found within the stroma of the 
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tumour resulting in the modification of the tumour microenvironment.  uPA is also a 
constituent of the cascade involved in the activation of metalloproteinases.  There are two 
inhibitors of uPA, plasminogen activator inhibitor (PAI)-1 and -2, which function by causing the 
internalization of the uPA ternary complex (Duffy, 1993;  Foekens et al, 2000;  Chambers et al, 
1995;  Sier et al, 1998).     
The ADAMs group of enzymes are responsible for regulating cell to cell and cell to ECM 
interactions that occur within the microenvironment.  The family of enzymes have been linked 
with the process of proteolytic shedding of proteins from the surface of cells.  This results in 
the rapid transformation of key signalling pathways (Murphy, 2008).  The ADAMs family of 
enzymes are all multi-domain type 1 transmembrane proteins.  Some members of the family, 
including ADAM12 lack the transmembrane and cytoplasmic regions of the structures.  About 
half of the family has proteolytic activity and are responsible for modulating the activity of 
adhesion molecules, membrane cytokines and growth factors and the receptors that they 
exert their effects through (Murphy, 2008).  The enzymes can cleave these transmembrane 
proteins allowing their solubilisation and release into the surrounding environment.  The 
upregulation of ADAMs enzymes has been implicated in a number of cancers including 
ADAM17.  ADAM17 has proteolytic activity and its structure consists of metalloprotease and 
disintegrin domains and a cytoplasmic domain that is often rich in SH3-binding sites (Seals and 
Courtneidge, 2003; Blobel, 2005).  It is involved in regulating the release of a number of 
proteins, including TGF-α, amphirgulin and HB-EGF, from the surface of cells which are know 
upon release to act as ligands for the EGFR. Aberrant regulation of this receptor is known to 
occur in a number of tumours and is therefore a common drug target.  The expression of 
ADAMs enzymes has also been identified at the invasive front of some tumours.  The stroma 
surrounding carcinomas has been implicated as a possible source for ADAMs. 
The release of soluble factors including the mitogenic peptides BK, ET-1, angiotensin II (Ang II), 
substance p, neurotenisn and GRP and cytokines including TGF-β, via intracellular and 
extracellular signalling mechanisms, into the surrounding microenvironment can stimulate 
autocrine and paracrine signalling within the reactive stroma.  The processes can encourage 
and support crosstalk between different cell types.  These signalling mechanisms are necessary 
for the maintenance of a normal physiological environment but dysregulation of the pathways 
can result in the enhancement of signalling which can be associated with disease progression. 
1.4 Mitogenic peptides  
Bradykinin (BK), endothelin-1 (ET-1) and angiotensin II (Ang II) are all examples of small 
regulatory peptides that have been implicated in the progression of a number of malignancies.  
Introduction   Chapter 1 
31 
 
They often act as ligands for specific G-protein coupled receptors (GPCRs).  As mentioned 
before the activation of GPCRs by mitogenic peptides can trigger many intracellular and 
extracellular signalling pathways.  Alteration of these signalling pathways can lead to 
deregulated cell behaviour and function. 
1.4.1   Bradykinin 
Bradykinin (BK) is an example of an important mediator of a wide variety of physiological and 
pathophysiological responses including pain, inflammation, cell division, mitogenicity and 
sperm motility (Bhoola et al, 1992.  Hall, 1997).  BK is produced from protein kininogens that 
are situated within plasma and tissue (Stephan et al, 2003).  BK exerts its effects through the 
B1 receptor (B1R) and B2 receptor (B2R) kinin receptors which are both GPCRs.  Upon their 
activation they can stimulate ERK 1 and 2 and mitogen activated protein kinases (MAPKs) via 
distinct pathways.  The activation of these pathways results in the release of PKC and the 
activation of EGFR (Adomeit, 1999), tyrosine kinases focal adhesion kinase and c-Src (Velarde, 
1999).   
BK and its receptors have been implicated in the progression of a number of cancers and a 
number of studies have investigated the involvement of the peptide in HNSCC.  BK can 
promote tumour progression in HNSCC by promoting cell proliferation and invasion (Thomas et 
al, 2006).  BK in this instance exerts its effects through both B1R and B2R.  Changes in the 
expression of each receptor can vary between cancer types.  In malignant prostate cancer an 
up-regulation of B1R is observed (Taub et al, 2003) whereas in human gliomas an increase in 
the expression of B2R was seen (Zhao et al, 2005).  B2R is also overexpressed in HNSCC in 
comparison to normal oral mucosa suggesting that the receptor may contribute to the 
progression of the disease (Zhang et al, 2008).  BK has been shown to increase the levels of 
COX-2 in HNSCC (Zhang et al, 2008).  Under basal conditions COX-2 is absent or present at very 
low levels within the oral mucosa (Vane et al, 1998).  BK causes an increase in COX-2 mRNA 
levels as a result of the peptide activating the EGFR.  This activation process triggers 
downstream signalling resulting in the activation of the MAPK pathway which results in an 
increase in COX-2 along with an increase in PGE2 production and release (Zhang et al, 2008).  
PGE2 and BK can both activate the EGFR in HNSCC and can cause an increase in cell 
proliferation and invasion (Thomas et al, 2006).  Both GPCR ligands can activate MAPK via an 
EGFR-dependent and an EGFR-independent mechanism (Thomas et al, 2006).  This process 
was inhibited when neutralising antibodies to TGF-α but not neutralising antibodies to HB-EGF 
or amphiregulin were used, suggesting that TGF-α is released from the cell surface of HNSCC 
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cells in response to PGE2 and BK (Thomas et al, 2006).  Further experiments conducted by 
Thomas et al (2006) showed that both the Src family kinases and ADAMs enzymes were 
involved in the signalling pathways activated by the treatment of HNSCC cells with PGE2 and 
BK.  The inhibition of the Src family kinases reduced MAPK phosphorylation and the siRNA 
knockdown of ADAM17 resulted in lower levels of TNF-α being released into the surrounding 
supernatant upon stimulation of HNSCC cells with BK (Thomas et al, 2006).  This shows that BK 
causes MMP mediated release of TGF-α which can then act as a ligand to activate EGFR in an 
autocrine mechanism (Thomas et al, 2006). 
1.4.2  Neurotensin 
Neurotensin is a neuropeptide, 13 amino acids in size (Carraway and Leeman, 1978) and 
located within the central nervous system and in jejunal and ileal mucosa, both of which 
contain endocrine cells (Evers et al, 1990;  Evers et al, 1992).  Neurotensin exerts its effects by 
binding to the neurotensin receptor 1 (NTSR1) and neurotensin receptor 2 (NTSR2), both of 
which are GPCRs (Vincent et al, 1999).  NTSR1 shows the highest affinity for neurotensin 
(Vincent et al, 1999).  Upon binding to the NTSR1, neurotensin can trigger intracellular 
signalling including MAPK and NF-κB which both promote inflammatory responses and induces 
the secretion of neutrophil chemoattractants including IL-8 (Zhao et al, 2003;  Zhao et al, 
2005).   
Neurotensin and NTSR1 have been implicated in a number of cancers including prostate, 
colon, lung and pancreatic (Thomas et al, 2003).  It is thought that the neuropeptide stimulates 
the expression of tumour-promoting genes through the activation of its receptor and the 
triggering of signalling pathways, including those associated with intracellular Ca2+, and the 
activation of transcription factors (Ehlers et al, 2000;  Zhao et al, 2003;  Leyton et al, 2002).  
Shimizu et al (2008) also identified that the expression of neurotensin and NTSR1 mRNA were 
elevated in HNSCC samples and was associated with metastatic spread and HNSCC 
progression.  Their increased expression also resulted in an increase in IL-8 and MMP-1 
transcripts within the HNSCC clinical samples (Shimizu et al, 2008).  Neurotensin could also 
contribute to cancer progression by the sustained proinflammatory response that it can trigger 
(Law et al, 2012). 
1.4.3 Substance P 
Substance P is an undecapeptide.  It belongs to a family of peptides called the tachykinin 
family.  Substance P exerts its effects by binding to the neurokinin 1 receptor (NK-1R) (Hökfelt 
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et al, 2001).  It plays a role in regulating the cardiovascular system, respiratory mechanisms, 
sensory perception, the control of movement, gastric motility, salivation and neuronal survival 
and degradation (Quartara and Maggi, 1998).  Substance P is also described as a neuropeptide 
and has been associated with the processes of inflammation, pain and depression (Kramer et 
al, 1998;  Harrison and Geppetti, 2001;  Bang et al, 2003).  Within the process of inflammation, 
substance P has been linked to the development and progression of mucosal inflammation 
(Koon and Pothoulakis, 2006).   
Substance P has also been implicated in tumour progression and is thought to act as a 
mitogenic peptide via the NK-1R.  The peptide is over expressed in a number of cancer cell 
lines including those isolated from neuroblastoma, glioma, melanoma and laryngeal cancers 
(Muñoz et al, 2004;  Muñoz et al, 2008).  Brener et al (2009) identified for the first time the 
presence of substance P and the NK-1R within HNSCCs.  The binding of substance P to its 
receptor is known to trigger the MAPK cascade and induce the activation of ERK 1 and 2 which 
results in increased cellular proliferation and cell apoptosis resistance (Koon et al, 2004).  
Substance P can also act as a ligand for the EGFR resulting in its activation and stimulating cell 
proliferation as a consequence (Weinstock et al, 1998).  
Little is known of the role of the mitogenic peptides, ET-1 and Ang II in HNSCC progression. 
1.4.4   Endothelin-1 
Endothelin-1 (ET-1) is a mitogenic peptide which acts primarily as a potent endogenous 
vasoconstrictor within the systemic and pulmonary circulatory systems (Yanagisawa et al, 
1988).  It also has various physiological roles including the maintenance of basal vascular tone, 
central respiratory regulation and renal homeostasis and is secreted mainly by endothelial and 
epithelial cells (Yanagisawa et al, 1988).  There are three members of the ET family: ET-1, ET-2 
and ET-3.  Each peptide is made up of 21 amino acids (Inoue et al, 1989). ET-1 and ET-2 have 
similar structures.  ET-3 however has a different structure.  It consists of only 15 amino acids 
that are present in ET-1 and ET-2 plus six additional amino acids (Levin, 1995;  Goldie, 1999;  
Walden et al, 1998;  Masaki, 2000).  The expression levels of the three different ETs vary in 
different cell types.  ET-1 is the most abundant ET and is found mainly in endothelial cells but is 
also present in epithelial cells and fibroblasts, ET-2 in the kidneys and the intestine and ET-3 is 
primarily found within the brain (Levin, 1995). The different localisation of the three ETs could 
reflect their different functional abilities (Nelson et al, 2003).  The presence of the different ETs 
results in a number of actions, which are mediated by the binding of ET to two cell surface 
GPCRs, ETAR and ETBR (Arai et al, 1990;  Sakurai et al, 1992).  The receptors are divided by the 
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different affinities that they have for the three different members of the ET family.  ETAR is 
highly specific for ET-1, whereas ETBR has equal affinity for ET-1, ET-2 and ET-3 (Rubanyi and 
Polokoff, 1994).  Each receptor has a different carboxy- terminal sequence and therefore 
generates divergent intracellular signals which influence tissue differentiation, growth and 
repair (Goldie, 1999). The ETAR upon activation couples to heterotrimeric Gα proteins 
including Gαq, Gαs, Gα12/13 (Horstmeyer et al, 1996;  Takigawa et al, 1995;  Gohla et al, 1999) 
and in some cell types Gαi (Hilal-Dandan et al, 1994;  Cadwallader et al, 1997).  The ETBR 
couples to Gαi and Gαq (Takigawa et al, 1995).  The binding of any of the three ET family 
members to ETAR or ETBR results in their activation and a change in concentration of various 
secondary messengers.  These include Ca2+, 1,2-diacylglycerol (DAG), IP3, arachiodonic acid and 
cyclic adenosine monophosphate (cAMP) (Horstmeyer et al, 1996).  ET-1 can act as a mediator 
of many cardiovascular and renal disorders and has recently been implicated in acting as a 
progression factor in many tumour types.  Antagonists designed to the molecule and their 
receptors have been tested as an anticancer therapy (Bagnato and Catt, 1998;  Battistini et al, 
1993;  Pirtskhalaishvili and Nelson, 2000, Nelson et al, 2003).   
1.4.4.1 Regulation of ET-1: The ET-axis 
Endothelin converting enzyme (ECE) is a type 2 membrane bound zinc metalloprotease and is a 
member of the neutral endopeptidase family.  ECE has a large extracellular or luminal C-
terminal catalytic domain and a small N-terminal cytoplasmic domain (Lambert et al. 2008).  
There are two ECE genes, ECE-1 and ECE-2, both of which are part of the M13 peptidase family 
(Dawson et al, 2006).  ECE-1 exists and is expressed as a covalent dimer (Schmidt et al, 1994;  
Takahashi et al, 1995;  Shimada et al, 1996).  It is present and active at both the cell surface 
and within intracellular organelles.  ECE-1 is distributed in a wider range of tissues throughout 
the body and at a higher expression level compared to ECE-2 (Schmidt et al, 1994;  Shimada et 
al, 1994;  Schmidt-Ott et al, 1998;  Emoto and Yanagisawa, 1995).  ECE-1 is expressed in the 
endothelium of all organs and is also expressed within nonvascular cells including within the 
tissues of the brain and within secretory granules in neuroendocrine cells (Xu et al, 1994;  
Takahashi et al, 1995;  Schmidt-Ott et al, 1998;  Korth et al, 1999).  The cellular distribution of  
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A             B 
 
Figure 1.6  The biosynthesis of ET-1:  The biosynthesis of ET-1 begins with the cleavage of prepro ET-1 to pro ET-1, followed by the cleavage of pro ET-1 to big ET-1 
by a furin-like endopeptidase.  The cleavage of big ET-1 to ET-1 is catalysed by endothelin converting enzyme-1 (ECE-1); a membrane bound metalloproteinase 
produces biologically active ET-1.  This final proteolytic cleavage by ECE-1 occurs between the Trp-21-Val/Ile-22 bond (A).  There are three member of the ET family 
(B) (Figure adapted from Grant et al, 2003). 
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ECE is important in determining the biosynthetic pathway and production of specific ETs and 
the ability of the enzyme to synthesise and hydrolyse other peptides including BK, neurotensin 
and substance P (Nelson et al, 2003). 
ECE-1 is responsible for the proteolytic cleavage of big-ET-1 to ET-1 between the Trp-21-
Val/Ile-22 bond (Rubanyi and Polokoff, 1994) (Figure 1.6).  The reaction can take place within 
the extracellular medium and in the secretory pathway (Xu et al, 1994;  Harrison et al, 1995;  
Parnot et al, 1997).  It is an essential step in the activation of ET-1 because its precursors have 
no biological activity (Figure 1.6) (Rubanyi and Polokoff, 1994). 
ECE-1 has four distinct isoforms:  ECE-1a, ECE-1b, ECE-1c and ECE-1d.  All four isoforms are 
derived from a single gene (Figure 1.7).  This is achieved through the use of alternative 
promoter regions for each isoform that direct expression of specific exons.  The four isoforms 
of ECE are located within the secretory pathway and within the endosomal system.  All four 
isoforms can exist as heterodimers and it has been suggested that this ability to 
heterodimerize may be responsible for the different subcellular locations of the different 
isoforms, again highlighting the importance that the location of ECE-1 plays in its function.  
ECE-1c is the most abundant isoform.  It is widely distributed throughout the plasma 
membrane (Muller et al, 2003).  The expression of ECE-1c is significantly elevated in tumours 
(Lambert et al, 2008).  It is present within the primary malignant stromal cells of the tumour 
but is absent in benign stromal cells.  The increase of ECE-1c in malignant stromal cells is 
thought to activate ET-1 and lead to a paracrine influence on the growth of the cells.  ECE-1c is 
situated close to the inactive form of ET-1, big ET and therefore when ECE-1c is present it 
allows ET-1 to be readily activated.  It is this activation of ET-1 that increases prostate cancer 
invasion and metastasis (Dawson et al, 2006). 
Neprilysin (NEP) is an endopeptidase (Kerr and Kenny, 1974).  It is 90-110 kDa in size and is 
localised at the cell surface (Sumitomo et al, 2000).  It has the ability to inactivate a number of 
peptides that are physiologically active.  NEP has the ability to inactivate a wide variety of 
physiologically active neuropeptides including ET-1, BK, neurotensin, atrial natriuretic factor, 
substance P, oxytocin, bombesin, bombesin-like peptides and Leu- and Met-enkephalins (Shipp 
et al, 1991;  Shipp and Look, 1993).  This results in a reduction in the local concentration of the 
specific peptides therefore reducing the level of receptor binding and signal transduction.  The 
loss of this NEP activity has been implicated in a number of malignancies including small cell 
lung cancer, prostate cancer and lung cancer (Papandreou et al, 1998).  The loss of activity of 
the surface endopeptidase results in the increased concentration of mitogenic peptides at the 
cell surface that the enzyme is normally responsible for inactivating.  The inactivation of these  
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Figure 1.7  The ECE-1 isoforms:  A schematic representation of ECE-1 and its four isoforms; -1a. -1b, -1c and -1d.  All four isoforms are derived from a single gene, 
through the use of alternative promoter regions.  The N-terminal cytoplasmic region of each isoform differs and is responsible for the targeting of each isoform to 
its correct location within the cell (Figure adapted from Muller et al, 2003). 
ECE-1a; located at the cell surface, 758 residues in size
ECE-1b; located within the endosomal system, 770 residues in size
ECE-1d; located within the endosomal system, 767 residues in size
ECE-1c; located at the cell surface, 754 residues in size
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mitogenic peptides have been related to the disruption of normal cellular homeostasis and has 
been suggested to contribute to tumour progression by triggering peptide mediated cell 
proliferation and neoplastic transformation (Papandreou et al, 1998).  NEP is important in 
regulating signal transduction processes including cell apoptosis, Akt-mediated survival and 
cell migration (Sumitomo et al, 2005).   
1.4.5 Angiotensin II 
Angiotensin II (Ang II) has mitogenic and angiogenic effects.  The renin-angiotensin system 
(RAS) is made up of a number of different peptides and their specific receptors.  Ang II is the 
main peptide effector of the RAS.  Ang II has two specific GPCRs; AT1R and AT2R, in which it can 
bind to and activate.  Ang II exerts most of its pathophysiological effects via AT1R which is 
expressed on a number of different cell types.  These include cell proliferation, production of 
growth factors and cytokines and fibrosis, which can lead to vascular thickening and 
atherosclerosis (Fujiyama et al, 2001;  Shah and Catt, 2003;  Tamarat et al, 2002).  The AT2R is 
mainly expressed during early stages of foetal development, however it is also expressed in the 
adrenal medulla, ovarian follicles and the uterus during an adult’s lifetime (Messerli et al, 
1996;  Touyz et al, 2000;  Velasquez, 1996).  The receptor seems to antagonise the effects of 
induced proliferation, angiogenesis and inflammatory responses that are activated via the 
AT1R (Lung et al, 2003;  Pupilli et al, 1999).  
1.4.5.1 The renin-angiotensin system 
Ang II is the main precursor peptide of the RAS (Figure 1.8).  Other components of the system 
including the enzymes responsible for the regulation of Ang II are outlined below: 
Angiotensin-converting enzyme (ACE) is a zinc-metalloproteinase that is highly conserved in a 
diverse selection of organisms (Riviere et al, 2007;  Macours et al, 2004).  Two forms of the 
enzyme exist in vertebrates.  Somatic ACE is made up of two homologous catalytic domains 
which both contain the zinc-dependent active site motif HEMGH (Lambert et al, 2010).  This 
form of ACE is expressed on the surface of endothelial and epithelial cells in a wide variety of 
tissues.  The other form of the enzyme is germinal ACE.  Germinal ACE is made up of a single 
catalytic domain and is expressed only within the testes.  Germinal ACE is known to play an 
essential role in fertility; its precise function however is not clear (Lambert et al, 2010).  Both 
isoforms of the enzyme are type-1 transmembrane glycoproteins which both contain an 
extracellular amino-terminal ectodomain and a short intracellular cytoplasmic tail.  The 
localisation of ACE to the membrane allows the enzyme to hydrolyse peptides within the 
extracellular milieu (Lambert et al, 2010).  ACE has the ability to hydrolyse a number of  
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Figure 1.8  The renin-angiotensin system: A schematic diagram to highlight the different components of the RAS.  Ang II, produced by the action of ACE, binds to 
its receptor, AT1R, to promote cardiovascular disease and cancer. These effects are opposed by Ang 1-7, produced from Ang II by ACE2, acting through its receptor, 
MasR. 
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peptides including Ang I, substance P, luteinizing hormone-releasing hormone and BK (Skidgel 
et al, 1984;  Skidgel and Erdos, 1985;  Rieger et al,. 1993).  The enzyme can do this by acting as 
a peptidyl dipeptidase or an endopeptidase.  Both domains have different affinities for 
different substrates and inhibitors (Georgiadis et al, 2003). 
Angiotensin-converting enzyme 2 (ACE2) is also a zinc-metalloproteinase.  It shares 42% 
sequence homology with ACE.  This sequence identity is found within the catalytic domain of 
both enzymes.  ACE2 consists of only one catalytic site and it cleaves its substrates at a specific, 
single C-terminal residue.  ACE2 and ACE have different and distinct substrates.  ACE2 and ACE 
can both cleave Ang I.  ACE2 has a lower affinity for the peptide in comparison to ACE and 
therefore the cleavage event between ACE2 and Ang I is less likely to occur (Rice et al, 2004).  
ACE2 can however cleave Ang II to Ang 1-7 suggesting that the enzyme may act in an opposing 
way to that in which ACE acts.  The enzyme is found throughout many tissues within the body 
(Gembardt et al, 2005) however it is only expressed at high levels in the heart, kidneys and 
testes (Tipnis et al, 2000).  ACE2 has a different specificity and physiological role to ACE.  Its 
activity is not altered by the presence of ACE inhibitors.  ACE2 is responsible for the production 
of Ang 1-9 from Ang I.  Ang 1-9 is then converted into Ang 1-7 by ACE.  ACE2 also has the ability 
to directly cleave Ang II in order to produce Ang 1-7 (Donoghue et al, 2000).   
Angiotensin 1-7 (Ang 1-7) is an endogenous, seven amino acid hormone that has both anti 
proliferative and vasodilator properties (Ferrario et al, 1997;  Tallent et al, 1999;  Santos et al, 
2000).  Ang 1-7 can be produced by the enzymatic breakdown of Ang I by a number of 
endopeptidases including NEP, prolyl oligopeptidase or thimet oligiopeptidase (Welches et al, 
1991;  Yamamoto et al, 1992;  Chappel et al, 1995;  Welches et al, 1993).  This cleavage event 
takes place at the Pro-7-Phe-8 bond (Welches et al, 1993) and it is considered that the event is 
actually predominantly catalyzed by the ACE2 enzyme.  Ang 1-7 can also be produced from Ang 
II by carboxypeptidases that cleave the mitogenic peptide at its C-terminus.  The peptide can 
also be targeted by the ACE enzyme; however in this case Ang 1-7 is metabolized and 
degraded to Ang 1-5 (Chappell et al, 1998). 
The heptapeptide has antiproliferative, diuretic, natriuretic and vasodilatory characteristics 
(Strawn et al, 1999;  Ferrario et al, 2002;  Ren et al, 2002;  Ferrario, 2003).  It can reduce blood 
pressure and prevent cardiac pathophysiology and attenuation of renal abnormalities that are 
caused by hypertension (Santos et al, 2004;  Averil et al, 2003;  Benter et al, 1995;  Moriguchi 
et al, 1995;  Stegbauer et al, 2004).  In some instances Ang 1-7 can antagonistic the effects 
triggered and activated by the binding of Ang II to its receptor, AT1R (Herath et al, 2007).   
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1.4.5.2 The role of the ET-axis and RAS in cancer progression 
Both the ET-axis and RAS have been implicated in cancer progression.  The expression of the 
components within the systems varies in malignant tissue in comparison to normal tissue.  The 
expression of the AT1R is increased in a number of malignancies.  Components of the RAS 
system have also been linked with tumour grading however no clear correlation has been 
observed and it very much depends on the tumour type as to how the components vary in 
malignant tissue to that of normal tissue (Louis et al, 2007;  Sitzmann et al, 1994).  In breast 
cancer over expression of the AT1R is associated with breast hyperplasia, however the 
expression levels begin to decrease as the tissue becomes invasive (De Paepe et al, 2002).  This 
is not the case in ovarian cancer where an increase in AT1R expression directly correlates with 
increased invasiveness (Suganuma et al, 2005).  Therefore increased invasiveness of malignant 
tissue may not solely be dictated by an increase in the AT1R on its own but may require 
changes in other components of the RAS too (Ager et al, 2008).   
It is thought that the mitogenic peptides, ET-1 and Ang II, the main precursor peptides of both 
systems, may play a role in cancer progression by modulating a number of cellular processes 
(Bagnato and Catt, 1998;  Battistin et al, 1993;  Pirtskhalaishrili and Nelson, 2000).   
1.4.5.2.1 Cell proliferation 
ET-1 can stimulate cell proliferation via the activation of its specific GPCRs, ETAR and ETBR 
which results in the stimulation of a number of kinases including PKC, IGF-1 and MAPK 
(Bagnato and Catt, 1998;  Battistini et al, 1993;  Pirtskhalaishrili and Nelson, 2000).  The 
activation of these kinases causes rapid induction and activation of a number of early response 
genes including c-FOS, c-MYC and c-JUN which can affect the processes of cellular proliferation 
and apoptosis (Bagnato and Catt, 1998).  The transactivation of the EGFR by ET-1 leads to the 
phosphorylation of the receptor and the phosphorylation of SHC, a signal transduction 
mediator (Vacca et al, 2000).  SHC forms a complex with another signal transduction mediator, 
GRB2.  Both SHC and GRB2 can activate p38 and ERK which are both responsible for triggering 
the change in cell proliferation caused by ET-1 (Vacca et al, 2000).   
1.4.5.2.2 Cell apoptosis 
ET-1 can promote tumour formation and growth by allowing cells to avoid apoptosis.  In colon 
cancer ET-1 acts as a survival factor and inhibits apoptosis that is triggered by Fas ligand 
binding (Eberl et al, 2000;  Nelson et al, 1999).  In ovarian and prostate cancer ET-1 can 
activate anti-apoptotic signalling pathways including the BCL-2-dependent and PI3-K mediated 
AKT pathways which result in the activation of BCL-2-associated death promoter (BAD) and 
Caspase-9 which are both responsible for inhibiting apoptosis and promoting cell growth and 
survival (Vacca et al, 2000;  Sumitomo et al, 2001).   
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1.4.5.2.3 Angiogenesis 
Angiogenesis is described as the formation of new blood vessels.  It is an essential process for 
the growth and metastasis of solid tumours.  HNSCCs are highly invasive especially into 
surrounding bone and muscle and they also exhibit a high degree of neovascularity (Shemirani 
and Crowe, 2000).  ET-1 and Ang II can both promote angiogenesis.  The effects triggered by 
ET-1 vary depending on which specific GPCR receptor it works through, ETAR or ETBR.  The 
activation of the ETAR can induce zymogen secretion and the induction of mRNA transcription 
and the pro-enzyme activation of MMPs, which both contribute to tissue remodelling and 
tumour metastasis.  The activation of the receptor by ET-1 can also stimulate the uPA system 
(Salani et al, 2000;  Spinella et al, 2002;  Rosanò et al, 2001). The activation of the ETBR 
promotes VEGF production and an increase in levels of hypoxia inducible factor-1α (HIF-1α) 
resulting in increased cell proliferation and vascular permeability both of which are processes 
associated with tumour angiogenesis and growth (Spinella et al, 2002).  VEGF is 34-50 kDa in 
size and is a mitogen associated with endothelial cells that plays a significant role in mediating 
angiogenesis during both non-pathological and pathological events (Moriyama et al, 1997).  
VEGF is over expressed in a number of cancers (Barr et al, 2008;  Holtz et al, 2008;  Kamat et al, 
2007).  Over expression of VEGF and its receptor has been observed in malignant HNSCC 
therefore suggesting that angiogenesis plays a role in HNSCC development (Shemirani and 
Crowe, 2000).  The VEGF protein and mRNA correlate with malignancy progression (Denhart et 
al, 1997).  Ang II and the activation of the ETBR by ET-1 can increase the production and 
expression of VEGF by increasing activation of HIF-1 which directly regulates the transcription 
of VEGF (Page et al, 2002).   
Ang II can stimulate the expression of a number of growth factors and pro-angiogenic agents 
that contribute to increased angiogenesis (Folkman, 1975).  As mentioned before Ang II can 
trigger an increase in expression of VEGF, similar to ET-1 (Pupilli et al, 1999), an increase in 
PDGF (Fujita et al, 2002), angiopoeitin 2 (Yasumatsu et al, 2004) and BFGF (Wysocki et al, 
2006).  The increase in VEGF and endothelial nitric oxide synthase levels also by Ang II can 
trigger a promotion in revascularization of damaged blood vessels.  The increase in expression 
of these factors is achieved by Ang II through the activation of the AT1R (Tamarat et al, 2002).   
There is evidence to support the theory that mitogenic peptides including Ang II and ET-1 may 
lead to vasoactivity which increases the blood flow to the tumour resulting in an increase in 
the efficacy of radiotherapy and also improve the delivery of chemotherapeutic drugs (Bell et 
al, 1996;  Blackman et al, 2003).   
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Both systems have been targeted for the proliferative activities.  The angiogenic effects caused 
by Ang II can be blocked by the use of ACE inhibitors however side effects of using this drug 
treatment include pro-angiogenic effects in a number of vascular injuries.  This is thought to be 
due to the increase in BK levels as a result of the inhibition of the ACE enzyme that is 
responsible for the degradation of the mitogenic peptide (Madeddu et al, 2007).  It has been 
suggested that it may therefore be more advantageous to block the receptor in which Ang II 
binds to, the AT1R in order to inhibit its proliferative effects (Ager et al, 2008).  Inhibitors, 
including perindoprilat, to the ACE enzyme can dramatically reduce the expression levels of 
VEGF by inhibiting the activity of the VEGF promoter (Yasumatsu et al, 2004).  The VEGF 
promoter contains several binding sites.  The inhibition of the enzyme can also reduce Ang II 
levels and lower stromal vascularisation (Yasumatsu et al, 2004). 
1.4.5.2.4 Migration and invasion 
ET-1 is over expressed in both primary and metastatic ovarian carcinomas in comparison to 
normal ovarian tissues.  The activation of the ETAR by ET can result in the phosphorylation and 
activation of MAPKs which stimulate the phosphorylation of p125FAK and paxillin.  The 
phosphorylation of these two molecules results in the activation of signals which are thought 
to be influence migration and invasion of cancerous cells (Vacca et al, 2000;  Bagnato et al, 
1997).   
1.4.5.2.5 EMT 
It ovarian cancer ET-1 acts as a growth factor and is responsible for the activation of signalling 
pathways that control EMT and promote tumour progression (Rosanò et al, 2005).  The 
addition of ET-1 results in the production of an ovarian cancer cell that is spindle like and holds 
a mesenchymal phenotype (is becoming more migratory and has a fibroblast like shape) 
instead of a normal polarized phenotype which includes the loss of E-cadherin, β-catenin and 
ZO-1 and the addition of the mesenchymal markers vimentin and N-cadherin (Rosanò et al, 
2005).   
Fibrosis diseases are characterised by increased ECM formation and the differentiation of 
myofibroblasts.  Fibrosis diseases include liver cirrhosis, pulmonary fibrosis and cardiovascular 
disease and it is common practice for inhibitors that target components of the RAS system to 
be used in their treatment.  Activated hepatic stellate cells can secrete Ang II.  The secretion of 
Ang II can lead to the promotion of fibrosis, increased myofibroblast proliferation and 
differentiation and increased collagen synthesis (Bataller et al, 2005).  α-SMA is also increased 
and E-cadherin reduced, both of which regulate EMT (Chen et al, 1999).  Ang II also activates 
NF-kB which can in turn lead to the increased expression of intracellular adhesion molecules 
and inflammatory cytokines including TNF-α, IL-6 and TGF-β (Wolf et al, 2002;  Ozawa et al, 
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2007;  Ruiz-Ortega et al, 2006).  These processes can all promote EMT and therefore 
contribute to increased invasiveness of the tumour.   In response to EMT VEGF expression can 
be increased as can other growth and angiogenic factors (Bates et al, 2007).   
1.4.5.2.6 Metastasis  
The treatment of ovarian cells with ET-1 increases the production of uPA, the uPA receptor and 
PAIs at a transcriptional level and an increase in the levels of secretion and activation of MMP-
2 and MMP-9 all through the activation of the ETAR (Rosanò et al, 2001).  These factors have 
been linked to an increase in the progression and metastatic ability of ovarian cancerous cells 
(Rosanò et al, 2001).  
1.4.5.3 The ET-axis and RAS in head and neck cancer progression 
Few studies have investigated the roles that the ET-axis and the RAS play in head and neck 
cancer progression.  Awano et al (2006) identified that higher levels of ET-1 were produced in 
oral squamous cell carcinoma (OSCC) cells compared to normal human epidermal 
keratinocytes (NHEK) cells and suggested that the peptide may be linked to the development 
of tumours within the oral cavity via the activation of the ETAR and/or ETBR.  Higher expression 
levels of ECE-1, the enzyme responsible for the activation of ET-1, was also observed in OSCC 
cells compared to normal cells, which may explain the increase in ET-1 levels observed.  The 
activity of ECE-1 could be inhibited by both a specific inhibitor and siRNA to the enzyme. It was 
shown that an inhibitor specific to ECE-1 inhibited proliferation of OSCC cells as did siRNA 
targeting of ECE-1 (Awano et al, 2006). 
The overexpression of ET-1 in the saliva of patients suffering with OSCC has also been 
observed (Pickering et al, 2007).  The definite role played by ET-1 in OSCC is not fully 
understood however Pickering et al (2007) suggest that like in other malignancies ET-1 may 
contribute to the invasive and metastatic properties that OSCC exhibit.  ET-1 is also 
overexpressed in a number of malignancies that have a high incidence of bone metastasis and 
it has been suggested that this property of ET-1 may contribute to the intense pain associated 
with OSCC (Pickering et al, 2007).   
Ishibashi et al (2003) demonstrated that high levels of ET-1 in patients suffering with 
oesophageal SCC, correlated with a poor prognosis.  The group identified that a high 
expression level of VEGF correlated with an increased depth of invasion, the presence of a 
mutation in p53 and the presence of lymph node metastasis (Ishibashi et al, 2003).  In ovarian 
cancer it has been demonstrated that ET-1 stimulates the secretion of VEGF and Ishibashi et al 
(2003) have proposed that the mitogenic peptide may cause the same effect in cases of 
oesophageal SCC.   
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mRNA transcripts for components of the RAS including renin, the enzyme responsible for 
producing Ang I, angiotensinogen, the peptide Ang I is hydrolysed from, ACE, AT1R and AT2R 
have been identified in rat gingival tissue suggesting that the production of Ang II and other 
vasoactive peptides within this tissue is possible (Santos et al, 2009).  The presence of all the 
essential components shows that a local RAS is capable of generating Ang II in rat gingival 
tissue independently of the systemic RAS (Campbell, 1987; Paul et al, 2006;  Phillips et al, 
1993).  
1.4.6 Hypothesis and aims 
The hypothesis of this thesis is that the deregulation of the ET-axis and RAS contribute to the 
progression of head and neck cancer. 
The overall aim of this study is therefore to investigate the molecular mechanisms used by 
both ET-1 and Ang II to promote head and neck cancer progression.  The expression and 
function of components of both the ET-axis and RAS will be investigated.  The role of the 
tumour microenvironment in head and neck cancer progression will also be examined with 
particular focus on the involvement of fibroblasts within this environment.   
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2.1 Materials  
2.1.1 Chemicals 
Chemicals routinely used were purchased from Sigma-Aldrich (UK), unless otherwise stated 
and were of the highest analytical grade. 
2.1.2 Antibodies 
The monoclonal antibodies to α-smooth muscle actin (α-SMA), clone 1A4 (1:1,000) and β-actin, 
clone AC-74 (1:4,000) were purchased from Sigma-Aldrich (UK).  The anti-human endothelin 
converting enzyme-1 (ECE-1) (1:500) antibody was purchased from R&D Systems (UK).  The 
antibody is specific to human ECE-1 and does not cross-react with recombinant human ECE-2 
or recombinant human membrane metallo-endopeptidases-like 2 enzymes.  Anti-mouse, anti-
rabbit and anti-goat IgG horseradish peroxidase-conjugated secondary antibodies (1: 2,000) 
were all purchased from Amersham Ltd (UK).   
2.1.3 Peptides and recombinant proteins 
Endothelin-1 (ET-1), bradykinin (BK), epidermal growth factor (EGF), angiotensin 1-7 (Ang 1-7) 
and angiotensin II (Ang II) were all purchased from Sigma-Aldrich (UK).  Transforming growth 
factor (TGF)-β was purchased from R&D Systems (UK).   
2.1.4 Oligonucleotides 
The following oligonucleotides and primer sequences were synthesized by Sigma-Aldrich (UK).
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Primer Name Forward sequence Reverse Sequence Reference 
U6 5’ CTCGCTTCGGCAGCACA 3’ 5’ AACGTTCACGAATTTGCGT 3’ Baroukh et al (2009) 
ETAR 5’ GCTTCCTGGTTACCACTCATCAA 3’ 5’ GTCTGCTGTGGGCAATAGTTG 3’ Rayhman et al (2008) 
ETBR 5’ TTCATCCCGTTCAGAAGACA 3’ 5’ CCAATGGCAAGCAGAAATAGA 3’ Montgomery and Patterson (2008) 
ET-1 5’ CTGCCACCTGGACATCATTTG 3’ 5’ TCTCACGGTCTGTTGCCTTTG 3’ Rayhman et al (2008) 
ECE-1 5’ GGACTTCTTCAGCTACGCCTGT 3’ 5’ CTAGTTTCGTTCATACACGCACG 3’ Kindly donated by Dr. L. Lambert (University of Leeds) 
NEP 5’ CCTGGAGATTCATAATGGATCTTGT 3’ 5’ AAAGGGCCTTGCGGAAAG 3’ Kindly donated by Dr. L. Lambert (University of Leeds) 
COX-2 5’ GCTCAGCCATACAGCAAATC 3’ 5’ TGTGTTTGGAGTGGGTTTCA 3’ Wakimoto et al (2008) 
AT1R 5’ ACCTGGCTATTGTTCACCCAA 3’ 5’ ACAAGCATTGTGCGTCGAAG 3’ Dubois et al (2010) 
AT2R 5’ GTTCCCCTTGTTTGGTGTAT 3’ 5’ CATCTTCAGGACTTGGTCAC 3’ Okamura et al (1999) 
MasR 5’ TTCCGGATGAGAAGAAATCC 3’ 5’ ATGGCCAGAAGAAAGCTCAT 3’ Reis et al (2011) 
ACE 5’ ATGAAGACCTGTTATGGGCATGG 3’ 5’ ATTTCGGGTAAAACTGGAGGATGG 3’ Nakamura et al (2011) 
α-SMA  5’ GAAGAAGAGGACAGCACTG 3’ 5’ TCCCATTCCCACCATCAA 3’ Yue et al (2008) 
Table 2.1 Oligonucleotide sequences
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2.1.5 Bacterial strains 
In order to multiply the quantity of expression vectors the DH5α E.coli strain was used (New 
England Biolabs, UK).  
2.1.6 Plasmids 
The mammalian expression vector containing cDNA encoding human ECE-1c (complete coding 
sequence of human ECE-1c inserted by blunt-ended ligation into pcDNA3) was kindly donated 
by Dr. A. Whyteside (University of Leeds) and the mammalian expression vector containing 
cDNA encoding human ACE (complete coding sequence of human somatic ACE inserted by 
blunt-ended ligation into pIRES-neo) was kindly provided by Dr. E. Parkin (University of 
Lancaster).  
2.1.7 Cells 
The cell lines used in this study are listed below: 
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Cell Line Derivation Source Reference  
Cal27 Tongue, OSCC Dr. C. Murdoch Gioanni et al (1988) 
H357 Tongue, OSCC Dr. S. Whawell Prime et al (1990) 
SCC4 Tongue, OSCC Dr. C. Murdoch Rheinwald and Beckett 
(1980) 
FaDu Pharyngeal, OSCC Dr. C. Murdoch Rangan (1972) 
B16 Tongue, OSCC Dr. K. Hunter Burns et al (1993) 
D19 Lateral tongue, Dysplasia Dr. K. Hunter McGregor et al (2002) 
D20 Lateral tongue, Dysplasia Dr. K. Hunter McGregor et al (2002) 
B22 Metastasis Dr. K. Hunter Burns et al (1993) 
Normal oral 
keratinocytes 
(NOKs) 
 Collected with South Sheffield ethics 
committee approval, as described in 
Hearnden et al (2009) 
 
Normal oral 
fibroblasts 
(NOFs) 
 Collected with South Sheffield ethics 
committee approval, as described in 
Hearnden et al (2009) 
 
Table 2.2 Head and neck primary cells and cell lines utilised
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2.1.8 Cell culture reagents 
Dulbecco’s modified Eagle’s medium (DMEM), Roswell Park Memorial Institute medium (RPMI-
1460), Ham's F12 nutrient mix, foetal bovine serum (FBS), Dulbecco's phosphate buffered 
saline (PBS), L-glutamine, adenine, transferrin, 3,3’,5-triiodo-L-thyronine, hydrocortisone and 
trypsin/EDTA were all purchased from Bio Whitaker (UK).  The transfection reagents 
Oligofectamine and FuGENE 6 were bought from Invitrogen (UK) and Promega (UK), 
respectively.  Transwell inserts and companion plates were purchased from Corning (UK).  
Matrigel was purchased from Becton Dickinson (UK). 
 
2.2 Methods  
2.2.1 Cell culture 
2.2.1.1 Routine maintenance of cell culture 
The HNSCC-derived cell lines Cal27, H357 and SCC4 and human primary NOFs (used within 
passage 3-10) were routinely cultured in DMEM supplemented with 2 mM L-glutamine and 
10% (v/v) FBS. The FaDu cell line was routinely grown in RMPI-1460 supplemented with 2 mM 
L-glutamine and 10% (v/v) FBS.  Human primary NOKs (used up to passage 3) and D19, D20, 
B16 and B22 cell lines were all routinely cultured in Green’s media consisting of a 3:1 ratio of 
DMEM and Ham’s F12 supplemented with 2mM L-glutamine, 1.8x10-4 M adenine, 5 µg/mL 
transferrin, 2x10-7 M 3,3’,5-triiodo-L-thyronine, 4 µg/mL hydrocortisone, 10 ng/mL EGF and 
10% (v/v) FBS.  All cells were grown in antibiotic-free media at 37°C and 5 % (v/v) CO2.  
Following two washes with PBS, cells were routinely passaged using trypsin/EDTA digestion.  
For cell line references please see Table 2.2. 
2.2.1.2 Cryogenic preservation and recovery 
Cells at ~90% confluency were washed twice in PBS before being harvested using trypsin/EDTA 
digestion.  Cells were resuspended in normal growth media containing 50% (v/v) FBS and 10% 
(v/v) DMSO.  1x106 cells were divided into 1 ml aliquots and added to cryotubes.  The tubes 
were placed at -80°C in a cryo-cooler and left overnight.  For long-term storage the cells were 
placed into liquid nitrogen. 
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2.2.2 Cell treatments 
2.2.2.1 Preparation of conditioned media 
NOFs were seeded at 300,000 cells/well in a 6-well plate in DMEM containing 10% (v/v) FBS 
and were left to adhere overnight at 37°C and 5% (v/v) CO2.  The following day NOFs were 
serum starved for 24 h in DMEM. 
Cells were treated with ET-1 (0-100 nM (Figure 4.1B)), BK (1 µM (Clementi et al, 1999)), Ang 1-
7 (100 nM (Zhang et al, 2010)) and/or Ang II (0-1000 nM (Figure 4.3A)) or TGF-β (2-20 ng/ml 
(Kellermann et al, 2008)) and incubated for 4-48 h at 37°C and 5% (v/v) CO2.  Where indicated, 
NOFs were pre-treated with an ETAR antagonist, an ETBR antagonist (BQ-123 and BQ-788, 
respectively, both 1 µM (Spinella et al, 2002); Sigma-Aldrich, UK) individually or in 
combination, an MMP/ADAMs inhibitor (GM6001, 10 µM (Mei et al, 2001); Chemicon), an 
AT1R antagonist (Telmisartan, 1 µM (Storka et al, 2008); Sigma-Aldrich, UK), a mas receptor 
(MasR) antagonist (A-779, 1 µM (Zhang et al, 2010); Bioquote) or an ECE-1 inhibitor (SM-
19712, 10 µM (Roosterman et al, 2008); Sigma-Aldrich, UK), for 30 min before addition of 
mitogenic peptides.   Media was collected from the NOFs after incubation, filtered and added 
either directly to SCC4 cells (for COX-2 expression analysis) or to the bottom well of a Transwell 
chamber (for migration and invasion assays).  Where appropriate, the conditioned media was 
incubated for 30 min at 37°C with rotation following addition of neutralising antibodies to HB-
EGF, TGF-α and amphiregulin (10 µl/ml, all R&D Systems, UK) or mouse IgG (Dako) before 
addition to the Transwell.   
2.2.2.2 Treatment of HNSCC cell lines 
SCC4 or H357 cells were serum starved 24 h prior to experimentation in DMEM.  Cells were 
treated with ET-1 (10 nM), BK (1 µM), EGF (48.4 μM (Fowler et al, 1995)), Ang 1-7 (100 nM) 
and/or Ang II (100 nM) or TGF-β (2-20 ng/ml).  Where indicated SCC4 or H357 cells were pre-
treated with an AT1R antagonist (Telmisartan, 1 µM), an AT2R antagonist (PD123319, 500 nM 
(Mlinar et al, 1995); Sigma-Aldrich, UK), a MasR inhibitor (A-779, 1 µM), an EGFR antagonist 
(Tyrphostin, AG 1478, 125 nM (Pierce et al, 2000); Sigma-Aldrich, UK), an ECE-1 inhibitor (SM-
19712, 10 µM), non-specific COX inhibitor (Ibuprofen, 100 µM (Ouellet et al, 2001); Sigma-
Aldrich, UK) or specific COX-2 inhibitor (Celecoxib, 50 µM (Niederberger et al, 2001); Sigma-
Aldrich, UK) for 30 min at 37°C and 5% (v/v) CO2 before the experimental use of the cells.   
The inhibitors and antagonists used in this study are listed in Table 2.3. 
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Name Chemical 
name 
Kd IC50 Other information Reference 
EGFR antagonist AG1478   3 nM Is a specific inhibitor of EGF-receptor tyrosine kinase activity, can also 
abolish EGFR autophosphorylation and Src family kinase.  
Osherov and 
Levitzki, 2002 
AT1R antagonist Telmisartan 1.7 (± 1.2) nM   Telmisartan dissociates very slowly from AT1R, When administered 
intravenously in rats, telmisartan is 10-fold more potent than irbesartan 
and comparable to candesartan, two other AT1R antagonists. 
Maillard et al, 2002 
AT2R antagonist PD123319 0.09 nM 30 nM Completely inhibits AT2R activity in a monophasic manner.  Servant et al, 1993 
MasR inhibitor A-779   10 μM A-779 does not change the dipsogenic, pressor, or myotropic effects of Ang 
II an does not affect the antidiuretic effect of vasopressin or the contractile 
effects of angiotensin III, bradykinin, or substance P on the rat ileum 
therefore highlighting it is a potent and selective antagonist for Ang 1-7. 
Santos et al, 1994 
ECE-1 inhibitor SM-19712   42 nM SM-19712 inhibited ECE activity but had no effect on other 
metalloproteases such as NEP and ACE, showing that it has a high 
specificity for ECE. 
Umekawa et al, 
2000 
COX inhibitor Ibuprofen   57 μM Has a time independent mechanism and is selective towards COX-1. Noreen et al, 1997 
COX-2 inhibitor Celecoxib   0.04 µM Has an IC50 of 15 µM for COX-1.  Can demonstrate potent, anti-
inflammatory activity, has potency equivalent to standard NSAIDs and 
showed no acute GI toxicity, has good bioavailability, is well distributed and 
has an excellent safety profile. 
Penning et al, 1997 
ETAR antagonist BQ-123   7.3 nM BQ-123 interacts competitively with ETAR. Ihara et al, 1992 
ETBR antagonist BQ-788   1.2 nM BQ-788 interacts competitively with ETBR and it does not significantly 
inhibit the binding of Ang II or calcitonin-gene related peptide. 
Ishikawa et al, 
1994 
MMP/ADAMs 
inhibitor 
GM6001 0.18-26.0 nM 0.104-263.0 nM Inhibits a wide range of MMPs including MMP-2, MMP-3, MMP-26, MMP-
8, MMP-9, MMP-1, MMP-12, MMP-14, MMP-15, MMP-16, ADAM-9, 
ADAM-10, ADAM-12 and ADAM-17. 
www.drugable.com 
Table 2.3 Inhibitor and antagonist information
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2.2.2.3 COX-2 analysis 
SCC4 cells were seeded at 100,000 cells/well in a 12-well plate in DMEM containing 10% (v/v) 
FBS and were left to adhere overnight at 37°C and 5% (v/v) CO2.  The following day SCC4 cells 
and NOFs were serum starved for 24 h in DMEM. 
NOFs were treated and incubated with ET-1 (10 nM) for 4 h at 37°C and 5% (v/v) CO2.  SCC4 
cells were subsequently stimulated with the conditioned NOFs media for a further 4 h before 
the cells were lysed, total RNA isolated (as described in Section 2.2.3.4) and cDNA analysed by 
SYBR green qPCR (as described in Section 2.2.3.4). 
2.2.3 Molecular analysis  
2.2.3.1 Transformation of competent cells 
Chemically competent DH5α E.coli cells (New England Biolabs, UK) were thawed on ice.  
Plasmid DNA (1 pg-100 ng) was added to the competent cells.  The cells and DNA were flicked 
4-5 times in order to mix the solution.  The mixture was incubated on ice for 2 min.  The 
bacteria were subjected to heat shock treatment at 42°C for 30 s before being returned to ice 
for a further 2 min.  950 µl of super optimal broth with catabolite repression (S.O.C) medium 
(Invitrogen, UK) was added to the transformation mix.  50-100 µl of the transformed mix was 
added to Luria-Bertani (LB)-agar (Fisher Scientific, UK) plates supplemented with 50 µg/ml 
ampicillin (Sigma-Aldrich, UK) and incubated overnight at 37-42°C in order to select for 
successful transformants.   
2.2.3.2 Plasmid maxi prep from transformants  
Cells harbouring the plasmid were cultured in LB liquid media (Fisher Scientific, UK) 
supplemented with ampicillin (50 µg/ml).  The mixture was incubated overnight at 37°C with 
agitation.  The cells were harvested using centrifugation at 10,000 g for 15 min.  DNA was 
isolated from the bacterial cells using the Qiagen Spin Maxiprep kit (UK) according to 
manufacturer’s instructions.  DNA from each sample was quantified using a NanoDrop 
spectrophotometer (Fisher Scientific, UK). 
2.2.3.3 Transfection  
2.2.3.3.1 Transient transfection of siRNA or miRNA in cells 
Cells were seeded in 6-well plates in DMEM containing 10% (v/v) FBS and were left to adhere 
overnight at 37°C and 5% (v/v) CO2.  The following day cells at approximately 60% confluency 
were transfected using Oligofectamine reagent (Invitrogen, UK).  10 µl Oligofectamine was 
added to Opti-MEM medium (Invitrogen, UK) to a final volume of 50 µl.  This mixture was 
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added to siRNA targeted to ADAM17, microRNA (miR)-145, a negative siRNA control or a 
negative miRNA control (Applied Biosystems) prepared to a final concentration of 50 nM in 50 
µl Opti-MEM.  The Oligofectamine and siRNA or miRNA mixture was left to incubate at room 
temperature for 30 min before addition to NOFs.  Prior to transfection, NOFs were washed 
twice in 1 ml volumes of Opti-MEM medium.  The transfection mixture was added to the 
washed NOFs and left for 4 h at 37°C and 5 % (v/v) CO2.   500 µl of Opti-MEM was added to the 
cells and they were incubated for 24 h and media and cells collected for further 
experimentation and/or analysis, as described below. 
2.2.3.3.2 Transient transfection of plasmid in cells 
Cells were seeded in 6-well plates in DMEM containing 10% (v/v) FBS and were left to adhere 
overnight at 37°C and 5% (v/v) CO2.  The following day cells at approximately 60% confluency 
were transfected using FuGENE 6 transfection reagent (Promega, UK).    3 µl FuGENE 6 was 
added to Opti-MEM medium to a final volume of 50 µl.  This mixture was added to DNA which 
had been prepared to a final concentration of 1 μg in 50 µl in Opti-MEM medium (a 3:1 ratio of 
FuGENE 6:DNA).  The FuGENE 6 and DNA mixture was left to incubate at room temperature for 
20 min before its addition to the SCC4 cells or NOFs.  Prior to transfection, SCC4 cells or NOFs 
were washed twice in 1 ml volumes of Opti-MEM medium.  The transfection mixture was 
added to the washed cells and left for 4 h at 37°C and 5% (v/v) CO2.   500 µl of Opti-MEM was 
added to the cells and they were incubated for 24 h and media and cells collected for further 
experimentation and/or analysis, as described below. 
2.2.3.4 RNA isolation and quantitative real-time PCR 
Total RNA was isolated from cell lines, and primary NOKs and primary NOFs using the RNeasy 
mini kit (Qiagen, UK) according to the manufacturer’s instructions.  RNA from each sample was 
quantified using a NanoDrop spectrophotometer (Fisher Scientific).  High Capacity cDNA 
Reverse Transcription kit (Applied Biosystems) was used for synthesis of cDNA according to the 
manufacturer’s instructions.  The following RT-PCR programme was used for total RNA for 
SYBR green analysis: 25°C for 10 min, 37°C for 120 min, 90°C for 5 min.  The following RT-PCR 
programme was used on RNA for miRNA analysis: 16°C for 30 min, 42°C for 30 min, 85°C for 5 
min.  A 2720 Thermal Cycler from Applied Biosytems was used to conduct the cDNA synthesis.  
cDNA was subsequently analysed by SYBR green qPCR or Taqman qPCR using a Step One real-
time PCR system thermal cycling block (Applied Biosystems).  The Standard Thermal Cycle 
protocol was used.  The cycling parameters were 40 cycles with each cycle being comprised of 
heating to 50°C for 2 min, 95°C for 10 min, 95°C for 15 sec and 60°C for 1 min. 
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For primer sequences used for SYBR green quantification please see Table 2.1. Taqman probes 
for ADAM17, ACE2, miR-145 and β2microglobulin were obtained from Applied Biosystems. All 
values were normalised to U6, a small nuclear ribonucleoprotein, (SYBR) or β2microglobulin 
(Taqman) expression levels and the relative expression of each transcript was calculated using 
the ΔΔCT method (Livak and Schmittgen, 2001).  Where indicated, amplicons were also 
analysed by agarose gel electrophoresis (as described in Section 2.2.3.5) and visualised with 
ethidium bromide under UV transillumination.  
2.2.3.5 Agarose gel electrophoresis 
Samples were separated by electrophoresis on a 1.5% (w/v) agarose gel in 1 X TAE (40 mM 
Tris-acetate, 1 mM EDTA, pH 8.0) containing ethidium bromide to a final concentration of 5 
μg/ml.  Samples were loaded in gel-loading buffer (0.25% (w/v) bromophenol blue, 40% (w/v) 
sucrose in H20) and electrophoresed in 1 X TAE at 100 V.  Bands were visualised under UV 
transillumination and HyperLadder I (Bioline, UK) was used as a molecular weight standard. 
2.2.4 Cell migration assay 
Migration was monitored using Transwell Permeable Supports with a PET track etched 
membrane containing 8 µm pores (Corning, UK).  SCC4 or H357 at 90% confluency were serum 
starved for 24 h prior to experimentation.  Cells were trypsinised and resuspended in serum 
free DMEM.  Cells were pelleted at 200 g for 5 min and resuspended in DMEM containing 0.1% 
(w/v) BSA at 5x105 cells/ml.  Cells were either left untreated or were treated with ET-1 (10 nM), 
BK (1 µM), EGF (48.4 μM), Ang II (100 nM) and/or Ang 1-7 (100 nM) and 200 µl cell suspension 
was added to the top of the Transwell insert.   
The EGFR antagonist (AG 1478, 125 nM), AT1R antagonist (Telmisartan, 1 µM), AT2R antagonist 
(PD123319, 1 µM), MasR antagonist (A-779, 1 µM), ECE-1 inhibitor (SM-19712, 10 µM), non-
specific COX inhibitor (Ibuprofen, 100 µM) or specific COX-2 specific inhibitor (Celecoxib, 50 
µM) were incubated with the SCC4 cell suspension for 30 min at 37°C and 5% (v/v) CO2 before 
the addition of the SCC4 cell suspension to the Transwell insert.  500 µl of DMEM containing 
conditioned media collected from NOFs pre-treated for 30 min with ETAR antagonist (BQ-123, 
1 µM) and/or ETBR antagonist (BQ-788, 1 µM), AT1R antagonist (Telmisartan, 1 µM), AT2R 
antagonist (PD123319, 1 µM), MasR antagonist (A-779, 1 µM), MMP/ADAMs inhibitor 
(GM6001, 10 µM), ECE-1 inhibitor (SM-19712, 10 µM) before the addition of ET-1 (0-100 nM), 
BK (1 µM), Ang 1-7 (100 nM) and/or Ang II (0-1000 nM) or TGF-β (2-20 ng/ml) for 4-48 h at 
37°C and 5% (v/v) CO2 (as described in individual figure legends) or DMEM containing 10% 
(v/v) FBS was added to the bottom well of the Transwell chamber to act as an attractant.  The 
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EGFR inhibitor was also added to the media collected from the NOFs before it was added to 
the bottom of the Transwell chamber.  
Migration assays were left for 16 h at 37°C and 5% (v/v) CO2. After the incubation period, cells 
were swabbed away from the inside of the migration insert and media was removed by 
suction from the bottom of the Transwell chamber. Cells adhering to the underside of the 
insert were fixed for 10 min in 500 µl 100% (v/v) methanol, added to the top and bottom of 
the chamber.  Cells were washed in 500 µl volumes of PBS and were stained with 500 µl 
volumes of 0.1% (w/v) crystal violet for 20 min.  Cells were washed and left in PBS and 
enumerated by light microscopy at 40x magnification.  Three fields of view from each insert 
were counted and an average taken. 
2.2.5 Cell invasion assay 
Invasion was monitored using Transwell Permeable Supports (Corning, UK) containing 100 µl of 
growth factor-depleted Matrigel (BD Biosciences) diluted 1:45 in serum free DMEM (Lang et al, 
2000).  Invasion assays were prepared 24 h prior to experimentation and left overnight at 37°C 
and 5% (v/v) CO2 to allow the Matrigel to set.   
SCC4 or H357 at 90% confluency were serum starved for 24 h prior to experimentation.  Cells 
were trypsinised and resuspended in serum free DMEM.  Cells were pelleted at 200 g for 5 min 
and resuspended in DMEM containing 0.1% (v/w) BSA at 5x105 cells/ml.  Cells were either left 
untreated or were treated with ET-1 (10 nM), Ang II (100 nM) and/or Ang 1-7 (100 nM) and 
200 µl cell suspension was added to the top of the Transwell chamber.  The Matrigel was not 
removed from the wells before the cells were added.  500 µl of DMEM containing conditioned 
media collected from NOFs pre-treated for 30 min with ETAR antagonist (BQ-123, 1 µM) and/or 
ETBR antagonist (BQ-788, 1 µM) or AT1R antagonist (Telmisartan, 1 µM) before further 
treatment with ET-1 (10 nM), BK (1 µM), Ang 1-7 (100 nM) and/or Ang II (100 nM) for 4-48 h at 
37°C and 5% (v/v) CO2 (as described in individual figure legends) or DMEM containing 10% 
(v/v) FBS was added to the bottom well of the Transwell chamber to act as an attractant.  
Invasion assays were left for 40 h at 37°C and 5% (v/v) CO2. After the incubation period, cells 
and Matrigel were swabbed away from the inside of the invasion insert and media was 
removed by suction from the bottom of the Transwell chamber. Cells adhering to the 
underside of the insert were fixed for 10 min in 500 μl 100% (v/v) methanol, added to the top 
and bottom of the chamber.  Cells were washed in 500 µl PBS and were stained with 500 µl 
0.1% (w/v) crystal violet for 20 min.  Cells were washed and left in PBS and enumerated by 
Materials and Methods  Chapter 2 
58 
 
light microscopy at 40x magnification.  Three fields of view from each insert were counted and 
an average taken. 
2.2.6 Cell proliferation assay 
Proliferation assays were carried out in 96-well plates.  NOFs were trypsinised, resuspended in 
DMEM containing 10% (v/v) FBS, counted and seeded at 2,000 cells/well.  Cells were left to 
adhere overnight at 37°C and 5% (v/v) CO2. 
The following day media was removed and wells were washed in 100 µl PBS.  Cells were 
incubated with an ETAR antagonist (BQ-123, 1 µM) and/or an ETBR antagonist (BQ-788, 1 µM) 
or a water control in 500 µl of serum free DMEM for 30 min before the addition of ET-1 (10 
nM).  At each time point 20 µl of MTS reagent (Promega, UK) was added to each well and the 
plate was incubated for 1 h at 37°C and 5% (v/v) CO2.  A fluorescence reading was recorded at 
492 nm using a fluorescence spectrophotometer (Tecan).   
2.2.7 Gel contraction assay  
Fibroblast:collagen lattices were made in 24-well plates.  NOFs (250,000/well) were 
resuspended in DMEM containing 10% (v/v) FBS and were mixed with rat-tail collagen (7.5 
mg/ml) and 10X DMEM.  The pH of the mixture was adjusted to pH 7 using 0.1 M NaOH and to 
a final volume of 300 µl.  300 µl of the fibroblast:collagen mixture was added to each well and 
allowed to incubate for 45 min.  500 µl of DMEM containing 10% (v/v) FBS was then added 
carefully to each well and the lattices were allowed to incubate at 37°C and 5% (v/v) CO2 for 4 
h.  After this time period the media from each well was carefully removed and replaced with 
500 µl serum free media.  The lattices were left to incubate at 37°C and 5% (v/v) CO2 overnight.   
The following day the serum free DMEM media was removed from each well and a scalpel was 
used to carefully detach the collagen lattice from the sides of the well.  Each lattice was 
immediately incubated with an ETAR antagonist (BQ-123, 1 µM), an ETBR antagonist (BQ-788, 1 
µM) or a water control in 500 µl of serum free DMEM for 30 min before the addition of either 
ET-1 (10 nM), Ang II (100 nM), DMEM containing 10% (v/v) FBS, thrombin (0.5 units/ml; Sigma-
Aldrich, UK). 
Each lattice was photographed 30 min after treatment and the distance contracted by each gel 
was measured.  
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2.2.8 Scratch assay 
Scratch assays were carried out in 12-well plates.  NOFs were seeded at 100,000 cells/well in 
DMEM containing 10% (v/v) FBS and were left to adhere overnight at 37°C and 5% (v/v) CO2.  
The following day the media was removed and replaced with serum free DMEM and the cells 
were again left to incubate overnight.   
A horizontal ‘scratch’ was made across each well using the sharp end of a 200 µl pipette tip.  
The media was removed and the cells were washed twice in 1ml volumes of PBS.  Cells were 
incubated with receptor antagonists an ETAR antagonist (BQ-123, 1 µM) and/or an ETBR 
antagonist (BQ-788, 1 µM) or a water control in 500 µl of serum free DMEM for 30 min.  The 
cells were then treated with either ET-1 (10 nM), Ang 1-7 (100 nM) and/or Ang II (100 nM), 
DMEM containing 10% (v/v) FBS, TGF-β (2-20 ng/ml).  Mitomycin C (Sigma-Aldrich, UK) at 1 
µg/ml was also added to each well to prevent cellular proliferation.  Each well was 
photographed at two points along the scratch at 0 h and 24 h.  The cells were allowed to 
incubate at 37°C and 5% (v/v) CO2 between time points.  The distance between each edge of 
the scratch was measured in order to determine the distance migrated by the NOFs. 
2.2.9 Protein analysis 
2.2.9.1 Preparation of cell lysates 
Cells were washed twice in PBS before being trypsinised and resuspended in DMEM containing 
10% (v/v) FBS.  Cells were pelleted in a centrifuge at 2000 g for 5 min.  The supernatant was 
discarded and the pellet was re-suspended in PBS and repelleted by centrifugation.  The 
supernatant was again discarded.  Pellets were resuspended in varying volumes of lysis buffer 
containing RIPA buffer (10X) (Cell Signaling Technology, Inc) containing Complete Mini 
Protease Inhibitor Cocktail (Roche (Fisher Scientific, UK); used according to manufacturer’s 
instructions) and Benzonase (Sigma-Aldrich, UK; used according to manufacturer’s 
instructions).  Samples were left on ice for 30 min and then centrifuged at 13000 g for 2 min 
before the supernatant was removed and collected and the pellet was discarded.     
2.2.9.2 Protein concentration assay 
Protein concentration was determined BCA Protein Assay Kit (Fisher Scientific; used according 
to manufacturer’s instructions) with bovine serum albumin (BSA; 1 mg/ml) acting as a standard 
(Laemmli, 1970). 
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2.2.10 SDS-PAGE and western blotting 
2.2.10.1 Preparation of samples 
Total protein extracts (50 µg) were run in each well.  LDS sample buffer (4X, Invitrogen, UK) 
and reducing agent (10X, Invitrogen, UK) were both added to each sample before it was placed 
on a heating block at 100°C for 10 min.  The sample was pulsed in a microcentrifuge. 
2.2.10.2 Gel electrophoresis 
Proteins were resolved by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) using 3-8% (v/v) polyacrylamide Tris-Acetate gels (Invitrogen, UK) or 4-12% (v/v) 
polyacrylamide Bis-Tris gels (Invitrogen, UK). Tris-Acetate gels were washed in Tris-Acetate SDS 
Running Buffer (20X, Invitrogen, UK) and Bis-Tris gels were washed in MES SDS Running Buffer 
(20X, Invitrogen, UK). Both buffers contained NuPAGE antioxidant (Invitrogen, UK; used 
according to manufacturer’s instructions). Gels were placed in an Invitrogen Mini Cell and 
protein samples were loaded to the correct well.  The centre chamber of the cell and the 
outside of the cell were filled with Tris-Acetate SDS Running Buffer 20X or MES SDS Running 
Buffer containing NuPAGE antioxidant.  Tris-Acetate gels were run for 1 h at 150 V and Bis-Tris 
gels were run for 35 min at 200 V. 
2.2.10.3 Electrotransfer: 
Sponge pads, a nitrocellulose membrane and filter paper were soaked in NuPAGE Transfer 
Buffer (Invitrogen, UK) containing 10% (v/v) methanol per gel beforehand.  For the 
electrotransfer of each gel, sponge pads were placed into the cassette followed by a piece of 
filter paper, Whatman Optitran reinforced nitrocellulose membrane (Sigma-Aldrich, UK), the 
gel and another piece of filter paper followed by more pads.  Each gel was transferred for 1 h 
at 30 V. 
2.2.10.4 Immunodetection 
Nitrocellulose membranes were non-specifically blocked using tris-buffered saline (10 mM 
Tris-HCl, pH 7.4) containing 0.5% (v/v) Tween 20 (TBS-T) with 5% (w/v) milk powder (Marvel, 
UK) and 3% (w/v) BSA (Sigma-Aldrich, UK) for 1 h at room temperature on a rocking platform. 
Membranes were incubated with the necessary primary antibody (β-actin (1:4,000), α-SMA 
(1:1,000), ECE-1 (1:500)) for 1-3 h at room temperature or overnight at 4°C on a rocking 
platform.  Nitrocellulose membranes were washed three times in TBS-T at 10 min intervals.  
The membrane was incubated with anti-mouse, anti-rabbit or anti-goat IgG horseradish 
peroxidase secondary antibody at 1:2,000 for 1 h at room temperature on a rotating surface.  
The nitrocellulose membrane was then washed three times in TBS-T at 15 min intervals.  
Materials and Methods  Chapter 2 
61 
 
2.2.10.5 Development of western blots 
Immunoreactive bands were visualized using enhanced chemiluminescence (ECL, Amersham 
Ltd., Amersham, UK).  Reagents A and B, in a 1:1 ratio, were mixed together and the 
nitrocellulose membrane submerged in the solution for 1 min at room temperature.  Each 
membrane was covered in Saran wrap and developed using CL-XPosure film (Fisher Scientific) 
and Compact X4 automatic processor (Xograph Imaging Systems). 
2.2.10.6 Stripping and reprobing of membranes 
Membranes were routinely stripped and reprobed with β-actin in order to determine loading 
efficiency.  Membranes were incubated with 50 ml stripping buffer (62.5 mM Tris pH 6.7, 2% 
SDS and 100 mM 2-βmecaptoethanol) at 50°C for 30 min.  Membranes were washed four 
times in large volumes of TBS-T at 15 min intervals and subjected to immunoblotting as 
described in Section 1.2.10.3. 
2.2.11 Statistical analyses 
Data are expressed as the mean ± SEM.  Each experiment was carried out in technical repeat 
and where appropriate three different patient samples were used.  Normal distribution of the 
data was assessed using the Sharpio-Wilk test; statistical analyses were made between two 
groups using a parametric Student t-test.  A value of p<0.05 was considered significant. 
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Chapter 3: The effect of mitogenic 
peptides on autocrine signalling in head 
and neck cancer progression 
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3.1 Introduction  
Endothelin-1 (ET-1), bradykinin (BK) and angiotensin II (Ang II) are all examples of small 
regulatory peptides that have been implicated in the progression of a number of malignancies.  
Many of these peptides originate from precursor molecules that have undergone 
posttranslational modifications involving several enzymatic events, resulting in the production 
of a mature peptide (Siegfried et al, 1992).  They often act as ligands for specific G-protein 
coupled receptors (GPCRs) and can signal via an autocrine mechanism in which they act on the 
same cell that they are secreted from.  The activation of specific GPCRs by mitogenic peptides 
can trigger many intracellular signalling pathways.  Alteration of these signalling pathways can 
lead to deregulated cell behaviour and function. 
ET-1 is a mitogenic peptide which acts primarily as a potent endogenous vasoconstrictor 
(Yanagisawa et al, 1988) but also has various other physiological roles including the 
maintenance of basal vascular tone, central respiratory regulation and maintaining renal 
homeostasis.  There are three members of the ET family: ET-1, ET-2 and ET-3.  Each peptide is 
made up of 21 amino acids (Inoue et al, 1989).  ET-1 is the most abundant ET and is the 
product of the cleavage of pre-pro ET-1 to big ET-1 by a furin-like endopeptidase, and then the 
cleavage of big ET-1 to ET-1 by endothelin converting enzyme-1 (ECE-1); a membrane bound 
metalloproteinase (Rubanyi and Polokoff, 1994).  This second proteolytic cleavage by ECE-1 
occurs between the Trp-21-Val/Ile-22 bond.  It is an essential step in the activation of ET-1 
because its precursors have no biological activity (Rubanyi and Polokoff, 1994).  The actions of 
ET-1 are mediated by the binding of the peptide to two GPCRs; ETAR and ETBR (Arai et al, 1990;  
Sakurai et al, 1992).   
ET-1 is produced at elevated levels in cancer cells (Levin, 1995) and various lines of evidence 
suggest that the peptide can play an important role in cancer progression (Nelson and 
Carducci, 2000). The binding of ET-1 to ETAR and/or ETBR in cancer cells by ET-1 results in the 
activation of downstream kinases and the stimulation of cellular signalling and proliferation.  
Kinases including protein kinase C (PKC) and mitogen-activated protein kinase (MAPK), factors 
including epidermal growth factor receptor (EGFR) and insulin-like growth factor-1 (IGF-1) and 
early response genes including c-myc, c-fos and c-jun can all be activated by ET-1 stimulation 
(Battistini et al, 1993;  Bagnato et al, 1997;  Pirtskhalaishvili and Nelson, 2000). GPCR ligands 
can transactivate the EGFR and the ability of gastrin-releasing peptide (GRP) receptor to 
activate the EGFR has been implicated in the modulation of head and neck squamous cell 
carcinoma (HNSCC) growth and invasion (Lui et al, 2003).  The mitogenic peptide is also known 
to stimulate angiogenesis by directly acting as a chemoattractant for endothelial cells and 
vascular smooth muscle cells (Salani et al, 2000) and by indirectly recruiting vascular 
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endothelial growth factor (VEGF) (Spinella et al, 2002).  ET-1 can also promote tumour growth 
by suppressing the apoptosis of cancer cells (Eberl et al, 2000).  ET-1 is also able to promote 
chemotaxis of prostate and ovarian cancer cells (Nelson et al, 1996;  Bagnato et al, 1995).   
Elevated levels of the peptide have been detected in oral specimens and in the saliva of 
patients diagnosed with oral cancer (Pickering et al, 2007).  Pickering et al (2007) also 
identified a link between ET-1 and bone metastasis in HNSCC.  Awano et al (2006) have also 
observed that ET-1 can promote an increase in proliferation of HNSCC cell lines and elevated 
levels of ET-1 have been associated with a poor prognosis (Ishibashi et al, 2003).  ET-1, ECE-1; 
the enzyme responsible for its activation and the receptors it exerts its effects through are 
collectively described as the ET-axis. 
Ang II, like ET-1, is a peptide with mitogenic and angiogenic effects.  In similar fashion to ET-1, 
it is generated by a proteolytic cascade, culminating in its production from angiotensin I (Ang I) 
by angiotensin converting enzyme (ACE), a key step in the renin-angiotensin system (RAS). ACE 
hydrolyses Ang I at the at the Phe-8-His-9 bond in order to produce Ang II.  The RAS is made up 
of a number of different peptides and their specific receptors.  Ang II is the main peptide 
effector of the RAS.  Ang II can exert its effects by binding to two specific GPCRs; AT1R and 
AT2R.  Ang II exerts most of its pathophysiological effects through the AT1R (Fujiyama et al, 
2001;  Shah and Catt, 2003;  Tamarat et al, 2002). 
Evidence suggests that the local RAS may influence tumourigenesis by affecting tissue 
angiogenesis, inflammation, apoptosis and cellular proliferation (Deshayes and Nahmias, 2005;  
Juillerat-Jeanneret et al, 2004;  De Paepe et al, 2001;  Uemura et al, 2003).  The expression of 
different components of the RAS are frequently known to undergo change in cancers in 
comparison to non-malignant tissue.  This is the case in breast, prostate, lung, skin, colon and 
cervical cancers (Deshayes and Nahmias, 2005) and the alterations in expression levels often 
correlate with poor patient outcomes (George et al, 2010).  The expression of the AT1R is 
frequently increased in a number of these malignancies including breast cancer (Ager et al, 
2008).  Components of the RAS system have also been linked with tumour grading however no 
clear correlation has been observed and it very much depends on the tumour type as to how 
the components vary in malignant tissue compared to normal tissue (Louis et al, 2007;  
Sitzmann et al, 1994).  Studies first identified a link between the RAS and tumourigenesis when 
patients who were administered ACE inhibitors as a long term treatment seemed to be 
protected against cancer (George et al, 2010).  Further studies have identified that antagonism 
of the RAS resulted in the suppression of angiogenesis, tumour growth and metastasis (George 
et al, 2010).   
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Figure 3.1  Ang II but not ET-1 stimulates HNSCC cells to migrate:  Migration of SCC4 cells 
when treated with ET-1 (10 nM) or EGF (48.4 μM) (A) and Ang II (100 nM) or EGF (48.4 μM) (B) 
and of another HNSCC cell line H357 when treated with Ang II (C) were assayed using a 2D 
Transwell migration assay.  Briefly, 1x105 serum starved cells treated as above were added to 
the top of the Transwell migration inserts (8 µm pore) in DMEM supplemented with 0.1% (w/v) 
BSA with DMEM containing 10% (v/v) FBS placed at the bottom of the well.  After 16 h, cells 
which migrated to the underside of the Transwell permeable membrane were fixed in 100% 
(v/v) methanol.  Migrated cells were stained using crystal violet (0.1% (w/v)) and counted using 
a light microscope.  Data plotted represent average number of cells which migrated relative to 
untreated control and were calculated from an average of 3 fields of view.  Each data point 
represents an average of at least 3 independent experiments.  Standard error mean (± SEM) 
are indicated.  A two-tailed student t-test was carried out and data deemed statistically 
significant when p<0.05 (*). 
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Nothing is known to date, however, of the effect of ET-1 and Ang II on the chemotaxis and 
invasion of HNSCC cells, key steps in the metastatic cascade. 
3.2 Ang II, but not ET-1, stimulates migration and invasion of HNSCC 
cells 
Here, the ability of the mitogenic peptide ET-1 to promote SCC4 (an epithelial HNSCC cell line 
isolated from the tongue; Table 2.2) cell migration in vitro was investigated.  SCC4 cells which 
had been serum starved for the previous 24 h were treated directly with ET-1, bradykinin (BK) 
or a phosphate buffered saline (PBS) vehicle control and their ability to migrate was assessed 
using a 2D Transwell migration assay.  The Transwell insert used is composed of a permeable 
membrane containing 8 µm pores.  DMEM containing 10% FBS was added to the bottom well 
of the Transwell migration assay, into which the insert sits.  The cells were allowed to migrate 
through the permeable membrane for 16 h.  Having migrated through the pores the cells 
adhere to the underside of the insert.  These migrated cells were fixed, stained counted (as 
previously described in Section 2.2.4).   
The treatment of SCC4 cells with ET-1 resulted in a small increase in cellular migration (1.3-
fold) in comparison to PBS vehicle treated cells (Figure 3.1A).  This increase in SCC4 cell 
migration did not reach statistical significance (p=0.13).  The increase in migration was not to 
the same level as that observed when the cells were treated with BK, another mitogenic 
peptide known to promote HNSCC cell migration via an autocrine mechanism (Thomas et al, 
2006).  BK stimulated SCC4 migration 3-fold in comparison to vehicle treated cells (Figure 
3.1A). 
The ability of Ang II to promote SCC4 cell migration was investigated using the same Transwell 
migration assay described previously.  Treatment of SCC4 cells with Ang II resulted in a 
significant increase of 1.5-fold in cell migration compared to PBS vehicle treated cells (Figure 
3.1B). Treatment of SCC4 cells with EGF, a known stimulant of cancer cell motility via EGFR 
activation (Gullick, 1991), was used as a positive control and resulted in a significantly higher 
increase in migration.  EGF stimulated SCC4 cells to migrate 3.0-fold compared to PBS vehicle 
treated cells.  This increase in HNSCC migration provoked by Ang II was also observed to a 
greater extent when H357 cells (another epithelial HNSCC cell line isolated from the tongue; 
Table 2.2) were treated with the mitogenic peptide (2.0- fold vs. 1.5-fold for H357 and SCC4 
cells, respectively), suggesting that this observation is not cell-line specific (Figure 3.1C). The 
results suggest that Ang II is able to directly stimulate HNSCC migration. 
Having established that Ang II stimulates the ability of HNSCC cells to traverse a synthetic 
basement membrane, its ability to induce their invasion was next investigated.  SCC4 and H357 
Results  Chapter 3 
67 
 
 
 
 
 
Figure 3.2  Ang II stimulates HNSCC cells to invade:  Invasion of SCC4 cells (A) and H357 cells 
(B) when treated with Ang II (100 nM) were assayed using a Matrigel invasion assay.  Matrigel, 
a murine tumour-derived extracellular matrix substitute was, coated onto invasion inserts and 
incubated for 24 h.  Briefly, 1x105 serum starved cells treated as above were added to the top 
of the invasion inserts in DMEM supplemented with 0.1% BSA (w/v) with DMEM containing 
10% (v/v) FBS placed at the bottom of the well.  After 40 h, cells which migrated to the 
underside of the Transwell permeable membrane were fixed in 100% (v/v) methanol.  Invaded 
cells were stained using crystal violet (0.1% (w/v)) and counted using a light microscope.  Data 
plotted represent average number of cells which invaded relative to untreated control and 
were calculated from an average of 3 fields of view.  Each data point represents an average of 
at least 3 independent experiments.  ± SEM are indicated.  A two-tailed student t-test was 
carried out and data deemed statistically significant when p<0.05 (*). 
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cells were treated with Ang II and their ability to invade was assessed using a 2D Matrigel 
invasion assay.  A layer of Matrigel, a murine tumour-derived extracellular matrix substitute, 
was added into the top of the migration insert.  Matrigel is commonly used to measure the 
ability of cells to invade (Lang et al, 2000).  The invasion of cancer cells through the basement 
membrane and the extracellular matrix (ECM) is a critical step in the process of metastasis.  
Matrigel contains a number of ECM components and therefore helps to create an environment 
in vitro more similar to that observed in vivo.  The Matrigel was added to the top of the 
Transwell insert and allowed to set overnight.  The following day SCC4 cells or H357 cells were 
treated with Ang II and were placed into the insert.  After 40 h cells were fixed, stained and 
counted as described in Section 2.2.5.  An increase in cellular invasion was observed in both 
cell lines of a similar magnitude to that observed for migration (1.6-fold increase for both SCC4 
cells and H357 cells) (Figure 3.2A and 3.2B for SCC4 and H357 cells, respectively). 
3.3 Ang II stimulates an increase in HNSCC migration and invasion 
through the AT1R 
The mechanism by which Ang II stimulates HNSCC cells to migrate and invade was next 
examined.  Ang II can exert its effects by binding to two specific GPCRs, AT1R and AT2R.  Ang II 
exerts most of its pathophysiological effects via AT1R, which is expressed on a number of 
different cell types.  These effects include increased cell proliferation, production of growth 
factors and cytokines and increased fibrosis, which can lead to vascular thickening and 
atherosclerosis (Fujiyama et al, 2001;  Shah and Catt, 2003;  Tamarat et al, 2002).  The AT2R is 
mainly expressed during early stages of foetal development, however it is also expressed in the 
adrenal medulla, ovarian follicles and the uterus during an adult’s lifetime (Messerli et al, 
1996;  Touyz et al, 2000;  Velasquez, 1996).  It has been suggested that the receptor can 
antagonise proliferation, angiogenesis and inflammatory responses that are activated via the 
AT1R (Pupilli et al, 1999).   
qPCR was used to determine the expression pattern of both the AT1R (Figure 3.3A) and AT2R 
(Figure 3.3B) in a panel of primary human normal oral keratinocytes (NOKs) and fibroblasts 
(NOFs) and cell lines derived from oral dysplasias, primary HNSCCs and a local metastasis.  The 
expression of AT1R was marked elevated in the primary HNSCC cell lines, which included Cal27s 
(an epithelial HNSCC cell line isolated from the tongue; Table 2.2), H357s, SCC4s and B16s (an 
epithelial HNSCC cell line isolated from the tongue; Table 2.2), in comparison to the NOKs and 
the cell lines D19 and D20, both of which are derived from oral dysplasias and the cell line B22, 
which was isolated from a local metastasis, all of which are described in Table 2.2.  Attempts 
were made to detect AT1R by western blot analysis but were unsuccessful.  There  
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Figure 3.3  AT1R is largely over expressed in HNSCC cell lines:  Primary human normal oral 
keratinocytes (NOKs) and fibroblasts (NOFs) and cell lines derived from oral dysplasias, primary 
HNSCCs and a local metastasis were cultured in growth media and at 90% confluency were 
washed in PBS, trypsinised and pelleted.  Total RNA was extracted from the cell pellets and 100 
ng was subjected to RT-PCR.  0.25 ng cDNA was analysed using qPCR for AT1R (A), AT2R (B) or 
U6 as a reference gene.  Each data point represents an average of 3 technical repeats.  ± SEM 
are indicated. 
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Figure 3.4  Ang II exerts its effects through the AT1R:  To determine which receptor Ang II was 
exerting its effects via, SCC4 cells were pre-treated with a specific receptor antagonist to AT1R, 
telmisartan (100 µM) (A) and a specific receptor antagonist to AT2R, PD123319 (100 µM) (B) 
for 30 min before the addition Ang II (100 nM) and were assayed using a 2D Transwell 
migration assay.  Briefly, 1x105 serum starved cells treated as above were added to the top of 
the Transwell migration inserts in DMEM supplemented with 0.1% BSA (w/v) with DMEM 
containing 10% (v/v) FBS placed at the bottom of the well.  After 16 h, cells which migrated to 
the underside of the Transwell permeable membrane were fixed in 100% (v/v) methanol.  
Migrated cells were stained using crystal violet (0.1% (w/v)) and counted using a light 
microscope.  Data plotted represent average number of cells which migrated relative to 
untreated control and were calculated from an average of 3 fields of view.  Each data point 
represents an average of at least 3 independent experiments.  ± SEM are indicated.  A two-
tailed student t-test was carried out and data deemed statistically significant when p<0.05 (*), 
p < 0.05 relative to Ang II treated cells (**), ns = not significant. 
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was no obvious pattern in the transcript levels of the AT2R within the panel of NOKs and cell 
lines derived from the oral dysplasias, primary HNSCCs and a local metastasis.  There was a 
slight trend towards the down-regulation of AT2R in primary HNSCC cell lines in comparison to 
NOKs and other cell lines.  There was no expression of the AT2R detectable within the NOFs.  
To determine which of these receptors are involved in the autocrine stimulation of HNSCC 
migration and invasion, SCC4 cells were pre-treated with specific receptor antagonists to 
either the AT1R (Figure 3.4A) or the AT2R (Figure 3.4B) for 30 min before the addition of the 
Ang II peptide.  Pre-treatment of SCC4 cells with the AT1R antagonist, telmisartan, blocked 
stimulation of cellular migration induced by Ang II.  Migration was reduced from 1.5-fold in 
comparison to PBS vehicle treatment to 0.8-fold in the presence of the telmisartan.  No 
difference in migration was observed when SCC4 were pre-treated with the AT2R antagonist, 
PD123319, the fold increase remained at 1.6-fold.  This observation suggests that Ang II is 
exerting its effects through AT1R. 
3.4 The over expression of ACE can stimulate HNSCC migration 
ACE is a zinc-metalloproteinase and is responsible for the production of Ang II from the 
biologically inactive precursor Ang I, which is a key step in the proteolytic cascade regulating 
the RAS.  Somatic ACE is expressed on the surface of endothelial and epithelial cells in a wide 
variety of tissues.  qPCR was used to determine the transcript levels of ACE within a panel of 
primary human NOKs and NOFs and cell lines derived from oral dysplasias, primary HNSCCs 
and a local metastasis as described in Table 2.2 (Figure 3.5A).  ACE transcript levels were 
detectable in all primary cells and cell lines.  The enzyme was greatly over expressed in NOFs.  
The effect of over expressing ACE on SCC4 migration was next examined.  SCC4 cells were 
transiently transfected using FuGENE 6 with a pIRES vector containing the somatic ACE coding 
region or a control pcDNA3 vector for 24 h.  After 24 h the transfected cells were trypsinised, 
counted and added to the Transwell insert.  DMEM containing 10% FBS was added to the 
bottom well of the Transwell migration assay, into which the insert was placed.  The cells were 
allowed to migrate through the permeable membrane for 16 h.  Once through the pores the 
cells were fixed, stained and counted as described in Section 2.2.4.  Over expression of ACE 
resulted in an increase in SCC4 migration of 1.5-fold in comparison to cells transfected with a 
control plasmid (Figure 3.5B).  qPCR analysis was conducted on the remaining SCC4 cells to 
determine the expression level of ACE after transfection (Figure 3.5C).  The expression of ACE 
increased 212.0-fold in SCC4 cells after transfection with the pIRES plasmid containing the 
coding region for somatic ACE in comparison to SCC4 cells transfected with the control 
pcDNA3 vector.  
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Figure 3.5  Over expression of ACE in SCC4 cells increases their migration capability:  ACE is a 
zinc-metalloproteinase and is responsible for the production of Ang II from Ang I.  Primary 
human NOKs and NOFs and cell lines derived from oral dysplasias, primary HNSCCs and a local 
metastasis were cultured in growth media and at 90% confluency were washed in PBS, 
trypsinised and pelleted.  Total RNA was extracted from the cell pellets and 100 ng was 
subjected to RT-PCR.  0.25 ng cDNA was analysed using qPCR for ACE (A) or U6 as a reference 
gene.  SCC4 cells were transiently transfected with an ACE vector or control vector for 24 h 
before they were added to the top of the Transwell migration inserts in DMEM supplemented 
with 0.1% (w/v) BSA and DMEM containing 10% (v/v) FBS placed at the bottom of the well.  
After 16 h, cells which migrated to the underside of the Transwell permeable membrane were 
fixed in 100% (v/v) methanol.  Migrated cells were stained using crystal violet (0.1% (w/v)) and 
counted using a light microscope (B).  Transfected SCC4 cells were harvested and RNA 
extracted.  qPCR analysis was used to measure the transcript levels of ACE (C).  Each qPCR data 
point represents an average of 3 technical repeats.  Each data point represents an average of 
at least 3 independent experiments.  ± SEM are indicated.  A two-tailed student t-test was 
carried out and data deemed statistically significant when p<0.05 (*), p<0.05 relative to control 
transfected cells.   
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3.5 Components of the ET-axis can influence HNSCC cell migration in an 
autocrine manner 
Although ET-1 resulted in only a small increase in SCC4 migration (1.3-fold) (Figure 3.1A), 
reports of elevated levels of ET-1 in HNSCC prompted the examination of transcript levels of 
components of the ET axis in cells derived from normal and diseased oral mucosa.  qPCR was 
used to determine the transcript levels of ET-1 within a panel of primary human NOKs and 
NOFs and cell lines derived from oral dysplasias, primary HNSCCs and a local metastasis as 
described in Table 2.2 (Figure 3.6A).  ET-1 transcript was present in all cell types but no 
significant pattern was observed.  ECE-1 converting enzyme is responsible for the catalytic 
activation of ET-1.  ECE-1 cleaves big ET to release biologically active ET-1. Neprilysin (NEP) is 
responsible for the inactivation of a number of physiologically active neuropeptides including 
ET-1, BK, neurotensin, atrial natriuretic factor and substance P (Shipp et al, 1991;  Shipp and 
Look, 1993).  ECE-1 and NEP are both zinc metalloproteases and are members of the M13 
family and share 40% homology with each other (Lambert et al, 2008).  qPCR was again used to 
determine the transcript levels of both ECE-1 (Figure 3.6B) and NEP (Figure 3.6C) in the same 
panel of cells.  ECE-1 was highly expressed in NOFs and all cell lines apart from H357s which 
only showed a slightly greater expression in comparison to NOKs.  NEP was highly expressed in 
NOFs and was down regulated in the primary HNSCC cell lines.  qPCR was used to determine 
the transcript levels of ETAR (Figure 3.7A) and ETBR (Figure 3.7B) within the same cells and cell 
lines.  ETAR transcript levels were highly expressed in NOFs and were present in all other cell 
types.  ETBR transcript was also readily detectable in NOFs and was reduced in HNSCC cell lines 
and the local metastasis, B22.  This is in keeping with previous findings that the receptor is 
reduced in HNSCC cell lines (Okawawa et al, 1998;  Viet et al, 2011).   
3.6 ECE-1 protein expression in cell lines  
As mentioned previously ECE-1 is responsible for the production of biologically active ET-1.  
SDS-PAGE and western blot analysis was used to determine ECE-1 protein expression in the 
panel of primary human NOKs and NOFs and cell lines derived from oral dysplasias, primary 
HNSCCs and a local metastasis described in Table 2.2.  ECE-1 was greatly overexpressed in 
NOFs and in all the cell lines in comparison to NOKs (Figure 3.8), this result was similar to that 
observed for qPCR analysis (Figure 3.6B).    
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Figure 3.6  Components of the ET-axis are present in HSCCC cell lines:  Primary human NOKs 
and NOFs and cell lines derived from oral dysplasias, primary HNSCCs and a local metastasis 
were cultured in growth media and at 90% confluency were washed in PBS, trypsinised and 
pelleted.  Total RNA was prepared from the cell pellets and 100 ng was subjected to RT-PCR.  
0.25 ng cDNA was analysed using qPCR for ET-1 (A), ECE-1 isoforms (B), NEP (C) or U6 as a 
reference gene.  Each data point represents an average of 3 technical repeats.  ± SEM are 
indicated. 
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Figure 3.7  ETAR and ETBR expression:  ET-1 can exert its cellular actions by binding to one, or 
both, of two GPCRs, ETAR and ETBR.  Primary human NOKs and NOFs and cell lines derived 
from oral dysplasias, primary HNSCCs and a local metastasis were cultured in growth media 
and at 90% confluency were washed in PBS, trypsinised and pelleted.  Total RNA was prepared 
from the cell pellets and 100 ng was subjected to RT-PCR.  0.25 ng cDNA was analysed using 
qPCR for ETAR (A), ETBR (B) or U6 as a reference gene.  Each data point represents an average 
of 3 technical repeats.  ± SEM are indicated. 
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Figure 3.8  ECE-1 protein expression:  Total protein was extracted from a panel of primary 
human NOKs and NOFs and cell lines derived from primary HNSCCs, oral dysplasias and a local 
metastasis and 50 μg separated by SDS-PAGE and immunoblotted for ECE-1.  A representative 
blot is shown (A). 
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3.7 The over expression of ECE-1c can stimulate HNSCC migration 
ECE-1 has four distinct isoforms:  ECE-1a, ECE-1b, ECE-1c and ECE-1d.  All four isoforms are 
derived from a single gene using alternative promoter regions.  ECE-1a and ECE-1c are both 
localised at the cell surface and ECE-1b and ECE-1d are found within intracellular 
compartments.  Each isoform has a different N-terminal cytoplasmic region and it is this 
characteristic that is responsible for the targeting of each isoform to its correct cellular 
location (Muller et al, 2003).  ECE-1c is the most abundant ECE-1 isoform and its expression is 
elevated significantly in a number of tumours including prostate (Muller et al, 2003).  SCC4 
cells were transiently transfected using FuGENE 6 with a pcDNA3 vector containing the ECE-1c 
coding region or a control pcDNA3 vector for 24 h.  After 24 h cells were trypsinised, counted 
and added to the Transwell insert.  DMEM containing 10% FBS was added to the bottom well 
of Transwell migration assay, into which the insert sits.  The cells were allowed to migrate 
through the permeable membrane for 16 h.  The cells were fixed, stained and counted as 
described in Section 2.2.4 (Figure 3.9A).  Over expression of ECE-1c resulted in a 1.4-fold 
increase in SCC4 migration in comparison to cells transfected with the control pcDNA3 vector.  
qPCR analysis was conducted on the remaining SCC4 cells to determine ECE-1 expression and 
therefore transfection efficiency (Figure 3.9B).  The expression of ECE-1 increased 9-fold in 
SCC4 cells after transfection with the pcDNA3 vector containing the ECE-1c coding region in 
comparison to SCC4 cells transfected with the control pcDNA3 vector. 
3.8 Inhibition of ECE-1 does not reduce HNSCC migration  
A broad range inhibitor to all four ECE-1 enzyme isoforms was used to determine if inhibiting 
the enzyme could reduce SCC4 cellular migration.  SCC4 cells were treated with SM-19712 
before their addition to the Transwell insert.  The presence of the inhibitor did not reduce 
SCC4 migration. 
3.9 Summary  
In this chapter the ability of ET-1 and Ang II to promote HNSCC migration via an autocrine 
mechanism was investigated.  Although ET-1 treatment of HNSCC cells resulted in a small 
increase in migration, this was not deemed statistically significant.  However recent studies 
have observed elevated levels of the mitogenic peptide in HNSCC cell lines and oral specimens 
(Awano et al, 2006;  Pickering et al, 2007) and it was therefore deemed necessary to 
determine the transcript levels of components of the ET-axis within a panel of primary cells 
and cell lines.  Notably ECE-1, the enzyme responsible for the activation of biologically active 
ET-1 was over expressed in nearly all the cell lines.  The transient transfection of a pcDNA3  
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Figure 3.9  Over expression of ECE-1c in SCC4 cells increases their migration capability:  ECE-1 
is a membrane bound metalloproteinase and is responsible for the proteolytic cleavage of big 
ET-1 to ET-1 between Trp-21-Val/Ile-22 bond.  This event results in biologically active ET-1.  
ECE-1 has four distinct isoforms:  ECE-1a, ECE-1b, ECE-1c and ECE-1d.  The expression of ECE-1c 
is elevated in a number of tumours including prostate cancer (Muller et al, 2003).  SCC4 cells 
were transiently transfected with a pcDNA3 vector containing the ECE-1c coding region or 
control pcDNA3 vector for 24 h before they were added to the top of the Transwell migration 
inserts in DMEM supplemented with 0.1% (w/v) BSA and DMEM containing 10% (v/v) FBS 
placed at the bottom of the well.  After 16 h, cells which migrated to the underside of the 
Transwell permeable membrane were fixed in 100% (v/v) methanol.  Migrated cells were 
stained using crystal violet (0.1% (w/v)) and counted using a light microscope (A).  Transfected 
SCC4 cells were harvested and RNA extracted.  qPCR analysis was used to measure the 
transcript levels of ECE-1c (B).  Each data point represents an average of at least 3 independent 
experiments.  ± SEM are indicated.  A two-tailed student t-test was carried out and data 
deemed statistically significant when p<0.05 (*), p<0.05 relative to control transfected cells.  
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Figure 3.10  ECE-1 inhibition does not block SCC4 migration:  ECE-1 is known to cleave 
biologically active ET-1 from big ET-1.  SCC4 cells were treated with an ECE-1 inhibitor, SM-
19712 (10 μM) (A) before they were added to the top of the Transwell migration inserts in 
DMEM supplemented with 0.1% (w/v) BSA and DMEM containing 10% (v/v) FBS placed in the 
bottom of the well.  After 16 h, cells which migrated to the underside of the Transwell 
permeable membrane were fixed in 100% (v/v) methanol.  Migrated cells were stained using 
crystal violet (0.1% (w/v)) and counted using a light microscope.  Each data point represents an 
average of at least 3 independent experiments.  ± SEM are indicated.  A two-tailed student t-
test was carried out and data deemed statistically significant when p<0.05 (*), ns = not 
significant. 
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vector containing the ECE-1c coding region into SCC4 resulted in a significant increase in their 
migration.  The previous findings in this chapter suggest that the production of ET-1 by ECE-1 is 
not responsible for this increase in HNSCC migration.  ECE-1 is known to hydrolyse and affect 
the activity of other peptides which could explain the increase in HNSCC migration.   
Ang II unlike ET-1 can stimulate HNSCC migration and invasion via an autocrine mechanism.  
This chapter has identified that Ang II in this case exerts its effects through the AT1R which is 
largely over expressed in primary HNSCC cell lines, implicating the receptor as a valuable 
diagnostic tool or possible therapeutic target in the treatment of HNSCC.  When SCC4 cells 
were transfected with a pIRES vector containing the coding region for somatic ACE, their ability 
to migrate increased.  This increase in HNSCC migration was to a similar extent as that 
observed when the cells were treated directly with the peptide therefore suggesting that the 
over expression of the ACE enzyme results in the production of more Ang II which can act on 
the SCC4 cells in an autocrine fashion stimulating their migration.   
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Chapter 4: The effect of mitogenic 
peptides on paracrine signalling in head 
and neck cancer progression 
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4.1 Introduction  
It is becoming increasingly apparent that the development and progression of epithelial 
tumours is profoundly influenced by the surrounding microenvironment, which is also known 
as the reactive stroma.  The tumour microenvironment consists of a number of different 
cellular components including fibroblasts, blood vessels and lymphatics, extracellular matrix 
(ECM) components and immune and inflammatory cells. Any or all of these stromal 
components can interact and communicate with cancer cells and influence their behaviour.  
Communication can also occur between different cells and cell types found within the reactive 
stroma.   
Studies have identified that endothelin-1 (ET-1) can be produced by a number of epithelial 
tumours including those of the pancreas, breast, lung, prostate, colon and endometrium 
(Bagnato and Catt, 1998).  The peptide is also produced by a number of cancer cell lines 
cultured in vitro.  These cell lines include those isolated from carcinomas of the stomach, 
prostate, breast and colon (Bagnato and Catt, 1998).  Lambert et al (2008) have identified that 
elevated levels of ET-1 are associated with metastatic prostate cancer and have been 
implicated in the cross talk that occurs between tumour and stromal cells.  This cellular 
communication promotes autocrine and paracrine signalling between the different cell types 
resulting in an increase in tumour growth.  Deregulation of the renin angiotensin system (RAS), 
including an increase in angiotensin II (Ang II) production has been identified in malignant 
tissue and also within the surrounding tumour microenvironment (George et al, 2010).  The 
RAS in the reactive stroma has been associated with an increase in vascular endothelial growth 
factor (VEGF) production and therefore increased angiogenesis (George et al, 2010). 
Both lines of evidence highlight that increased levels of mitogenic peptides can be found 
within the microenvironment.  The role that mitogenic peptides, including ET-1 and Ang II, play 
within this environment and the effect that they have on the components found within it are 
not fully elucidated.  Fibroblasts are the most numerous cell type found within the reactive 
stroma and those found within this tumour microenvironment frequently undergo changes in 
their phenotype.  It was therefore decided to examine the role of primary normal oral 
fibroblasts (NOFs) in mediating the effects of ET-1 and Ang II on head and neck squamous cell 
carcinoma (HNSCC) behaviour.   
4.2 NOFs potentiate the effect of ET-1 and Ang II on HNSCC motility 
In order to investigate the effect of the presence of NOFs on HNSCC migration, NOFs were 
seeded into the bottom of a 2D Transwell migration assay.  SCC4 cells and the seeded cells 
were treated with ET-1 and the ability of the SCC4 cells to migrate was assessed in the 
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Figure 4.1  NOFs potentiate the effect of ET-1 on HNSCC migration:  The tumour 
microenvironment plays a role in the progression of epithelial tumours.  To create an 
environment more similar to that observed in vivo, NOFs were seeded into the bottom 
Transwell migration well.  1x105 serum starved SCC4 cells were treated with ET-1 (10 nM) or 
BK (1 μM) and added to the top of the Transwell migration inserts (8 µm pore) in DMEM 
supplemented with 0.1% (w/v) BSA (A).  The presence of the NOFs within the assay 
potentiated the effect of ET-1 on SCC4 cell migration.  To determine the signalling mechanism 
involved in this paracrine activation, NOFs were treated with ET-1 (0 – 100 nM) for 4 h before 
the media was aspirated, filtered and added to the bottom Transwell migration well.  1x105 
serum starved SCC4 cells were left untreated and added to the top of the Transwell migration 
inserts in DMEM supplemented with 0.1% BSA (B).  NOFs were treated with the optimal 
concentration of ET-1, 10 nM and the conditioned media was added to the bottom Transwell 
migration well.  1x105 serum starved H357 cells were left untreated and added to the top of 
the Transwell migration inserts in DMEM supplemented with 0.1% BSA (w/v) (C).  After 16 h, 
cells which migrated to the underside of the Transwell permeable membrane were fixed in 
100% (v/v) methanol.  Migrated cells were stained using crystal violet (0.1% (w/v))  and 
counted using a light microscope.  Data plotted represent average number of cells which 
migrated relative to untreated control and were calculated from an average of 3 fields of view.  
Each data point represents an average of at least 3 independent experiments.  Standard error 
mean (± SEM) are indicated.  A two-tailed student t-test was carried out and data deemed 
statistically significant when p<0.05 (*).  
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Figure 4.2  ET-1 does not act as a chemoattractant for HNSCC cells:  To investigate the 
paracrine effect of ET-1 on HNSCC cell migration, ET-1 (10 nM) in serum free media was added 
to the bottom Transwell migration well.  1x105 serum starved SCC4 cells (A) or H357 cells (B) 
were left untreated and added to the top of the Transwell migration inserts in DMEM 
supplemented with 0.1% (w/v) BSA.  After 16 h, cells which migrated to the underside of the 
Transwell permeable membrane were fixed in 100% (v/v) methanol.  Migrated cells were 
stained using crystal violet (0.1% (w/v)) and counted using a light microscope.  Data plotted 
represent average number of cells which migrated relative to untreated control and were 
calculated from an average of 3 fields of view.  Each data point represents an average of at 
least 3 independent experiments.  ± SEM are indicated.  A two-tailed student t-test was carried 
out and data deemed statistically significant when p<0.05 (*). 
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presence of the NOFs.  The presence of NOFs dramatically enhanced the effect of ET-1 on SCC4 
cellular migration (3.0- vs. 1.3-fold in the presence and absence of NOFs, respectively; Figure 
4.1A and Figure 3.1A).  The presence of NOFs within the 2D migration model imitates an 
environment more similar to that that would be observed in vivo.  In contrast, inclusion of 
NOFs had little effect on the stimulation of SCC4 migration by bradykinin (BK) (3.8- vs. 3.3-fold 
in presence and absence of NOFs, respectively; Figure 4.1A and Figure 3.1A), suggesting BK 
acts in an autocrine manner, in keeping with previous observations (Thomas et al, 2006). 
The presence of the NOFs within the migration assay potentiates the effects of ET-1 on HNSCC 
migration suggesting that the presence of the NOFs results in an increased release of soluble 
factors from the cells which could contribute to the ET-1-mediated stimulation of SCC4 cell 
migration.  To determine the mechanisms involved in the paracrine activation of NOFs a 
system was designed in order to probe the signalling pathways concerned.  NOFs were treated 
with varying concentrations of ET-1 (0-100 nm) for 4 h before the media was removed, filtered 
and added to the bottom of the Transwell migration assay. Serum starved SCC4 cells were left 
untreated and added to the migration insert.  The cells were allowed to migrate for 16 h and 
were fixed, stained and counted using the same methods described previously (Section 2.2.4) 
(Figure 4.1B).  The conditioned media collected from the NOFs stimulated SCC4 migration in a 
dose responsive manner.  0.1 nM ET-1 treatment resulted in a 1.5-fold increase in SCC4 
migration, 1 nM ET-1 stimulated a greater increase of 2.5-fold.  10 nM ET-1 stimulated the 
optimal increase of 3.5-fold.  100 nM ET-1 treatment did not further increase SCC4 migration 
and instead migration decreased to only 2.4-fold.  These observations suggest that ET-1 may 
saturate its receptor (s) on the surface of the NOFs at concentrations above 10 nM (Ferguson, 
2001).  The dose response observed suggests that soluble factors released by the NOFs into 
the surrounding media as a result of ET-1 stimulation are responsible for the paracrine 
activation of SCC4 cells.  To determine if this paracrine effect was a general HNSCC 
phenomenon, rather than cell line specific, NOFs were treated with the optimal concentration 
of ET-1, 10 nM for 4 h.  Instead of using SCC4 cells, serum starved H357 cells were left 
untreated and placed into the Transwell insert.  An increase in migration of 5.0-fold was 
observed for the H357 cells suggesting that this observation is not cell-line specific (Figure 
4.1C).  The presence of 10 nM ET-1 alone, in the bottom of the Transwell migration assay, had 
no significant effect on HNSCC migration in the absence of NOFs (Figure 4.2A and 4.2B). 
Unlike ET-1, Ang II is able to stimulate HNSCC cell migration and invasion via an autocrine 
mechanism (Section 3.2).  Transwell migration assays were used to determine if Ang II can also 
stimulate SCC4 and H357 cells via a paracrine mechanism, similar to that observed for ET-1.   
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Figure 4.3  NOFs potentiate the effect of Ang II on HNSCC migration:  To investigate the effect 
of NOFs on HNSCC cell migration, NOFs were treated with Ang II (0 – 1000 nM) for 4 h before 
the media was aspirated, filtered and added to the bottom Transwell migration well.  1x105 
serum starved SCC4 cells were left untreated and added to the top of the Transwell migration 
inserts in DMEM supplemented with 0.1% (w/v) BSA (A).  NOFs were treated with the optimal 
concentration of Ang II, 100 nm and the conditioned media was added to the bottom 
Transwell migration well.  1x105 serum starved H357 cells were left untreated and added to 
the top of the Transwell migration inserts in DMEM supplemented with 0.1% (w/v) BSA (B).  
After 16 h, cells which migrated to the underside of the Transwell permeable membrane were 
fixed in 100% (v/v) methanol.  Migrated cells were stained using crystal violet (0.1% (w/v)) and 
counted using a light microscope.  Data plotted represent average number of cells which 
migrated relative to untreated control and were calculated from an average of 3 fields of view.  
Each data point represents an average of at least 3 independent experiments.  ± SEM are 
indicated.  A two-tailed student t-test was carried out and data deemed statistically significant 
when p<0.05 (*). 
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Figure 4.4  Ang II alone does not stimulate HNSCC cell line migration via a paracrine 
mechanism:  To investigate the paracrine effect of Ang II on HNSCC cell migration, Ang II (100 
nM) in serum free media was added to the bottom Transwell migration well.  1x105 serum 
starved SCC4 cells (A) or H357 cells (B) were left untreated and added to the top of the 
Transwell migration inserts in DMEM supplemented with 0.1% (w/v) BSA (A).  After 16 h, cells 
which migrated to the underside of the Transwell permeable membrane were fixed in 100% 
(v/v) methanol.  Migrated cells were stained using crystal violet (0.1% (w/v)) and counted using 
a light microscope.  Data plotted represent average number of cells which migrated relative to 
untreated control and were calculated from an average of 3 fields of view.  Each data point 
represents an average of at least 3 independent experiments.  ± SEM are indicated.  A two-
tailed student t-test was carried out and data deemed statistically significant when p<0.05 (*). 
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NOFs were treated with varying concentrations of Ang II (0-1000 nM) for 4 h and the 
conditioned media collected was added to the bottom of the Transwell migration well.  The 
effect on SCC4 migration was observed.  The conditioned media collected from the NOFs 
stimulated SCC4 migration in a dose responsive manner (Figure 4.3A).  1 nM Ang II treatment 
resulted in a 1.3-fold increase in SCC4 migration, 10 nM Ang II stimulated a higher fold increase 
of 2.0.  100 nM Ang II stimulated the optimal increase of 3.5-fold.  1000 nM Ang II treatment 
did not further increase SCC4 migration and instead migration decreased to only 2.0-fold.  
These observations suggest that Ang II may saturate its receptor (s) on the surface of NOFs at 
concentrations above 100 nM (Ferguson, 2001).  Again, the presence of NOFs dramatically 
enhanced the effect of the Ang II on SCC4 cellular migration (3.5- vs. 1.5-fold in the presence 
and absence of NOFs, respectively; Figure 4.3A and Figure 3.1B).  The results indicate that Ang 
II does stimulate the release of soluble factors from NOFs into the surrounding environment 
and that these can trigger pro-migratory paracrine signalling between the NOFs and cancer 
cells, a similar mechanism to that triggered by ET-1 stimulation.  It was next determined if the 
effect observed on SCC4 cells was cell line specific, or would also be seen in other HNSCC-
derived cells.  NOFs were treated with 100 nM Ang II for 4 h before the media was aspirated, 
filtered and added to the Transwell migration well.  Serum starved H357 cells were left 
untreated before they were added to the Transwell insert and allowed to migrate (Figure 
4.3B).  The presence of the conditioned media resulted in a fold increase of 3.0- in comparison 
to NOFs incubated with PBS alone.  Therefore it was apparent that the migration of HNSCC 
cells was dramatically enhanced in the presence of NOF conditioned media (3.5- vs. 1.5-fold in 
the presence and absence of conditioned media, respectively, for SCC4 and 3.0- vs. 1.8-fold in 
the presence and absence of conditioned media, respectively, for H357).  The presence of Ang 
II alone, in the lower chamber of the Transwell migration assay, resulted in a small but 
insignificant increase in HNSCC migration and invasion in the absence of NOFs (Figure 4.4A and 
4.4B). 
4.3 NOFs potentiate the effect of ET-1 and Ang II on HNSCC invasion 
Having demonstrated that both ET-1 and Ang II can promote HNSCC cell migration via the 
activation of paracrine signalling mechanisms between cancer cells and stromal NOFs, the 
effect of conditioned media on cellular invasion was investigated.  The ability of ET-1 to 
promote SCC4 invasion via a similar paracrine mechanism to that observed for HNSCC 
migration was investigated.  Matrigel is a murine-derived ECM substitute that is commonly 
used to measure the ability of cells to invade.  The ability of cancer cells to invade into and 
through the ECM is crucial in the metastasis process.  Matrigel was diluted 1:45 (v/v) in serum 
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Figure 4.5  NOFs potentiate the effect of ET-1 on HNSCC invasion:  The effect of NOFs on SCC4 
cell invasion was investigated. Matrigel, a murine tumour-derived extracellular matrix 
substitute was coated onto invasion inserts and incubated for 24 h. Conditioned media 
collected from NOFs treated with 10 nM ET-1 for 4 h serum free media treated with 10 nM ET-
1 II was added to the bottom Matrigel invasion well.  1x105 serum starved SCC4 cells were left 
untreated and added to the top of the Matrigel invasion inserts in DMEM supplemented with 
0.1% (w/v) BSA (A).  After 40 h, cells which migrated to the underside of the Transwell 
permeable membrane were fixed in 100% (v/v) methanol.  Invaded cells were stained using 
crystal violet (0.1% (w/v)) and counted using a light microscope.  Data plotted represent 
average number of cells which migrated relative to untreated control and were calculated 
from an average of 3 fields of view.  Each data point represents an average of at least 3 
independent experiments.  ± SEM are indicated.  A two-tailed student t-test was carried out 
and data deemed statistically significant when p<0.05 (*). 
  
Results  Chapter 4 
90 
 
 
 
 
 
Figure 4.6  NOFs potentiate the effect of Ang II on HNSCC invasion:  The effect of oral 
fibroblasts on HNSCC cell invasion was investigated.  Matrigel was coated onto invasion inserts 
and incubated for 24 h.  Conditioned media collected from NOFs treated with 100 nM Ang II 
for 4 h or serum free media treated with 100 nM Ang II was added to the bottom Matrigel 
invasion well.  1x105 serum starved SCC4 cells (A) or H357 cells (B) were left untreated and 
added to the top of the Matrigel invasion inserts in DMEM supplemented with 0.1% (w/v) BSA.  
After 40 h, cells which migrated to the underside of the Transwell permeable membrane were 
fixed in 100% (v/v) methanol.  Invaded cells were stained using crystal violet (0.1% (w/v)) and 
counted using a light microscope.  Data plotted represent average number of cells which 
migrated relative to untreated control and were calculated from an average of 3 fields of view.  
Each data point represents an average of at least 3 independent experiments.  ± SEM are 
indicated.  A two-tailed student t-test was carried out and data deemed statistically significant 
when p<0.05 (*). 
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free DMEM.  100 µl of diluted Matrigel was added to each invasion insert and allowed to set 
overnight.  The invasion assay was then undertaken using a similar experimental procedure as 
that used to test HNSCC migration.  Treatment of NOFs with ET-1 resulted in a similar increase 
of 4-fold in invasion of SCC4 cells to that observed in the previous migration experiment 
(Figure 4.5A).  This was in comparison to conditioned media collected from PBS vehicle treated 
NOFs.   
The ability of Ang II to promote both SCC4 and H357 invasion was also examined.  Conditioned 
media collected from NOFs treated with Ang II stimulated an increase in SCC4 cellular invasion 
of 4-fold and an increase in H357 cellular invasion of 2.4-fold, both in comparison to 
conditioned media collected from PBS treated NOFs (Figure 4.6A and 4.6B). 
4.4 ET-1 exerts its paracrine effects through both ETAR and ETBR 
The mechanism by which ET-1 stimulates NOFs to promote HNSCC migration and invasion was 
next examined. ET-1 can exert its cellular actions by binding to one or two or both GPCRs, ETAR 
and ETBR.  To examine which of these receptors was involved in the paracrine stimulation of 
HNSCC migration by ET-1 the expression pattern of both receptors in SCC4 and NOFs was 
determined.   qPCR was conducted on primary cells and cell lines to establish transcript levels 
of both ETAR and ETBR (Section 3.5).  Agarose gel analysis conducted on these samples 
confirmed that ETAR was detectable in both SCC4 and NOFs but ETBR was only detectable in 
NOFs (Figure 4.7A).  In order to determine which receptor ET-1 was exerting its effects 
through, cells were pre-treated with a specific ETAR antagonist, BQ-123 and a specific ETBR 
antagonist, BQ-788 for 30 min before the addition of the ET-1 for a further 4 h.  Serum starved 
SCC4 cells were left untreated and their ability to migrate in the presence of conditioned 
media collected from NOFs treated with each receptor antagonist was investigated (Figure 
4.7B).  The presence of both receptor antagonists significantly ablated SCC4 cellular migration 
stimulated by ET-1 treatment.  Treatment of NOFs with ET-1 alone resulted in a 3.0-fold 
increase in SCC4 migration.  When the NOFs were pre-treated with an antagonist to ETAR, BQ-
123 this resulted in a decrease of SCC4 migration to only 1.4-fold relative to vehicle control.  
When the NOFs were pre-treated with an   antagonist to ETBR, BQ-788 this resulted in a 
decrease of SCC4 migration to 1.7-fold compared to control.     
To determine which receptors are responsible for the paracrine stimulation of SCC4 invasion, a 
similar experiment to that described in the previous paragraph was conducted.  Conditioned 
media was collected from NOFs treated with ET-1 +/- receptor antagonists to ETAR, BQ-123 or 
ETBR, BQ-788.  The media was added to the bottom well of a 2D Matrigel invasion assay.  ET-1 
treatment of NOFs alone resulted in an increase in SCC4 invasion of 4.0-fold (Figure 4.7C).  Pre- 
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Figure 4.7  ET-1 mediates paracrine stimulation of HNSCC migration and invasion via ETAR 
and ETBR:  To determine which receptor ET-1 exerts its paracrine effects via RNA was extracted 
from SCC4 and NOFs and subjected to qPCR for ETAR, ETBR or U6 as a reference gene. 
Amplicons were separated by agarose gel electrophoresis and visualised by UV 
transillumination (A). OFs were pre-treated with a specific receptor antagonist to ETAR, BQ-123 
(1 μM) or to ETBR, BQ-788 (1 μM) for 30 min before the addition ET-1 (10 nM) for a further 4 h. 
Conditioned media was aspirated, filtered and added to the bottom Transwell migration well 
(B) or the bottom Matrigel invasion well (C).  1x105 serum starved SCC4 cells were left 
untreated and added to the top of the Transwell migration or Matrigel invasion inserts in 
DMEM supplemented with 0.1% (w/v) BSA. After 16 h (for migration) or 40 h (for invasion), 
cells which migrated to the underside of the Transwell permeable membrane were fixed in 
100% (v/v) methanol.  Migrated cells were stained using crystal violet (0.1% (w/v)) and 
counted using a light microscope.  Data plotted represent average number of cells which 
migrated relative to untreated control and were calculated from an average of 3 fields of view.  
Each data point represents an average of at least 3 independent experiments.  ± SEM are 
indicated.  A two-tailed student t-test was carried out and data deemed statistically significant 
when p<0.05 (*), p<0.05 relative to ET-1 treated cells (**). 
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treatment of NOFs with BQ-123 caused a reduction in SCC4 invasion.  Invasion was only 2.0-
fold greater than that observed for untreated NOFs in comparison to the 4.0-fold increase that 
was observed when NOFs were only treated with ET-1.  Pre-treatment of NOFs with BQ-788 
resulted in a similar reduction in SCC4 invasion that was only 1.7-fold greater than that 
observed for NOFs that were left untreated.  The blocking of ET-1 stimulated HNSCC invasion 
by the specific ETAR antagonist, BQ-123 and the specific ETBR antagonist, BQ-788 suggest that 
both receptors are involved in the paracrine signalling of NOFs. 
4.5 Ang II exerts its paracrine effects through AT1R 
It is known that Ang II can exert its effect through binding to one or two or both GPCRs, AT1R 
and AT2R.  As previously observed in Section 3.3 Ang II exerts its autocrine effects through the 
AT1R which is markedly elevated in HNSCC primary carcinoma cell lines.  The receptor is also 
expressed at readily detectable levels in NOFs (Figure 3.3A).  The receptor, by which Ang II is 
exerting its effects through in NOFs, was next examined.  Although the expression of AT1R was 
detectable in NOFs, the expression of AT2R was undetectable within the same cells (Figure 
3.3B); it was therefore decided to examine the effect of antagonising AT1R signalling on the 
responses observed to Ang II.  The pre-treatment of NOFs with a specific antagonist to the 
AT1R, telmisartan, resulted in the complete abrogation of Ang II-dependent SCC4 cellular 
migration and invasion in response to conditioned medium.  NOFs were pre-treated with the 
receptor antagonist for 30 min before the addition of Ang II for a further 4 h.  The effect of the 
antagonist on SCC4 migration and invasion in response to conditioned medium was 
determined by using a Transwell migration and a Matrigel invasion assay, respectively.  When 
NOFs were treated with Ang II alone it resulted in an increase in SCC4 migration of 2.5-fold in 
comparison to vehicle treated cells (Figure 4.8A).  This increase in migration was reduced to 
only 1.2-fold when telmisartan was present.  Ang II treated NOFs stimulated SCC4 cells to 
invade 3.0-fold when compared to vehicle treated cells (Figure 4.8B).  This was reduced to only 
0.8-fold when NOFs were pre-treated with telmisartan before the addition of Ang II.  all fold 
changes were plotted in relation to vehicle treated cells. 
4.6 ADAM17 plays an important role in ET-1- and Ang II-stimulated 
paracrine signalling and HNSCC migration 
The findings of this study indicate that ET-1 acts via both the ETAR and ETBR and Ang II via the 
AT1R in NOFs. The signalling pathways by which they stimulate paracrine signalling between 
stromal NOFs and HNSCC cells was next investigated. It has previously been identified that ET-
1 can stimulate the ADAM-mediated proteinase release of soluble, bioactive factors from the 
surface of cells (Murphy, 2008); the ability of a broad range MMP/ADAM inhibitor, GM6001, to  
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Figure 4.8  Ang II mediates paracrine stimulation of HNSCC migration and invasion via AT1R:  
Ang II exerts most of its pathophysiological effects by binding to the AT1R.  To determine if Ang 
II exerts its paracrine effects via this receptor NOFs were pre-treated with a specific receptor 
antagonist to AT1R, telmisartan (1 µM) for 30 min before the addition of Ang II (100 nM) for a 
further 4 h. Conditioned media was aspirated, filtered and added to the bottom Transwell 
migration well (A) or the bottom Matrigel invasion well (B).  1x105 serum starved SCC4 cells 
were left untreated and added to the top of the Transwell migration or Matrigel invasion 
inserts in DMEM supplemented with 0.1% BSA. After 16 h (for migration) or 40 h (for invasion), 
cells which migrated to the underside of the Transwell permeable membrane were fixed in 
100% (v/v) methanol.  Migrated cells were stained using crystal violet (0.1% (w/v)) and 
counted using a light microscope.  Data plotted represent average number of cells which 
migrated relative to untreated control and were calculated from an average of 3 fields of view.  
Each data point represents an average of at least 3 independent experiments.  ± SEM are 
indicated.  A two-tailed student t-test was carried out and data deemed statistically significant 
when p<0.05 (*), p<0.05 relative to Ang II treated cells (**). 
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influence the responses to ET-1 was next examined.   NOFs were pre-treated with GM6001 for 
30 min before the addition of ET-1.  The conditioned media was aspirated from the NOFs, 
filtered and added to the bottom of the Transwell migration well.  The application of the 
inhibitor blocked the ET-1 dependent paracrine stimulation of serum starved SCC4 cells that 
were left untreated before their addition to the Transwell insert.  The presence of the inhibitor 
reduced SCC4 migration from 2.2-fold when NOFs were treated with ET-1 only, compared to 
untreated cells, to 1.0-fold (Figure 4.9A).  This finding suggests that the soluble release of 
factors from the surface of NOFs and the involvement of a MMP or ADAMs enzyme, stimulated 
by treatment of the cells with ET-1, is a critical component in the paracrine signalling 
mechanism via which ET-1 promotes HNSCC cell migration and invasion.   
As ADAMs have also been implicated in mediating the effects of Ang II in a number of contexts 
(Murphy, 2008), the same experiment was conducted for Ang II treatment.  The treatment of 
NOFs with Ang II resulted in a 2.3-fold increase in SCC4 migration in comparison to vehicle 
treated cells (Figure 4.9B).  A reduction in SCC4 migration was also observed when NOFs were 
pre-treated with GM6001 before Ang II treatment.  The presence of the GM6001 reduced 
SCC4 migration to only 0.8-fold in comparison to vehicle treated cells.  This finding implies that 
Ang II is also working via a similar signalling mechanism to that used and triggered by ET-1 
stimulation. 
The underlying signalling mechanism was further investigated by using siRNA to knock down 
the expression of the most common ADAMs proteinase implicated in the release of soluble 
factors from the surface of cells; ADAM17 (Murphy, 2008).  NOFs were transiently transfected 
using siRNA to ADAM17 or siRNA to an insect transcript not expressed in human cells for 24 h.  
A mock transfection with Oligofectamine alone was also carried out.  Following transfection all 
NOFs were treated with ET-1 or vehicle control for 4 h.  The conditioned media collected from 
mock transfected NOFs treated with ET-1, resulted in an increase in SCC4 migration of 3.5-fold 
(Figure 4.10A).  This was in comparison to conditioned media collected from mock transfected 
NOFs treated with serum free media.  NOFs that were transfected with a scramble control 
duplex and treated with ET-1 provoked a similar increase in SCC4 migration to that observed 
for mock control, 3.2-fold.  The knockdown of ADAM17 using siRNA, resulted in a reduction in 
SCC4 migration to 1.7-fold compared to mock transfected NOFs treated with serum free 
media.  The reduction observed in SCC4 cell migration suggests that ADAM17 is vital in 
mediating the release of bioactive soluble factors from the surface of NOFs allowing them to 
act as ligands for HNSCC cells, stimulating their migratory ability.  qPCR and immunoblot 
analysis were performed on RNA and protein lysate collected from NOFs transfected with 
siRNA as described previously to determine the extent of ADAM17 knockdown after 
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transfection.  The transfection of NOFs with siRNA to ADAM17 resulted in a knockdown in 
transcript (Figure 4.10B) and protein (Figure 4.10C) levels by >50%; no significant effect was 
observed on the transcript levels of other ADAMs (-9, -10 and -15) expressed by the NOFs 
suggesting that ADAM17 is the only proteinase being targeted by the siRNA (Figure 4.10D).  
This mechanism was further investigated by the ADAM17 knockdown in NOFs 24 h prior to 
treatment with Ang II.  The conditioned media collected from siRNA targeting an insect 
transcript transfected NOFs treated with Ang II, resulted in an increase in SCC4 migration 1.9–
fold in comparison to NOFs transfected in the same way and treated with serum free media 
(Figure 4.11A).  The knockdown of ADAM17 using siRNA, followed by treatment with Ang II 
resulted in a reduction in SCC4 migration to 0.7-fold, compared to control transfected NOFs 
treated with serum free media.  The transfection of NOFs with siRNA to ADAM17 again 
abrogated the paracrine stimulation of Ang II on SCC4 cell migration.  qPCR analysis was 
performed on pelleted NOFs to determine the extent of ADAM17 knockdown after 
transfection.  The transfection of NOFs with siRNA to ADAM17 resulted in a knockdown in 
transcript levels by 50% (Figure 4.11B). 
4.7 The ET-1 and Ang II stimulated paracrine signalling mechanism 
involves the transactivation of EGFR  
It is apparent that the release of soluble factors, in part via ADAM17 proteinase activity, from 
the surface of NOFs is crucial in the paracrine stimulation of HNSCC migration and invasion.  
Epidermal growth factor receptor (EGFR) signalling is a pathway commonly deregulated in a 
number of cancers.  The pathway can be activated via the binding of soluble factors released 
from the cell via an autocrine manner, from other surrounding cells via a paracrine manner 
and via intracellular signalling mechanisms; ADAM17 has been implicated in this process 
(Blobel, 2005). These soluble factors can act as ligands for the EGFR.  Aberrant activation of the 
EGFR can promote an increase in cell proliferation, migration and invasion and is a common 
feature of many cancer types.  It was therefore decided to examine the involvement of EGFR 
signalling in the actions of ET-1 and Ang II in HNSCC. SCC4 cells were pre-treated with an 
antagonist of EGFR, AG 1478, for 30 min before the addition of the cells to the top of the 
Transwell migration well.  The presence of AG 1478 reduced the effect of conditioned media 
collected from NOFs pre-treated with ET-1 or Ang II on SCC4 migration.  SCC4 cell migration in 
the presence of ET-1 stimulated conditioned media was reduced from 3.0-fold to 1.2-fold 
(compared to vehicle only) when the SCC4 cells were pre-treated with the AG 1478 antagonist 
(Figure 4.12A).  SCC4 cell migration in the presence of Ang II stimulated conditioned media was 
reduced from 2.2-fold to 0.6-fold (compared to vehicle only) when the SCC4 cells were pre-
treated with the AG 1478 antagonist (Figure 4.12B).  This suggests that soluble ectodomains  
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Figure 4.9  The release of a soluble factor from the surface of NOFs is a critical step in ET-1 
and Ang II mediated HNSCC cell migration:  The signalling pathways in which ET-1 and Ang II 
stimulate paracrine signalling between NOFs and HNSCC cells was investigated.  ET-1 is known 
to stimulate the ADAM-mediated proteinase release of soluble, bioactive factors from the 
surface of cells.  NOFs were pre-treated with an ADAM inhibitor, GM6001 (10 µM) for 30 min 
before the addition of ET-1 (10 nM) (A) or Ang II (100 nM) (B) for a further 4 h. Conditioned 
media was aspirated, filtered and added to the bottom Transwell migration well.  1x105 serum 
starved SCC4 cells were left untreated and added to the top of the Transwell migration inserts 
in DMEM supplemented with 0.1% (w/v) BSA.  After 16 h, cells which migrated to the 
underside of the Transwell permeable membrane were fixed in 100% (v/v) methanol.  
Migrated cells were stained using crystal violet (0.1% (w/v)) and counted using a light 
microscope.  Data plotted represent average number of cells which migrated relative to 
untreated control and were calculated from an average of 3 fields of view.  Each data point 
represents an average of at least 3 independent experiments.  ± SEM are indicated.  A two-
tailed student t-test was carried out and data deemed statistically significant when p<0.05 (*), 
p<0.05 relative to ET-1 or Ang II treated cells (**). 
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Figure 4.10  ADAM17 plays an important role in ET-1-stimulated paracrine signalling and 
HNSCC migration:  ADAM17 is a member of the ADAMs proteinase family and is responsible 
for the release of soluble factors from the surface of cells.  NOFs were transiently transfected 
with siRNA to ADAM17 for 24 h.  The cells were treated with ET-1 (10 nM) for 4 h.  Conditioned 
media was aspirated, filtered and added to the bottom Transwell migration well.  1x105 serum 
starved SCC4 cells were left untreated and added to the top of the Transwell migration inserts 
in DMEM supplemented with 0.1% (w/v) BSA.  After 16 h, cells which migrated to the 
underside of the Transwell permeable membrane were fixed in 100% (v/v) methanol.  
Migrated cells were stained using crystal violet (0.1% (w/v)) and counted using a light 
microscope (A).  Transfected NOFs were harvested and RNA extracted or lysates prepared.  
qPCR analysis was used to measure the transcript levels of ADAM17 (B); to determine 
transfection efficiency, other ADAMs proteinases (ADAM9, 10 and 15, as indicated); to indicate 
the specificity of siRNA for ADAM17 (D) or U6 as a reference gene.  Cell lysates were separated 
by SDS-PAGE and immunoblotted for ADAM17 and β-actin (as a loading control). A 
representative blot is shown (C) and the intensity of the band corresponding to ADAM17, 
determined by densitometry and normalized to β-actin levels in the same sample, is indicated 
under each lane.  Each data point represents an average of at least 3 independent 
experiments, carried out in triplicate.  ± SEM are indicated.  A two-tailed student t-test was 
carried out and data deemed statistically significant when p<0.05 (*) relative to untreated 
control, ns = not significant.  
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Figure 4.11  ADAM17 plays an important role in Ang II-stimulated paracrine signalling and 
HNSCC migration:  ADAM17 is a member of the ADAMs proteinase family and is responsible 
for the release of soluble factors from the surface of cells.  NOFs were transiently transfected 
with siRNA to ADAM17 for 24 h.  The cells were treated with Ang II (100 nM) for 4 h.  
Conditioned media was aspirated, filtered and added to the bottom Transwell migration well.  
1x105 serum starved SCC4 cells were left untreated and added to the top of the Transwell 
migration inserts in DMEM supplemented with 0.1% (w/v) BSA.  After 16 h, cells which 
migrated to the underside of the Transwell permeable membrane were fixed in 100% (v/v) 
methanol.  Migrated cells were stained using crystal violet (0.1% (w/v)) and counted using a 
light microscope (A).  Transfected NOFs were harvested and RNA extracted or lysates 
prepared.  qPCR analysis was used to measure the transcript levels of ADAM17 (B). Each data 
point represents an average of at least 3 independent experiments, carried out in triplicate.  ± 
SEM are indicated.  A two-tailed student t-test was carried out and data deemed statistically 
significant when p<0.05 (*) relative to untreated control, ns = not significant. 
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released from the surface of the fibroblast cells via ADAM17 proteolysis, can act as ligands for 
EGFR resulting in its activation and triggering downstream signalling which results in the 
increased migratory ability of the HNSCC cells. The observation that the receptor antagonist to 
the EGFR resulted in a decrease in paracrine stimulation of SCC4 cells suggested the following 
experiment in which the inhibition of not only the EGFR but the combined effect of inhibition 
with ETAR and ETBR was investigated.  SCC4 cells were pre-treated with AG 1478 before their 
addition to the Transwell migration assay and NOFs were pre-treated with a specific ETAR 
antagonist, BQ-123 and a specific ETBR antagonist, BQ-788 for 30 min before their stimulation 
with ET-1.  The combined inhibition of both the ETAR and ETBR and the EGFR resulted in further 
reduction in migration in response to ET-1.  ET-1 treatment alone resulted in the usual increase 
in SCC4 migration.  In this experiment migration was increased 4.0-fold in comparison to 
vehicle treated cells (Figure 4.13A).  When SCC4 cells were pre-treated with AG 1478 before 
their addition to the migration assay their migration was reduced to only 2.0-fold.  The pre-
treatment of NOFs with BQ-123 reduced migration to only 2.2-fold and pre-treatment with 
BQ-788 reduced migration to 2.0-fold.  The presence of AG 1478 significantly reduced this 
further to 1.3- and 1.5-fold for BQ-123 and BQ-788, respectively.  The pre-treatment of NOFs 
with both the BQ-123 and the BQ-788 receptor antagonists further reduced the paracrine 
stimulation of SCC4 cellular migration to only 1.5-fold in comparison to treatment of the NOFs 
with the individual antagonists.    When AG 1478 was added this again significantly reduced to 
migration to only 1.0-fold.  All treatments were plotted relative to untreated NOFs and SCC4 
cells. 
To further investigate the suggestion that soluble factors released from the surface of NOFs 
can potentially act as ligands for the EGFR, conditioned media collected from ET-1 treated 
NOFs was incubated for 30 min with neutralising antibodies to three known EGFR ligands; 
tumour growth factor-α (TGF-α), heparin bound-EGF (HB-EGF) and amphiregulin, all of which 
have been implicated in the progression of a number of malignancies.  The incubation of the 
individual neutralising antibodies with conditioned media blocked stimulation of SCC4 
migration, further supporting the implication that EGFR transactivation is important in the 
paracrine stimulation of HNSCC cells (Figure 4.14A).  This inhibition of cell migration was 
further potentiated when the conditioned media was incubated with all three neutralising 
antibodies before its addition to the Transwell migration assay.  There was no change in SCC4 
migration when all three neutralising antibodies were added alone and in combination to 
media collected from vehicle treated NOFs.  When NOFs were treated with ET-1 and the 
conditioned media collected and added directly to the Transwell migration well without 
further incubation with the neutralising antibodies, migration was increased 3.0-fold in   
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Figure 4.12  EGFR transactivation is involved in the paracrine stimulation of HNSCC migration 
by ET-1 and Ang II:  EGFR signalling is a pathway commonly associated with deregulation in a 
number of cancers.  EGFR signalling is triggered by autocrine and paracrine stimulation.  
Soluble factors released from cells can act as ligands for the EGFR, resulting in its dimerisation.  
Conditioned media collected from NOFs treated with 10 nM ET-1 (A) or 100 nM Ang II (B) for 4 
h was added to the bottom Transwell migration well.  SCC4 cells were pre-treated with an 
EGFR antagonist, AG 1478 (125 nM) for 30 min.  1x105 serum starved cells treated as above 
were added to the top of the Transwell migration inserts in DMEM supplemented with 0.1% 
(w/v) BSA with DMEM. After 16 h, cells which migrated to the underside of the Transwell 
permeable membrane were fixed in 100% (v/v) methanol.  Migrated cells were stained using 
crystal violet (0.1% (w/v)) and counted using a light microscope.  Data plotted represent 
average number of cells which migrated relative to untreated control and were calculated 
from an average of 3 fields of view.  Each data point represents an average of at least 3 
independent experiments.  ± SEM are indicated.  A two-tailed student t-test was carried out 
and data deemed statistically significant when p<0.05 (*), p<0.05 relative to ET-1 or Ang II 
treated cells (**). 
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Figure 4.13  Combining treatment with antagonists to ETAR and ETBR and an inhibitor to 
EGFR further increase the inhibition of ET-1 stimulated HNSCC migration:  NOFs were pre-
treated with a specific receptor antagonist to ETAR, BQ-123 (1 μM) or to ETBR, BQ-788 (1 μM) 
for 30 min before the addition ET-1 (10 nM) for a further 4 h. Conditioned media was 
aspirated, filtered and added to the bottom Transwell migration well.  SCC4 cells were pre-
treated with an EGFR antagonist, AG 1478 (125 nM) for 30 min before their addition to the top 
of a Transwell migration insert (A).  1x105 serum starved SCC4 cells treated as above were 
added to the top of the Transwell migration or Matrigel invasion inserts in DMEM 
supplemented with 0.1% (w/v) BSA. After 16 h cells which migrated to the underside of the 
Transwell permeable membrane were fixed in 100% (v/v) methanol.  Migrated cells were 
stained using crystal violet (0.1% (w/v)) and counted using a light microscope.  Data plotted 
represent average number of cells which migrated relative to untreated control, or as 
indicated by bars and were calculated from an average of 3 fields of view.  Each data point 
represents an average of at least 3 independent experiments.  ± SEM are indicated.  A two-
tailed student t-test was carried out and data deemed statistically significant when p<0.05 (*). 
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Figure 4.14  Neutralising antibodies to EGFR ligands can block ET-1 stimulated HNSCC 
migration:  The effect of neutralising antibodies on ET-1 paracrine stimulated SCC4 migration 
was investigated. NOFs were treated with ET-1 (10 nM) for 4 h before the media was aspirated 
and filtered.  The conditioned media collected was incubated alone and in combination with 
neutralising antibodies to three EGFR ligands; TGF-α, HB-EGF and amphiregulin (10 μl/ml).  The 
media and antibodies were incubated together on a blood wheel for 30 min before being 
added to the bottom Transwell migration well.  1x105 serum starved SCC4 cells were left 
untreated and added to the top of the Transwell migration inserts in DMEM supplemented 
with 0.1% BSA (w/v) (A).  After 16 h, cells which migrated to the underside of the Transwell 
permeable membrane were fixed in 100% (v/v) methanol.  Migrated cells were stained using 
crystal violet (0.1% (w/v)) and counted using a light microscope.  Data plotted represent 
average number of cells which migrated relative to untreated control and were calculated 
from an average of 3 fields of view.  Each data point represents an average of at least 3 
independent experiments.  ± SEM are indicated.  A two-tailed student t-test was carried out 
and data deemed statistically significant when p<0.05 (*), p<0.05 relative to ET-1 treated cells 
(**). 
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comparison to vehicle treated NOFs.  SCC4 migration was reduced when conditioned media 
was incubated with a neutralising antibody to TGF-α to 1.3-fold, 1.2-fold with a neutralising 
antibody to HB-EGF, 1.5-fold with a neutralising antibody to amphiregulin and when all three 
were combined migration was reduced to 0.8-fold.  Incubation of conditioned media with an 
isotype control antibody had no effect on SCC4 migration.  All results were plotted relative to 
untreated cells. 
4.8 EGFR transactivation by ET-1 induces COX-2 expression 
The results of this study have shown that ET-1 promotes HNSCC cell migration in the presence 
of NOFs via a paracrine mechanism.  The ability of the mitogenic peptide to regulate genes 
known to be altered by EGFR signalling during this process was next investigated.  BK, another 
mitogenic peptide, is known to cause an increase in cyclooxygenase-2 (COX-2) expression in 
HNSCC cells via the phosphorylation and activation of the EGFR and the mitogen-activated 
protein kinase (MAPK) pathway (Zhang et al, 2008).  Elevated expression of COX-2 is known to 
be associated with an invasive phenotype and a poor prognosis in HNSCC (Chan et al, 1999).  
COX-2 is responsible for the conversion of arachidonic acid into prostaglandin E2 (PGE2) which 
can promote increased proliferation, cell survival, angiogenesis, migration and invasion of 
tumour cells.  
In order to assess any involvement of COX-2 in the observed effects of ET-1, SCC4 cells were 
seeded into 12-well titre plates and were allowed to adhere overnight.  The following day cells 
were serum starved for 24 h.  SCC4 cells were pre-treated with the EGFR antagonist, AG 1478 
or a vehicle control for 30 min before being treated directly with conditioned media that was 
prepared from NOFs treated with ET-1 or vehicle control for 4 h.  Cells were pelleted 4 h after 
treatment and subjected to qPCR analysis.  qPCR analysis of mRNA isolated from SCC4 cells 
pre-treated with vehicle control and then treated with conditioned media collected from NOFs 
treated with ET-1, showed that ET-1 increased the expression of COX-2 1.7-fold compared to 
untreated SCC4 cells (Figure 4.15A).  The pre-treatment of SCC4 cells with AG 1478 before 
treatment with conditioned media collected from NOFs treated with ET-1, blocked the 
increase in COX-2 expression. Treatment of SCC4 with AG 1478 resulted in a decrease in COX-2 
transcript levels (0.5-fold in comparison to vehicle treated cells), suggesting that EGFR 
signalling may regulate basal COX-2 expression as well as that induced by ET-1.  To investigate 
if COX-2 directly contributed to promoting the migration of HNSCC cells in this system, cells 
were pre-treated with the COX inhibitor ibuprofen; which inhibits both COX-1 and COX-2, or 
the COX-2 specific inhibitor celecoxib for 30 min before their addition to the migration insert.  
The presence of both inhibitors blocked the induction of SCC4 cell migration to 0.3-fold and 
1.0-fold, respectively, invoked by conditioned media collected from ET-1 stimulated NOFs  
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Figure 4.15  Paracrine transactivation of EGFR by ET-1 stimulates COX-2 expression and 
function:  In order to investigate the change in COX-2 gene expression in response to 
conditioned media treatment SCC4 cells were seeded and serum starved before being pre-
treated with an EGFR antagonist, AG 1478 (125 nM) for 30 min (A).  NOFs were treated with a 
ET-1 (10 nM) for 4 h. Conditioned media was aspirated, filtered and either added directly to 
the SCC4 cells or added to the bottom Transwell migration well.  Seeded SCC4 cells were 
treated for 4 h before being pelleted and RNA extracted and subject to qPCR analysis for COX-2 
or U6 as a reference gene.  SCC4 cells were pre-treated with a COX inhibitor, ibuprofen (100 
µM) or a COX-2 inhibitor, celecoxib (50 µM) for 30 min (B).  1x105 serum starved SCC4 cells 
treated as above were added to the top of the Transwell migration inserts in DMEM 
supplemented with 0.1% BSA (w/v). After 16 h cells which migrated to the underside of the 
Transwell permeable membrane were fixed in 100% (v/v) methanol.  Migrated cells were 
stained using crystal violet (0.1% (w/v)) and counted using a light microscope.  Data plotted 
represent average number of cells which migrated relative to untreated control, or as 
indicated by bars and were calculated from an average of 3 fields of view.  Each data point 
represents an average of at least 3 independent experiments.  ± SEM are indicated.  A two-
tailed student t-test was carried out and data deemed statistically significant when p<0.05 (*), 
p<0.05 relative to ET-1 treated cells (**). 
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(Figure 4.14B).  Untreated SCC4 cells migrated 3.2-fold more in the presence of ET-1 
stimulated conditioned media than in unstimulated conditioned media.  The fold change was 
plotted relative to vehicle treated cells.  The inhibitors also reduced SCC4 migration when 
conditioned media was collected from NOFs treated with vehicle control.  Ibuprofen reduced 
migration to 0.4-fold and celecoxib reduced it to 0.5-fold, both in comparison to vehicle 
treated SCC4 cells and NOFs.  These findings corroborate previous suggestions of a critical role 
for COX-2 in stromal-epithelial interactions in HNSCC (Thomas et al, 2006). 
4.9 miR-145 reduces the ability of NOFs to promote SCC4 migration 
It has recently been shown that microRNAs (miRNAs) regulate the expression of different 
genes that play important roles in cancer cell invasion, migration and metastasis (Nicoloso et 
al, 2009).  miRNAs are short, naturally occurring non-coding RNAs which regulate the 
expression of target genes.  The mature miRNA is single stranded and made up of around 21 to 
25 nucleotides (Kim, 2005).  The production of miRNAs is executed in a well-coordinated 
manner.  miRNAs begin their life as a long section of primary transcript, around several 
kilobases in length called the pri-miRNA.  This is produced in a polymerase II-dependent 
manner.  The transcript contains a hairpin structure, a 5’ CAP structure and a 3’ 
polyadenylated tail.  The stem-loop structure is cleaved by the nuclear RNase III known as 
Drosha and its double stranded binding protein DGCR8, to produce pre-miRNA.  The remaining 
regions are thought to be degraded in the nucleus.  This maturational process of miRNAs is 
stimulated and regulated in response to proliferative stimuli and cellular differentiation.  Once 
the pre-miRNA is produced it is transported out of the nucleus into the cytoplasm.  This 
transportation process is triggered and executed by exportin-5 and its cofactor Ran-GTP.  
Exportin-5 is a nuclear export factor and is also thought to stabilise pre-miRNA.  The export 
factor targets its cargo and transports it into the cytoplasm through a nuclear pore.  In the 
cytoplasm a RNase III nuclease called Dicer processes the pre-miRNA into a duplex of around 
22 nucleotides in length via a process known as dicing.  The miRNA duplex does not remain in 
this form for long.  It is incorporated into a RNA induced silencing complex (RISC) that also 
contains argonaute.  After the production of this complex only one strand is selected from it to 
become the mature miRNA and will therefore remain in the mature RISC.  This strand is known 
as the guide strand.  The other remaining strand is degraded.  The decision as to which strand 
is chosen and which strand is discarded is thought to be based on the stability of duplex in the 
5’ half (Kim, 2005).  miRNAs regulate gene expression at a post-transcriptional level through 
the selective silencing of target messenger RNAs (mRNAs) (Medina and Slack, 2008).  They 
achieve this by binding to specific sequences in the 3’ untranslated region (3’UTR) of their  
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Figure 4.16  miR-145 can inhibit ET-1-stimulated paracrine HNSCC migration:  NOFs were 
transiently transfected with miR-145 for 24 h.  The cells were treated with ET-1 (10 nM) for 4 
h.  Conditioned media was aspirated, filtered and added to the bottom Transwell migration 
well.  1x105 serum starved SCC4 cells were left untreated and added to the top of the 
Transwell migration inserts in DMEM supplemented with 0.1% (w/v) BSA.  After 16 h, cells 
which migrated to the underside of the Transwell permeable membrane were fixed in 100% 
(v/v) methanol.  Migrated cells were stained using crystal violet (0.1% (w/v)) and counted using 
a light microscope (A).  Transfected NOFs were harvested and RNA extracted or lysates 
prepared.  qPCR analysis was used to measure the transcript levels of miR-145 (B).  Each data 
point represents an average of at least 3 independent experiments, carried out in triplicate.  ± 
SEM are indicated.  A two-tailed student t-test was carried out and data deemed statistically 
significant when p<0.05 (*) relative to untreated control, p<0.05 relative to miR-control 
transfection +ET-1 treatment (**). 
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target gene’s transcripts (Zeng and Cullen, 2005).  Computer analysis studies have suggested 
that the miRNAs could target up to 10% of all human genes (John et al, 2004).   
It is known that miRNAs can act as tumour suppressors (Calin and Croce, 2006) and miR-145 
has been shown to be down regulated in a number of malignancies (Sachdeva et al, 2009).  
Work conducted previously in the lab has shown that miR-145, a putative tumour-suppressor 
(unpublished data generated in the laboratory), is down-regulated in oral cancer and can 
repress migration of cancer cells in response to mitogenic peptides, by down regulating 
ADAM17.  The work presented in this project has identified the involvement of ADAM17 in 
mitogenic peptide-induced stromal epithelial cross-talk; it was therefore decided to examine 
the effect of modulating miR-145 on this pathway.  qPCR data has identified the presence of 
mature miR-145 in NOFs (unpublished data generated in the laboratory).  The effect that over 
expressing miR-145 in NOFs has on the migration of SCC4 cells in the presence and absence of 
ET-1 and Ang II was investigated.  NOFs were transiently transfected with miR-145 or miR-
control for 24 h before treatment with ET-1, Ang II or serum free media for a further 4 h.  After 
this time period the media was aspirated, filtered and added to the bottom of the Transwell 
migration assay.  Serum starved SCC4 cells were left untreated and were added to the top 
chamber of the assay.  The cells were allowed to migrate for 16 h before they were fixed, 
stained and counted as described in Section 2.2.4.  Cells transfected with miR-control followed 
by ET-1 treatment resulted in an increase in SCC4 migration of 3.4-fold (Figure 4.16A).  This 
stimulation of migration was significantly reduced to 0.9-fold when NOFs were transfected 
with miR-145 before treatment with ET-1.  Transfection of NOFs with miR-145 followed by 
treatment for 4 h with serum free media also resulted in a small but significant decrease of 
0.4-fold in SCC4 migration in comparison to NOFs transfected with miR-control and treated 
with serum free media.  qPCR analysis was conducted on transfected NOFs to confirm the over 
expression of miR-145.  Transient transfection of the cells with miR-145 resulted in an increase 
of 29-fold in the expression of the mature miRNA (Figure 4.16B). 
NOFs transfected with miR-control and treated with Ang II resulted in an increase in migration 
of SCC4 cells of 1.9-fold in comparison to treatment with serum free media of NOFs also 
transfected with miR-control (Figure 4.17A).  When NOFs were transfected with miR-145 and 
again treated with Ang II this resulted in a decrease in SCC4 migration to 0.6-fold.  NOFs that 
were transfected with miR-control and treated with serum free media again resulted in a small 
decrease in SCC4 migration of 0.7-fold similar to that observed in the ET-1 set of experiments.  
However this reduction in SCC4 migration was not significant.  qPCR analysis was conducted on 
transfected NOFs to confirm the over expression of miR-145.  Transient transfection of the 
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cells with miR-145 resulted in an increase of 25-fold in the expression of the mature miRNA 
(Figure 4.17B).   
miR-145 is known to target ADAM17 and could therefore be restricting the ET-1 and Ang II 
stimulated release of bioactive ligands which trigger migration via binding to the EGFR on 
HNSCC cells.  This level of inhibition is greater than that observed with siRNA knockdown of 
ADAM17 in NOFs, suggesting the involvement of other miR-145 targets. 
4.10 The over expression of ECE-1c in NOFs potentiates the paracrine 
stimulation of HNSCC migration 
ECE-1c is one of the four ECE-1 isoforms.  It is the most abundantly expressed and is located at 
the cell surface (Muller et al, 2003).  The expression of ECE-1c is known to be elevated in a 
number of cancers (Muller et al, 2003).  This project has identified that ECE-1 is also over 
expressed in cell lines isolated from primary HNSCCs, oral dysplasias and a local metastasis and 
NOFs in comparison to NOKs (Figure 3.6B and Figure 3.8A).  This study has shown that 
heterologous over-expression of ECE-1c in SCC4 cells stimulated an increase in their migration 
1.4–fold in comparison to cells transfected with a control plasmid (Figure 3.9A).  This result 
and that concluding that ECE-1 is over expressed in NOFs in comparison to NOKs prompted the 
effect of the over expression of ECE-1c in NOFs on the paracrine stimulation of SCC4 cell 
migration to be investigated.  NOFs were transiently transfected using FuGENE 6 with a 
pcDNA3 vector containing the ECE-1c coding region or a control pcDNA3 vector for 24 h.  After 
24 h the cells were treated for a further 4 h with serum free media.  After the allocated time 
period the media was aspirated, filtered and added to the bottom well of Transwell migration 
assay.  SCC4 were left untreated and added to the top of the Transwell migration assay.  The 
cells were allowed to migrate through the permeable membrane for 16 h before they were 
fixed, stained and counted using the method described in Section 2.2.4.  Over expression of 
ECE-1c in NOFs, resulted in an increase in SCC4 migration of 3.4-fold in comparison to NOFs 
transfected with the plasmid control (Figure 4.18A).  qPCR analysis was conducted on NOFs to 
determine the level of expression of ECE-1.  The expression of ECE-1 increased dramatically 
(50-fold) in NOFs after transfection with the ECE-1c isoform in comparison to the level 
normally expressed within the cells (Figure 4.18B).   
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Figure 4.17  miR-145 can inhibit Ang II-stimulated paracrine HNSCC migration:  NOFs were 
transiently transfected with miR-145 for 24 h.  The cells were treated with Ang II (100 nM) for 
4 h.  Conditioned media was aspirated, filtered and added to the bottom Transwell migration 
well.  1x105 serum starved SCC4 cells were left untreated and added to the top of the 
Transwell migration inserts in DMEM supplemented with 0.1% (w/v) BSA.  After 16 h, cells 
which migrated to the underside of the Transwell permeable membrane were fixed in 100% 
(v/v) methanol.  Migrated cells were stained using crystal violet (0.1% (w/v)) and counted using 
a light microscope (A).  Transfected NOFs were harvested and RNA extracted or lysates 
prepared.  qPCR analysis was used to measure the transcript levels of miR-145 (B).  Each data 
point represents an average of at least 3 independent experiments, carried out in triplicate.  ± 
SEM are indicated.  A two-tailed student t-test was carried out and data deemed statistically 
significant when p<0.05 (*) relative to untreated control, p<0.05 relative to miR-control 
transfection +Ang II treatment (**). 
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Figure 4.18  Over expression of ECE-1c in NOFs promotes migration of SCC4 cells:  NOFs were 
transiently transfected with a pcDNA3 vector contain the ECE-1c coding region for 24 h before 
the addition of serum free media for 4 h.  The conditioned media was aspirated, filtered and 
added to the bottom Transwell migration well.  1x105 serum starved SCC4 cells were left 
untreated and added to the top of the Transwell migration inserts in DMEM supplemented 
with 0.1% (w/v) BSA. After 16 h, cells which migrated to the underside of the Transwell 
permeable membrane were fixed in 100% (v/v) methanol.  Migrated cells were stained using 
crystal violet (0.1% (w/v)) and counted using a light microscope (A).  Transfected NOFs were 
harvested and RNA extracted or lysates prepared.  qPCR analysis was used to measure the 
transcript levels of ECE-1 (B).  Each data point represents an average of at least 3 independent 
experiments.  ± SEM are indicated.  A two-tailed student t-test was carried out and data 
deemed statistically significant when p<0.05 (*), p<0.05 relative to control transfected cells. 
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Figure 4.19  ECE-1 inhibition does not block pacracrine stimulated SCC4 migration:  ECE-1 is 
known to cleave biologically active ET-1 from big ET-1.  NOFs cells were treated with an ECE-1 
inhibitor, SM-19712 (10 μM) (A).  The conditioned media was aspirated, filtered and added to 
the bottom Transwell migration well.  1x105 serum starved SCC4 cells were left untreated and 
added to the top of the Transwell migration inserts in DMEM supplemented with 0.1% (w/v) 
BSA.  After 16 h, cells which migrated to the underside of the Transwell permeable membrane 
were fixed in 100% (v/v) methanol.  Migrated cells were stained using crystal violet (0.1% 
(w/v)) and counted using a light microscope.  Each data point represents an average of at least 
3 independent experiments.  ± SEM are indicated.  A two-tailed student t-test was carried out 
and data deemed statistically significant when p<0.05 (*), ns = not significant. 
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4.11 Inhibition of ECE-1 activity in NOFs does not reduce paracrine-
stimulated HNSCC migration  
Having shown that over-expression of ECE-1c in NOF is able to modulate the behaviour of 
HNSCC cells, the effect of inhibiting ECE-1 activity in NOFs on SCC4 migration was investigated.  
NOFs were treated with a broad range ECE-1 inhibitor, SM-1972 for 4 h before the media was 
aspirated, filtered and added to the bottom well of the Transwell migration assay.  Untreated 
SCC4 cells were added to the assay and allowed to migrate for 16 h (as described in Section 
2.2.4).  Treatment of NOFs with the SM-1972 inhibitor resulted in a decrease in SCC4 migration 
0.8-fold in comparison to untreated NOFs (Figure 4.19A).  This reduction in SCC4 migration 
however was not significant.    
4.12 The over expression of ACE in NOFs potentiates the paracrine 
stimulation of HNSCC migration 
Evidence has been provided in this thesis that the over expression of ACE in SCC4 cells 
stimulated an increase in their migration 1.5–fold in comparison to cells transfected with a 
pcDNA3 control plasmid (Figure 3.5B).  The effect of over expression of ACE in NOFs on the 
paracrine stimulation of SCC4 cell migration was investigated.  NOFs were transiently 
transfected using FuGENE 6 with a pIRES vector containing the coding region of somatic ACE or 
a control pcDNA3 vector for 24 h.  After 24 h NOFs were treated for a further 4 h with serum 
free media.  The conditioned media was added to the Tanswell migration assay and the ability 
of SCC4 cells to migrate was investigated (as previously described in Section 2.2.4).  Over 
expression of ACE in NOFs, resulted in an increase in SCC4 migration of 2.7-fold in comparison 
to NOFs transfected with a control vector (Figure 4.20A).  qPCR analysis was conducted on 
NOFs to determine the level of expression of ACE.  The expression of ACE increased 36-fold in 
NOFs after transfection with somatic ACE in comparison to the level normally expressed within 
the cells (Figure 4.20B).  
4.13 Summary 
The invasion and migration of cancer cells is increasingly recognised to be influenced by factors 
derived from adjacent tumour-associated stroma.  The contextual signals regulating these 
stromal-tumour interactions, however, remain poorly understood.  Within this chapter a role 
for the mitogenic peptides ET-1 and Ang II, in promoting pro-metastatic cross-talk between 
HNSCC cells and adjacent NOFs was investigated.   
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Figure 4.20  Over expression of ACE in NOFs promotes migration of SCC4:  NOFs were 
transiently transfected with a pIRES vector containing somatic ACE for 24 h before the addition 
of serum free media for 4 h.  The conditioned media was aspirated, filtered and added to the 
bottom Transwell migration well.  1x105 serum starved SCC4 cells were left untreated and 
added to the top of the Transwell migration inserts in DMEM supplemented with 0.1% (w/v) 
BSA. After 16 h, cells which migrated to the underside of the Transwell permeable membrane 
were fixed in 100% (v/v) methanol.  Migrated cells were stained using crystal violet (0.1% 
(w/v)) and counted using a light microscope (A).  Transfected NOFs were harvested and RNA 
extracted or lysates prepared.  qPCR analysis was used to measure the transcript levels of ECE-
1c (B).  Each data point represents an average of at least 3 independent experiments.  ± SEM 
are indicated.  A two-tailed student t-test was carried out and data deemed statistically 
significant when p<0.05 (*), p<0.05 relative to control transfected cells. 
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Initial studies within the chapter identified that ET-1 can exert its effects through both the ETAR 
and the ETBR.  Ang II binds to and exerts its effects through the AT1R.  The treatment of NOFs 
with ET-1 and Ang II activates ADAM17 mediated release of EGFR ligands including TGF-α, HB-
EGF and amphiregulin which trigger EGFR signalling resulting in an increase in the migration 
and invasion of HNSCC cells.  ET-1 mediated paracrine transactivation of EGFR also increased 
COX-2 levels in the HNSCC cells, providing a molecular insight into the mechanisms by which 
the elevated levels of ET-1 observed in head and neck cancers may contribute to disease 
progression.   
This chapter also identifies that the miRNA, miR-145, is an important regulator of paracrine 
stimulation of HNSCC migration triggered by treatment of NOFs with ET-1 and Ang II.  miR-145 
can repress the activation of ADAM17 which as mentioned before is crucial in the ability of the 
mitogenic peptides to exert their effects on the promotion of migration of the HNSCC cells.   
Final experiments conducted within this chapter begin to look at the role of the enzymes 
responsible for the production of biologically active ET-1 and Ang II.  The over expression of 
ECE-1c in NOFs, resulted in the paracrine stimulation of HNSCC migration.  This result is similar 
to that observed for the over expression of ACE within the same cell type.  These findings 
suggest that the enzymes could be responsible for the production of both ET-1 and Ang II at a 
local level within the head and neck tumour microenvironment.  The inhibition of ECE-1 
however does not result in a decrease in the paracrine stimulation of HNSCC cells suggesting 
that other factors aside from the enzyme are responsible for the production of ET-1.   
The findings within this chapter provide novel molecule detail regarding the role of the tumour 
microenvironment and the tumour-stromal interactions that occur within it in contributing to 
the progression of HNSCC.  The chapter also identifies potential targets for new drug therapies 
in the treatment of the disease. 
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Chapter 5: The effect of ET-1 and Ang II on 
the phenotype of normal oral 
fibroblasts 
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5.1 Introduction  
Tumour cells do not exist alone; the development and progression of epithelial tumours is 
profoundly influenced by the surrounding tumour microenvironment (the reactive stroma).  
The stroma is composed of fibroblasts, blood vessels, lymphatics, extracellular matrix 
components and immune cells (Stover et al, 2007).  Factors released by the tumour cells, and 
other cells in the microenvironment, can bind to the surrounding fibroblasts, the most 
common cell type found within the stroma, and cause a change in their phenotype.  
Fibroblasts are non-vascular, non-epithelial and non-inflammatory cells found within 
connective tissue (Tarin and Croft, 1969).  Fibroblasts play an important role in regulating the 
differentiation of epithelial cells, extra cellular matrix (ECM) deposition, inflammation and 
wound healing. Fibroblasts can become activated by factors present within the tumoural 
environment; assuming a myofibroblastic phenotype resembling that of fibroblasts found in 
healing wounds and fibrosis. The change in their activation state can result in alterations in the 
factors that they release.  These factors in turn can bind to the nearby epithelial tumour cells 
promoting and producing stromal-tumour interactions.  The importance of the tumour 
microenvironment in the progression of epithelial tumours is becoming increasingly 
recognized and suggestions have been made that it could present a possible new target for the 
development of therapeutic approaches for the treatment of cancer.   
The previous data and experiments presented in this thesis have implicated normal oral 
fibroblasts (NOFs) in the paracrine signalling mechanism responsible for the increase in head 
and neck squamous cell carcinoma (HNSCC) cell migration and invasion.  Endothelin-1 (ET-1) 
and angiotensin II (Ang II) are both capable of promoting paracrine signalling between NOFs 
and HNSCC cells via the stimulation and release of pro-invasive factors. It was therefore 
hypothesised that both ET-1 and Ang II stimulate paracrine signalling between NOFs and 
malignant epithelial cells by modifying the NOFs phenotype.  The effect of both peptides on 
the NOFs phenotype including their ability to promote proliferation, migration and cellular 
contraction of the cells was therefore investigated. 
5.2 ET-1 stimulates proliferation of NOFs 
An increase in cellular proliferation is associated with an ‘activated’ fibroblast phenotype.  The 
effect of ET-1 on the proliferation NOFs was investigated.  NOFs were seeded into 96-well titre 
plates and allowed to reach 40% confluency.  The cells were treated with ET-1 and allowed to 
proliferate for 48 h.  The treatment of NOFs with ET-1 resulted in a small (10%) but significant 
(p<0.05) increase in their proliferation (Figure 5.1A).  The pre-treatment of NOFs with a specific  
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Figure 5.1  ET-1 stimulates NOF proliferation:  Fibroblasts found within the stroma of the 
tumour microenvironment can undergo phenotypic changes including an increase in their 
proliferative ability.  In order to determine the effect of ET-1 on the proliferation of NOFs, the 
cells were treated with ET-1 (10 nM) and assayed using a MTS proliferation assay (A).  Briefly, 
NOFs were cultured in 96 well titre plates and allowed to adhere overnight.  The cells were 
pre-treated with a specific receptor antagonist to ETAR, BQ-123 (1 µM) and/or a specific 
receptor antagonist to ETBR, BQ-788 (1 µM) for 30 min before the addition of ET-1 (10 nM).  20 
µL MTS reagent was added to each well at 0 h and 48 h time points and fluorescence was 
measured at 492 nm. Each data point represents an average of at least 3 independent 
experiments, carried out in triplicate.  ± SEM are indicated.  A two-tailed student t-test was 
carried out and data deemed statistically significant when p<0.05 (*) relative to untreated 
control, or as indicated by bars. 
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ETAR antagonist, BQ-123 and a specific ETBR antagonist, BQ-788 both alone and in combination 
blocked the proliferation of the cells stimulated by ET-1 treatment.  This again suggests that 
ET-1 is exerting its effect through both receptors.  Treatment of NOFs with the ETBR antagonist 
resulted in a greater reduction in NOF proliferation in comparison to treatment with the 
receptor antagonist to ETAR (25% vs. 20% in comparison to ET-1 treated NOFs, respectively).  
Treating NOFs with receptor antagonists to both receptors resulted in the greatest inhibition 
of proliferation of 30% in comparison to ET-1 treated NOFs. 
5.3 ET-1 and Ang II promote migration of NOFs 
When fibroblasts acquire a more activated phenotype, a common characteristic associated 
with the change is the ability of the cell to migrate more.  A wound healing model was used to 
determine the effect of ET-1 on NOF migration.  NOFs were seeded and allowed to grow until 
they reached confluency.  The cells were serum starved overnight and the following day a 
‘scratch’ was made through the confluent monolayer using a pipette tip (Figure 5.2A).  The 
cells were washed and treated with ET-1 receptor antagonists or vehicle controls in serum free 
DMEM.  Mitomycin C was added to the cells at the same time as the treatments in order to 
inhibit proliferation of the NOFs.  The migration of the cells can thus be distinguished from 
their ability to proliferate into and reduce the ‘scratch’ diameter.  The treatment of NOFs with 
ET-1 significantly increased the migration of the cells, almost to a similar extent as that 
observed in response to serum.  ET-1 treatment of the NOFs resulted in a 90% increase in cell 
migration in comparison to untreated cells (Figure 5.2B).  DMEM containing 10% (v/v) FBS was 
used within the experiment to act as a positive control. When the cells were treated with 
DMEM containing 10% (v/v) FBS, NOFs increased their migration by 100% in comparison to 
untreated cells.  Pre-treatment of NOFs with BQ-123, and/or BQ-788, blocked the migration of 
the cells stimulated by ET-1 treatment.  When the NOFs were pre-treated with the receptor 
antagonists to either ETAR or ETBR, a reduction in migration of 90% was observed, in 
comparison to cells treated with ET-1.  This reduction was further increased to 100% when 
cells were pre-treated with both antagonists in combination.  This result was also plotted in 
comparison to ET-1 treated cells. 
The wound healing model was used again in order to determine the effect of Ang II on NOF 
migration (Figure 5.3A).  In this experiment transforming growth factor-β (TGF-β) was used as 
a positive control (Leask and Abraham, 2004).  The treatment of NOFs with TGF-β resulted in a 
75% increase in NOFs migration in comparison to untreated cells (Figure 5.3B).  Treatment 
with Ang II also resulted in an increase in the migratory nature of the NOFs.  Ang II stimulated 
NOF migration by 50% compared to untreated cells.  These findings suggest that the treatment  
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Figure 5.2  ET-1 stimulates NOF migration:  Fibroblasts found within the stroma of the tumour 
microenvironment have been shown to have a more migratory phenotype.  The migration of 
NOFs treated with ET-1 (10 nM) was assayed using a wound healing assay.  Briefly, NOFs were 
cultured as a confluent monolayer in 12-well titre plates and allowed to adhere.  A scratch was 
made through the serum starved cells using a pipette tip.  The cells were pre-treated with a 
specific receptor antagonist to ETAR, BQ-123 (1 µM) and/or a specific receptor antagonist to 
ETBR, BQ-788 (1 µM) for 30 min before the addition of ET-1 (10 nM) or DMEM containing 10% 
(v/v) serum.  Mitomycin C (1 µg/µl) was added to inhibit proliferation.  Photographs were 
taken at two positions along the scratch at 0 h and 24 h time points (A) and the distance 
between the two edges of the scratch were measured (B) and the distance migrated by the 
cells was calculated. Each data point represents an average of at least 3 independent 
experiments, carried out in duplicate.  ± SEM are indicated.  A two-tailed student t-test was 
carried out and data deemed statistically significant when p<0.05 (*) relative to untreated 
control, or as indicated by bars. 
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Figure 5.3  Ang II stimulates NOF migration:  TGF-β is a well characterized stimulant of 
myofibroblast transdifferentiation.  Migration of NOFs treated with Ang II (100 nM) was 
assayed using a wound healing assay.  Briefly, NOFs were cultured as a confluent monolayer in 
12-well titre plates and allowed to adhere.  A scratch was made through the serum starved 
cells using a pipette tip.  The cells were treated with Ang II (100 nM) or TGF-β (20 ng/μl).  
Mitomycin C (1 µg/µl) was added to inhibit proliferation.  Photographs were taken at two 
positions along the scratch at 0 h and 24 h time points (A) and the distance between the two 
edges of the scratch were measured (B) and the distance migrated by the cells was calculated. 
Each data point represents an average of at least 3 independent experiments, carried out in 
duplicate.  ± SEM are indicated.  A two-tailed student t-test was carried out and data deemed 
statistically significant when p<0.05 (*) relative to untreated control. 
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of NOFs with either the ET-1 or Ang II results in a phenotypic change in the cells, stimulating 
them to migrate more. 
5.4 ET-1 and Ang II stimulate contraction of NOFs 
When fibroblasts become ‘activated’ they acquire a more contractile phenotype.   ET-1 is 
known to promote human skin fibroblast contraction (Guidry and Hook, 1991).  The 
contraction of fibroblasts is an important action in the processes of wound healing and dermis 
reconstitution (Grinnel, 1994).  ET-1 is also capable of modifying the ECM (Levin, 1995), 
increasing collagen I and III synthesis, and it can decrease the mRNA and protein levels of 
matrix mettaloproteinase-1 (MMP-1) in dermal fibroblasts (Xu et al, 1998;  Shi-Wen et al, 
2001).  A fibroblast:collagen contraction model was used to determine the ability of ET-1 to 
stimulate the contraction of NOFs.  NOFs were mixed with collagen and seeded into 24-well 
plates.  After incubation overnight in serum free media the fibroblast:collagen gels were 
detached from the edges of each well and treated with ET-1.  The ability of each gel to contract 
and decrease in size after 30 min was measured (Figure 5.4A).  The decrease in gel size reflects 
the increased contractile capability acquired by the NOF cells. Treatment of fibroblast:collagen 
gels  with ET-1 resulted in a decrease in gel size of 25% in comparison to fibroblast:collagen 
gels which were treated with serum free media only (Figure 5.4B).  Thrombin is known to 
stimulate fibroblast contraction and was used as a positive control in this experiment (Fang et 
al, 2004).  Treatment of fibroblast:collagen gels with thrombin resulted in a 30% reduction in 
their size in comparison to vehicle treated gels.  In order to investigate through which receptor 
ET-1 was exerting its effects the gels were pre-treated with BQ-123 and BQ-788, both alone 
and in combination, for 30 min before treatment with ET-1.  Treatment with BQ-123 resulted 
in contraction of the gels by only 10% and treatment with BQ-788 resulted in contraction 
similar to that observed when gels were treated with serum free media only.  This reduction in 
contraction was further increased when both receptor antagonists were utilised together.  The 
stimulation of a contractile phenotype in NOFs by ET-1 appeared to be predominantly 
mediated by ETBR, with antagonism of ETAR having a smaller effect. 
The fibroblast:collagen models were also used to determine the effect of Ang II on the NOF 
contractile phenotype.  The presence of the peptide resulted in a decrease in gel size of 40% in 
comparison to gels treated with serum free media only (Figure 5.5A).  Thrombin was again 
used as a positive control within this experiment and treatment of the fibroblast:collagen gels 
with the enzyme reduced gel size to 40% compared to untreated cells, a similar observation to 
that observed with Ang II treatment. 
Both peptides appear to be able to promote a more contractile phenotype in NOFs.  
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Figure 5.4  ET-1 invokes NOFs to have a more contractile phenotype:  The acquisition of NOFs 
to a more activated state usually coincides with a more contractile phenotype.  The contractile 
nature of NOFs when treated with ET-1 was assayed using a fibroblast:collagen contraction 
model.  Briefly, NOFs were added to collagen and seeded into 24 well titre plates and allowed 
to incubate overnight.  The fibroblast:collagen gels were detached from the edges of each well 
and pre-treated with specific receptor antagonists to ETAR (1 µM) and/or ETBR (1 µM) for 30 
min before the addition of ET-1 (10 nM) or thrombin (0.5 units/ml).  The distance each gel 
contracted was photographed (A) and the decrease in gel size after 30 min was measured (B).  
Each data point represents an average of at least 3 independent experiments, carried out in 
duplicate.  ± SEM are indicated.  A two-tailed student t-test was carried out and data deemed 
statistically significant when p<0.05 (*) relative to untreated control, or as indicated by bars. 
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Figure 5.5  Ang II invokes NOFs to have a more contractile phenotype:  The contractile nature 
of NOFs when treated with Ang II was assayed using a fibroblast:collagen contraction model.  
Briefly, NOFs were added to collagen and seeded into 24 well titre plates and allowed to 
incubate overnight.  The fibroblast:collagen gels were detached from the edges of each well 
and treated with Ang II (100 nM) or thrombin (0.5 units/ml).  The distance each gel contracted 
was photographed and the decrease in gel size after 30 min was measured (A).  Each data 
point represents an average of at least 3 independent experiments, carried out in duplicate.  ± 
SEM are indicated.  A two-tailed student t-test was carried out and data deemed statistically 
significant when p<0.05 (*) relative to untreated control. 
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5.5 The effect of ET-1 and Ang II on myofibroblast transdifferentiation 
of NOFs  
TGF-β is a well-characterized stimulant of myofibroblast transdifferentiation.  Myofibroblast 
transdifferentiation can be characterised by the increase in expression of a number of proteins 
including α-smooth muscle actin (α-SMA) and MMP-2; a member of the MMP family which is 
responsible for the degradation of the ECM in normal physiological conditions including tissue 
remodelling and embryonic development and in disease including the process of metastasis 
and arthritis.  Both α-SMA and MMP-2 are described as ‘markers’ of myofibroblasts (Sobral et 
al, 2011).  TGF-β mediated transdifferentiation of NOFs into myofibroblasts not only increases 
the levels of α-SMA and MMP-2 within the cells but also results in their increased ability to 
promote cancer cell migration.  The ability of treatment with ET-1 to trigger NOFs to acquire an 
activated, myofibroblast-like phenotype was explored.  Within this experiment TGF-β was used 
as a positive control.  The treatment of NOFs with the TGF-β resulted in an increase in the 
expression levels of α-SMA transcript (2.5-fold) (Figure 5.6A) and protein (2.5-fold) (Figure 
5.6B) and MMP-2 transcript (1.7-fold) (Figure 5.6C) levels in comparison to vehicle treated 
cells.  Treatment of NOFs with ET-1 however did not significantly increase the transcript levels 
of α-SMA or MMP-2.  ET-1 treatment resulted in only a small increase of 1.1-fold in both α-
SMA and MMP-2 transcript levels and a 1.3-fold increase in α-SMA protein levels.  All fold 
changes were plotted relative to untreated cells. 
The ability of Ang II to stimulate NOFs to acquire an activated, myofibroblast-like phenotype 
was next investigated.  NOFs were again treated with TGF-β within the same experiment in 
order for the cytokine to act as a positive control.  Unlike ET-1, Ang II treatment resulted in a 
significant increase in the transcript levels of both α-SMA (Figure 5.7A) and MMP-2 (Figure 
5.7B) (1.6-fold and 1.4-fold in comparison to untreated cells, respectively).  This result was 
similar to that observed when NOFs were treated with TGF-β.  TGF-β stimulated an increase in 
the expression of α-SMA 2.5-fold and the expression of MMP-2 1.7-fold compared to cells left 
untreated.  The increase in α-SMA transcript expression could be inhibited to only 0.6-fold by 
the pre-treatment of NOFs with an AT1R antagonist, telmisartan (Figure 5.7C).  This finding 
suggests that the receptor is critical in the ability of Ang II to promote myofibroblast 
transdifferentiation.  SDS-Page and western blot analysis also showed that a small increase 
(1.2-fold) in α-SMA protein levels after treatment with Ang II was also observed (Figure 5.7D).  
Treatment with TGF-β resulted in an increase in α-SMA protein levels of 1.6-fold.  Both results 
were plotted in comparison to cells left untreated. 
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Figure 5.6  ET-1 does not stimulate markers of myofibroblast transdifferentiation:   
Myofibroblast transdifferentiation can be characterised by an increase in expression of α-SMA 
and MMP-2, a secretory component of the ECM, both of which are described as ‘markers’ of 
myofibroblasts.  TGF-β is a well characterized stimulant of myofibroblast transdifferentiation 
and is known to increase expression of α-SMA and MMP-2.  The ability of ET-1 to stimulate an 
increase in expression of α-SMA and MMP-2 in NOFs was assessed.  Briefly, serum starved 
NOFs were treated with ET-1 (10 nM) or TGF-β (5 ng/µl) for 48 h before cells were harvested 
and RNA extracted or lysates prepared.  qPCR analysis was used to measure the transcript 
levels of α-SMA (A), MMP-2 (C) or U6 as a reference gene.  Each data point represents an 
average of at least 3 independent experiments, carried out in duplicate.  ± SEM are indicated.  
A two-tailed student t-test was carried out and data deemed statistically significant when 
p<0.05 (*) relative to untreated control, ns = not significant.  Cell lysates were separated by 
SDS-PAGE and immunoblotted for α-SMA and β-actin (as a loading control). A representative 
blot is shown (B) and the intensity of the band corresponding to α-SMA, determined by 
densitometry and normalized to β-actin levels in the same sample, is indicated under each 
lane. 
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Figure 5.7  Ang II stimulates markers of myofibroblast transdifferentiation:  The ability of Ang 
II to stimulate an increase in expression of α-SMA and MMP-2 in NOFs was assessed.  Briefly, 
serum starved NOFs were treated with Ang II (100 nM) or TGF-β (5 ng/µl) for 48 h before cells 
were harvested and RNA extracted or lysates prepared.  qPCR analysis was used to measure 
the transcript levels of α-SMA (A), MMP-2 (B) or U6 as a reference gene.  qPCR for α-SMA was 
also carried out on RNA extracted from NOFs pre-treated with telmisartan (100 nM), a specific 
AT1R antagonist, for 30 min before the addition of 100 nM Ang II for a further 48 h (C).  Each 
data point represents an average of at least 3 independent experiments, carried out in 
duplicate.  ± SEM are indicated.  A two-tailed student t-test was carried out and data deemed 
statistically significant when p<0.05 (*) relative to untreated control.  Cell lysates were 
separated by SDS-PAGE and immunoblotted for α-SMA and β-actin (as a loading control). A 
representative blot is shown (D) and the intensity of the band corresponding to α-SMA, 
determined by densitometry and normalized to β-actin levels in the same sample, is indicated 
under each lane. 
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5.6 The combined treatment of NOFs with ET-1, Ang II and TGF-β can 
further potentiate paracrine and autocrine migration and 
myofibroblast transdifferentiation   
Research conducted has identified that ET-1, Ang II and TGF-β can interact with each other to 
alter the behaviour of cells and the regulatory systems responsible for the control of the 
individual peptides (Lagares et al, 2010;  Shi-Wen et al, 2007;  Shephard et al, 2004;  Alvarez et 
al, 2011).  The synergistic effect of both peptides and the cytokine on the paracrine stimulation 
of HNSCC migration was therefore investigated.  NOFs were treated with ET-1, Ang II and/or 
TGF-β alone or in combination for 4 h before the media was aspirated, filtered and added to 
the Transwell migration assay.  The effect on the migration of serum starved SCC4 cells was 
observed.  The treatment of NOFs with ET-1 resulted in an increase in SCC4 migration 1.8-fold 
in comparison to untreated NOFs (Figure 5.8A).  Ang II treatment resulted in a similar increase 
in SCC4 migration, 1.6-fold greater than untreated NOFs.  Treatment of NOFs with TGF-β 
stimulated SCC4 cells to migrate 2.0-fold compared to NOFs which were left untreated.  The 
combined treatment of NOFs with ET-1 and Ang II resulted in an increase in SCC4 migration 
2.1-fold greater than the effect on SCC4 migration stimulated by untreated NOFs.  This 
however was not a significant increase in comparison to migration stimulated by ET-1 or Ang II 
treatment alone.  There was a similar observation when NOFs were treated with ET-1 and TGF-
β in combination.  The combined treatment resulted in an increase in SCC4 migration of 2.3-
fold but this was not significantly greater than each treatment alone.  The combined treatment 
of NOFs with Ang II and TGF-β caused an increase in SCC4 migration 3.0-fold greater than 
untreated NOFs and this was a significant increase in SCC4 stimulated migration in comparison 
to Ang II treatment alone.  It was however not significant in comparison to TGF-β alone.  Finally 
NOFs were treated with ET-1, Ang II and TGF-β in combination.  This treatment method 
resulted in an increase in SCC4 migration 3.7-fold greater than untreated NOFs.  This further 
stimulation of SCC4 migration by combined treatment of all three peptides was significantly 
greater than the migration stimulated by NOFs treated with the three peptides individually. 
A similar experiment was conducted to investigate the direct effect on NOF phenotype caused 
by combining the peptide treatments.  A wound healing model was used to determine the 
effect of ET-1, Ang II and/or TGF-β alone or in combination on NOFs.  Mitomycin C was again 
added at the same time as the treatment to inhibit NOF proliferation.  Treatment of NOFs with 
ET-1 resulted in an 80% increase in their migrational ability compared to NOFs treated with 
serum free media only (Figure 5.9A). When NOFs were treated with Ang II, their migration 
increased 70%. TGF-β treatment stimulated their migration 60% more compared to cells that 
were left untreated.  The treatment of NOFs with ET-1 and Ang II in combination resulted in a  
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Figure 5.8  The combined treatment of NOFs with ET-1, Ang II and/or TGF-β can further 
potentiate paracrine stimulated HNSCC migration:  NOFs were treated with ET-1 (10 nM), Ang 
II (100 nM) and/or TGF-β (5 ng/μL) alone and in combination for  4 h. Conditioned media was 
aspirated, filtered and added to the bottom Transwell migration well.  Serum free media 
treated with ET-1 (10 nM), Ang II (100 nM) and/or TGF-β (5 ng/μL) was used as a control.  
1x105 serum starved SCC4 cells were left untreated and added to the top of the Transwell 
migration inserts in DMEM supplemented with 0.1% (w/v) BSA.  After 16 h, cells which 
migrated to the underside of the Transwell permeable membrane were fixed in 100% (v/v) 
methanol.  Migrated cells were stained using crystal violet (0.1% (w/v)) and counted using a 
light microscope.  Data plotted represent average number of cells which migrated relative to 
untreated control and were calculated from an average of 3 fields of view.  Each data point 
represents an average of at least 3 independent experiments.  ± SEM are indicated.  A two-
tailed student t-test was carried out and data deemed statistically significant when p<0.05 (*), 
p<0.05 relative to ET-1, Ang II or TGF-β only treated cells (**). 
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Figure 5.9  The combined treatment of NOFs with ET-1, Ang II and/or TGF-β can further 
potentiate autocrine stimulated migration:  Briefly, NOFs were cultured as a confluent 
monolayer in 12-well titre plates and allowed to adhere.  A scratch was made through the 
serum starved cells using a pipette tip.  The cells were treated with ET-1 (10 nM), Ang II (100 
nM) and/or TGF-β (5 ng/μl) alone or in combination.  Mitomycin C (1 µg/µl) was added to 
inhibit proliferation.  Photographs were taken at two positions along the scratch at 0 h and 24 
h time points and the distance between the two edges of the scratch were measured (B) and 
the distance migrated by the cells was calculated. Each data point represents an average of at 
least 3 independent experiments, carried out in duplicate.  ± SEM are indicated.  A two-tailed 
student t-test was carried out and data deemed statistically significant when p<0.05 (*) 
relative to untreated control, or as indicated by bars.  p<0.05 relative to ET-1, Ang II or TGF-β 
only treated cells (**). 
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significantly greater increase in migration of 120% compared to NOFs treated with ET-1 or Ang 
II alone.  The treatment of NOFs with ET-1 and TGF-β in combination and Ang II and TGF-β in 
combination produced similar results.  Both combinations of treatments stimulated migration 
of NOFs 130% more compared to cells that were left untreated.  The combined treatment of 
ET-1 and TGF-β only stimulated NOF migration significantly more than TGF-β treatment alone 
and not ET-1 treatment alone.  The combined treatment with Ang II and TGF-β however did 
stimulate migration of the cells significantly more than the individual treatment with each 
peptide alone.  Finally the treatment of NOFs with ET-1, Ang II and TGF-β stimulated NOF 
migration 140% more than the migration of untreated NOFs.  This result was significantly 
greater than any increase in migration observed when cells with treated with each peptide 
individually. 
The synergistic effect of ET-1, Ang II and/or TGF-β on myofibroblast transdifferentiation was 
investigated next.  The effect on α-SMA transcript levels was used as a marker to determine 
the peptides and cytokines ability to promote transdifferentiation of the NOFs.  NOFs were 
treated with ET-1, Ang II and/or TGF-β alone or in combination for 48 h.  Treatment of NOFs 
with ET-1 did not result in an increase in α-SMA transcript levels in comparison to NOFs 
treated with serum free media only (Figure 5.10A). When NOFs were treated with Ang II there 
was a small increase in α-SMA transcript levels of around 1.2-fold compared to untreated cells.  
TGF-β treatment of NOFs resulted in a 2.5-fold increase in α-SMA transcript levels compared to 
untreated cells.  The treatment of NOFs with ET-1 and Ang II in combination resulted in a 
greater increase in α-SMA transcript levels of 1.5-fold compared to NOFs treated with ET-1 or 
Ang II alone.  The treatment of NOFs with ET-1 and TGF-β in combination resulted in a 
significantly greater stimulation of α-SMA transcript levels.  ET-1 and TGF-β combined 
treatment increased transcript levels 4.2-fold compared to untreated NOFs.  Ang II and TGF-β 
combined treated of NOFs produced similar results.  This combined treatment resulted in an 
increase in α-SMA transcript levels of 3.1-fold compared to untreated cells.  The treatment of 
NOFs with ET-1, Ang II and TGF-β stimulated α-SMA transcript levels 3.2-fold more than 
untreated NOFs.  SDS-PAGE and western blot analysis also showed an increase in α-SMA 
protein levels when NOFs were treated with ET-1, Ang II and/or TGF-β in combination in 
comparison to the individual treatment of the cells with ET-1 or Ang II (Figure 5.10B). 
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Figure 5.10  The effect of combining treatment of NOFs with ET-1, Ang II and/or TGF-β on α-
SMA transcript and protein levels:  NOFs were treated with ET-1 (10 nM), Ang II (100 nM) 
and/or TGF-β (5 ng/μl) alone or in combination for 48 h before the cells were harvested and 
RNA extracted or lysates prepared.  qPCR analysis was used to measure the transcript levels of 
α-SMA (A) or U6 as a reference gene.  Cell lysates were separated by SDS-PAGE and 
immunoblotted for α-SMA.  A representative blot is shown (B).  Each data point represents an 
average of at least 3 independent experiments, carried out in triplicate.  ± SEM are indicated.   
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5.7 Summary 
Work conducted in this thesis has identified that both ET-1 and Ang II can promote tumour-
stromal interactions between NOFs and HNSCCs resulting in an increase in the migration and 
invasion of the epithelial tumour cells.  The aim of the work in this chapter was to elucidate the 
mechanism by which the mitogenic peptides are stimulating this communication network 
between the two cell types.  Was the treatment of NOFs with ET-1 and Ang II resulting in a 
change in their phenotype?  Fibroblasts found within the tumour microenvironment are 
known to undergo a phenotypic change in response to both factors found within the reactive 
stroma and those released from the nearby epithelial cancer cells.  Work in this chapter was 
conducted in order to determine the phenotypic changes triggered by treatment of NOFs with 
both ET-1 and Ang II and to determine if they could stimulate the transdifferentiation of NOFs 
into myofibroblasts; a common characteristic associated with fibroblasts found within the 
reactive stroma of the tumour microenvironment.  The treatment of NOFs with ET or Ang II 
resulted in an increase their ability to migrate, proliferate and contract; all of which are 
characteristics associated with a more ‘activated’ phenotype.  ET-1, unlike Ang II however did 
not stimulate NOFs to transdifferentiate into myofibroblasts as indicated by its ability to not 
stimulate a significant increase in α-SMA transcript and protein levels and MMP-2 transcript 
levels.  Both α-SMA and MMP-2 are deemed markers of myofibroblasts transdifferentiation.  
Ang II on the other hand did stimulate NOFs to transdifferentiate into myofibroblasts in part 
through the activation of the AT1R.   
The final section of this chapter included work that focused on the synergistic effects of both 
the ET-1 and Ang II mitogenic peptides and that of the TGF-β cytokine, a factor known to 
promote myofibroblast transdifferentiation.  The combined treatment of ET-1, Ang II and/or 
TGF-β resulted in a further increase in the paracrine stimulation of HNSCC migration, NOF 
migration and α-SMA transcript levels suggesting that the peptides and cytokine can work 
together to further potentiate the effects triggered by individual treatment of NOFs with ET-1, 
Ang II and TGF-β alone. 
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Chapter 6: The identification of Ang 1-7 as 
a novel inhibitor of mitogenic peptide 
stimulated HNSCC migration and 
invasion  
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6.1 Introduction  
Another arm of the renin angiotensin system (RAS) has recently been identified.  Angiotensin 
1-7 (Ang 1-7) is an endogenous, seven amino acid hormone that has both anti proliferative and 
vasodilator properties (Ferrario et al, 1997;  Tallent et al, 1999;  Santos et al, 2000).  Ang 1-7 
can be produced by the enzymatic breakdown of angiotensin I (Ang I) by a number of 
endopeptidases including neprilysin (NEP), prolyl oligopeptidase or thimet oligiopeptidase 
(Welches et al, 1991;  Yamamoto et al, 1992;  Chappel et al, 1995;  Welches et al, 1993).  This 
cleavage event takes place at the Pro-7-Phe-8 bond (Welches et al, 1993).  It is considered that 
the production of Ang 1-7 is actually predominantly catalyzed by the angiotensin converting 
enzyme 2 (ACE2), which cleaves a single phenylalanine amino acid from the C-terminal of 
Angiotensin II (Ang II).  It has been suggested that Ang 1-7 could have anti-proliferative effects, 
could act as a vasodilator and depressor (Ferrario et al, 1997), could inhibit angiogenesis 
(Machado et al, 2000;  Machado et al, 2001) and have the ability to antagonize the effects 
triggered by Ang II (Herath et al, 2007).  Treatment with ACE inhibitors, which result in an 
increase in Ang 1-7, have been linked to a reduction in the risk of cancer, particularly within 
the breast and lung (Lever et al, 1998).  The ability of Ang 1-7 to oppose the profibrotic actions 
of Ang II in animal models of renal and cardiovascular disease has also been described.  Ang 1-
7 is thought to act in this instance through its receptor, Mas receptor (MasR) (Santos et al, 
2003;  Santos et al, 2008).  Ang 1-7 treatment has also been shown to reduce transcript levels 
of endothelin-1 (ET-1) in cardiac fibroblasts (Iwata et al, 2005) and reduce the cerebral damage 
and behavioural deficits caused by ET-1 induced middle cerebral artery occlusion in a model of 
cerebral ischemia (Mecca et al, 2011).  Both studies implicate that Ang 1-7 may inhibit the 
activity of other mitogenic peptides. Nothing is known of the role of Ang 1-7 in head and neck 
squamous cell carcinoma (HNSCC).   
6.2 Ang 1-7 inhibits Ang II-induced autocrine cancer cell migration and 
invasion  
The transcript levels of components of the RAS were examined in order to determine the 
ability of the oral mucosa to produce and/or respond to Ang 1-7.  qPCR was used to determine 
the expression pattern of both ACE2 (Figure 6.1A) and the MasR (Figure 6.1B) in the same 
panel of primary human normal oral keratinocytes (NOKs) and normal oral fibroblasts (NOFs) 
and cell lines derived from oral dysplasias, primary HNSCCs and a local metastasis that was 
used previously and described in Table 2.2.  ACE2 transcript levels were highest in NOKs and 
present at lower levels in cell lines derived from oral dysplasias, primary HNSCCs and a local 
metastasis.  There was no expression of ACE2 detectable within the NOFs.  The greatest levels 
of MasR transcripts were detectable within the different primary HNSCC cell lines.  Transcripts  
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Figure 6.1  ACE2 and MasR expression:  Ang 1-7 is produced from Ang II by the action of ACE2 
(Herath et al, 2007).  Ang 1-7 exerts its cellular effects via the MasR.  Primary human NOKs and 
NOFs and cell lines derived from oral dysplasias, primary HNSCCs and a local metastasis were 
cultured in growth media and at 90% confluency were washed in PBS, trypsinised and pelleted.  
Total RNA was prepared from the cell pellets and 100 ng was subjected to RT-PCR.  0.25 ng 
cDNA was analysed using qPCR for ACE2 (A), MasR (B), B2M or U6 as a reference gene.  RNA 
from NOFs, H357 and SCC4 were subjected to RT-PCR for MasR.  Amplicons were separated by 
agarose gel electrophoresis and visualised by UV transillumination.  Each data point represents 
an average of 3 technical repeats.  ± SEM are indicated. 
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of the receptor were also detectable within NOKs, NOFs and cell lines derived from oral 
dysplasias and local metastasis but to a lower degree.   
The ability of Ang 1-7 to influence HNSCC migration and invasion in the presence and absence 
of Ang II was next investigated.  SCC4 cells were treated with Ang 1-7 alone and in combination 
with Ang II.  The treatment of SCC4 cells with Ang 1-7 alone caused a small increase in cell 
migration (1.1-fold) in comparison to cells that were left untreated, however this increase was 
not significant (Figure 6.2A).  The treatment of SCC4 cells with both Ang 1-7 and Ang II resulted 
in significant abrogation of Ang II stimulated SCC4 migration.  Ang II alone stimulated cellular 
migration 1.5-fold in comparison to PBS vehicle treated cells.  This was reduced to 0.8-fold 
when SCC4 were treated with Ang II and Ang 1-7 in combination.  The same pattern of results 
was also observed for Ang II stimulated SCC4 invasion in the presence of Ang 1-7 (Figure 6.2B).  
The presence of the Ang 1-7 peptide resulted in a decrease in SCC4 invasion from 1.6-fold 
stimulated by Ang II treatment alone, to 0.9-fold compared to untreated cells.  This reduction 
in cellular migration and invasion stimulated by Ang II treatment suggests that Ang 1-7 is able 
to have an inhibitory effect on the events triggered by Ang II. 
In order to investigate if Ang 1-7 was causing its inhibitory effects via signalling through the 
MasR, SCC4 cells were treated with a specific MasR inhibitor, A-779.  SCC4 cells were pre-
treated with the inhibitor for 30 min before the addition of Ang 1-7 and/or Ang II.  Treatment 
of SCC4 cells with Ang II alone resulted in a 1.5-fold increase in SCC4 migration (Figure 6.2C).  
The combined treatment of SCC4 cells with Ang II and Ang 1-7 decreased this level of migration 
to only 0.6-fold again highlighting the ability of Ang 1-7 to inhibit the effects triggered by Ang 
II.  The presence of the MasR inhibitor, A-779 blocked this inhibitory effect and resulted in an 
increase in SCC4 migration of 1.4-fold in comparison to vehicle treated cells.  All fold values 
were plotted in relation to PBS vehicle treated cells. 
6.3 Ang 1-7 inhibits Ang II-induced paracrine cancer cell migration and 
invasion 
The co-application of Ang 1-7 with Ang II significantly abrogates the ability of Ang II to promote 
HNSCC cell migration and invasion via an autocrine mechanism.  The effect of exogenous Ang 
1-7 on Ang II-stimulated paracrine signalling between NOFs and HNSCC cells was next 
investigated. As observed for direct application, treatment of SCC4 cells with conditioned 
media from NOFs incubated with Ang 1-7 and Ang II significantly inhibited the stimulation of 
cell migration and invasion observed in response to Ang II alone.  The treatment of NOFs with 
Ang 1-7 alone resulted in a significant increase of 1.5-fold in comparison to vehicle treated  
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Figure 6.2  Ang 1-7 abrogates Ang II stimulated migration and invasion of HNSCC:  The ability 
of Ang 1-7 to block Ang II stimulated migration and invasion of SCC4 cells was investigated.  
SCC4 cells were treated with Ang 1-7 (100 µM) and/or Ang II (100 µM) and assayed using a 2D 
Transwell migration assay (A) or a Matrigel invasion assay (B).  To investigate if Ang 1-7 is 
acting via the MasR in this instance, migration of SCC4 when pre-treated with a specific 
receptor antagonist to MasR, A-779 (100 µM) (C) for 30 min before the addition Ang II both 
alone and in combination with Ang 1-7 were assayed using a 2D Transwell migration assay.  
Briefly, 1x105 serum starved SCC4 cells were treated as above and added to the top of the 
Transwell migration or Matrigel invasion inserts in DMEM supplemented with 0.1% (w/v) BSA 
with DMEM containing 10% (v/v) FBS placed at the bottom of the well.  After 16 h (for 
migration) or 40 h (for invasion), cells which migrated to the underside of the Transwell 
permeable membrane were fixed in 100% (v/v) methanol.  Migrated cells were stained using 
crystal violet (0.1% (w/v)) and counted using a light microscope.  Data plotted represent 
average number of cells which migrated relative to untreated control and were calculated 
from an average of 3 fields of view.  Each data point represents an average of at least 3 
independent experiments.  ± SEM are indicated.  A two-tailed student t-test was carried out 
and data deemed statistically significant when p<0.05 (*), p < 0.05 relative to Ang II treated 
cells (**), p < 0.05 relative to Ang II and Ang 1-7 treated cells in combination (***). 
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Figure 6.3  Ang 1-7 blocks the paracrine stimulation of HNSCC migration stimulated by Ang II:  
The ability of Ang 1-7 to inhibit paracrine stimulation by Ang II was investigated.  NOFs were 
pre-treated with Ang 1-7 (100 nM) and/or a specific MasR antagonist, A-779 (1 µM) for 30 m 
before the addition of Ang II for a further 4 h.  The conditioned media was aspirated, filtered 
and added to the bottom Transwell migration well (A, C -/+ A-779) or the bottom Matrigel 
invasion well (B).  1x105 serum starved SCC4 cells were left untreated and added to the top of 
the Transwell migration or Matrigel invasion inserts in DMEM supplemented with 0.1% (w/v) 
BSA. After 16 h (for migration) or 40 h (for invasion), cells which migrated to the underside of 
the Transwell permeable membrane were fixed in 100% (v/v) methanol.  Migrated cells were 
stained using crystal violet (0.1% (w/v)) and counted using a light microscope.  Data plotted 
represent average number of cells which migrated relative to untreated control and were 
calculated from an average of 3 fields of view.  Each data point represents an average of at 
least 3 independent observations.  ± SEM are indicated.  A two-tailed student t-test was 
carried out and data deemed statistically significant when p<0.05 (*), p<0.05 relative to Ang II 
treated cells (**), p<0.05 relative to Ang 1-7 and Ang II treated cells in combination (***).  
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NOFs, in SCC4 migration (Figure 6.3A).  Ang 1-7 however, did not stimulate SCC4 invasion 
under the same experimental circumstances.  As previously observed, Ang II stimulated 
migration of SCC4 cells 3.1-fold and invasion of SCC4 cells 3.0-fold.  This was reduced in both 
circumstances to 1.5-fold for migration and invasion when NOFs were treated with both Ang 1-
7 and Ang II (Figure 6.3A and 6.3B, respectively).  Each fold change was plotted in relation to 
cells lefts untreated within each individual experiment.  To determine if Ang 1-7 was inhibiting 
Ang II stimulated SCC4 migration and invasion through the MasR, the MasR-specific antagonist, 
A-779 was used.  NOFs were pre-treated with the receptor antagonist for 30 min before the 
addition of Ang 1-7 and Ang II.  Prior incubation with A-779 again reversed this inhibition, a 
similar result to that observed for autocrine Ang II-stimulated HNSCC migration and invasion.  
In this experiment treatment of NOFs with Ang II stimulated SCC4 migration 2.8-fold in 
comparison to vehicle treated cells (Figure 6.3C).  This was reduced to 1.0-fold with combined 
treatment with Ang II and Ang 1-7.  Pre-treatment with A-779 returned this value to around 
2.5-fold.   
6.4 Ang 1-7 can also block the paracrine stimulation of HNSCC 
migration by ET-1 and BK but not EGF 
Having established that Ang 1-7 can abrogate Ang II-induced paracrine effects on SCC4 
migration, the signalling mechanisms involved were next investigated.  Results within this 
thesis have identified that Ang II can promote the release of stimulatory factors by activating 
members of the ADAMs family of cell surface proteinases.  These factors include heparin 
bound-epidermal growth factor (HB-EGF), tumour growth factor-α (TGF-α) and amphiregulin; 
ligands of the EGF receptor (EGFR).  In order to examine whether Ang 1-7 was mediating its 
effects by interfering with this stimulation of ligand release, the ability of Ang 1-7 to reduce the 
activation of HNSCC migration provoked by other peptides was investigated.  NOFs were 
treated for 4 h with Ang 1-7 combined with Ang II, ET-1, bradykinin (BK) and/or EGF which 
stimulated EGFR directly.  After 4 h the media was removed, filtered and added to the bottom 
well of a Transwell migration assay.  Untreated SCC4 cells were added to the top chamber of 
the assay and their ability to migrate investigated.  After 16 h the migrated SCC4 cells were 
fixed, stained and counted using the method described in Section 2.2.4.  The presence of 
conditioned media collected from NOFs treated with Ang 1-7 and Ang II, Ang 1-7 and ET-1 and 
Ang 1-7 and BK all caused a significant decrease in SCC4 cell migration (0.8-fold, 3.7-fold and 
1.8–fold, respectively in comparison to 3.4–fold, 5.6-fold and 2.8–fold with Ang II, ET-1 and BK 
treatment alone) (Figure 6.4).  The combined treatment of NOFs with Ang 1-7 and EGF did not 
inhibit SCC4 paracrine migration in comparison to EGF treatment alone (3.4-fold vs. 3.5–fold, 
respectively).  Each fold change was plotted in comparison to cells left untreated. 
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Figure 6.4  Ang 1-7 blocks the paracrine stimulation of HNSCC migration stimulated by 
mitogenic peptides:  NOFs were pre-treated with Ang 1-7 (100 nM) for 30 m before the 
addition of Ang II (100 nM), ET (10 nM), BK (1 µM) and/or EGF (48.4 μM) alone or in 
combination for a further 4 h.  The conditioned media was aspirated, filtered and added to the 
bottom Transwell migration well.  1x105 serum starved SCC4 cells were left untreated and 
added to the top of the Transwell migration in DMEM supplemented with 0.1% (w/v) BSA. 
After 16 h cells which migrated to the underside of the Transwell permeable membrane were 
fixed in 100% (v/v) methanol.  Migrated cells were stained using crystal violet (0.1% (w/v)) and 
counted using a light microscope.  Data plotted represent average number of cells which 
migrated relative to untreated control and were calculated from an average of 3 fields of view.  
Each data point represents an average of at least 3 independent observations.  ± SEM are 
indicated.  A two-tailed student t-test was carried out and data deemed statistically significant 
when p<0.05 (*), p<0.05 relative to Ang II, ET-1, BK or EGF only treated cells (**). 
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6.5 Summary  
This chapter has identified that a recently identified effector peptide of the RAS, Ang 1-7 can 
inhibit the effects on HNSCC migration and invasion stimulated by Ang II treatment.  Ang 1-7 is 
a small peptide that is thought to be able to inhibit the effects triggered by Ang II.  Ang 1-7 is 
produced from Ang II via the catalytic activity of ACE2 and the peptide has been identified as a 
ligand for the MasR.  qPCR analysis identified the expression pattern of both components of 
the RAS, ACE2 and MasR within a panel of primary cells and cell lines.  Both components are 
found within all cell types apart from ACE2 which is not detectable within NOFs.  This result 
suggests that Ang 1-7 can be produced at a local level within the tumour microenvironment.  
Within this chapter experiments have indicated that the treatment of both HNSCCs and NOFs 
with Ang 1-7 results in the inhibition of migration and invasion triggered by stimulation with 
Ang II.  Inhibitors to the MasR block the antagonising effect of Ang 1-7 on Ang II stimulated 
autocrine and paracrine activity suggesting that the peptide is exerting its effects through this 
receptor.  Ang 1-7 can also inhibit the paracrine stimulation of HNSCC cell migration triggered 
by the treatment of NOFs with other mitogenic peptides including ET-1 and BK.  This suggests 
that Ang 1-7 does not inhibit Ang II activity exclusively and this finding fuels the possibility that 
the peptide could be used as a novel therapeutic application in the treatment of head and 
neck cancer 
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7.1 Introduction 
Head and neck cancer is the 6th most common malignancy worldwide and contributes to 3% of 
all cancers diagnosed in the United Kingdom (UK) each year (Cancer Research UK, 2012).  Head 
and neck cancer has a five-year survival rate of around 50% and little improvement has been 
made in this figure over the past three decades (Cancer Research UK, 2012).  The main 
treatment options are surgery and courses of radiotherapy (Scully and Porter, 2000) and an 
early diagnosis, prior to metastatic spread, is vital for a good prognosis (La Vecchia et al, 1997, 
Woolgar, 1999).  The prognosis of head and neck cancer is also affected by the positioning of 
the lesion within the mouth (La Vecchia et al, 1997).  Compared to some more studied cancers, 
little is known about the mechanisms underlying head and neck cancer progression and there 
is an urgent need for this to be addressed and novel therapeutic strategies to be developed.   
Mitogenic peptides have been implicated in the progression of many types of cancer.  Their 
expression and that of the enzymes controlling their levels are known to alter during 
tumourigenesis.  Bradykinin (BK), endothelin-1 (ET-1) and angiotensin II (Ang II) are three 
examples of mitogenic peptides.  Although the role of BK has been extensively studied in head 
and neck carcinogenesis (Thomas et al, 2006;  Zhang et al, 2008), little is known of the role of 
ET-1 or Ang II.   
7.2 The role of the ET-axis in promoting head and neck cancer 
progression via an autocrine mechanism 
ET-1 is 21 amino acids in length and acts primarily as a potent endogenous vasoconstrictor 
(Yanagisawa et al, 1988).  ET-1 is the product of the cleavage of pre-pro ET-1 to big ET-1 by a 
furin-like endopeptidase, and then the cleavage of big ET-1 to ET-1 by endothelin converting 
enzyme-1 (ECE-1), a membrane-bound metalloproteinase (McMahon et al, 1991;  Rubanyi and 
Polokoff, 1994).  ET-1 is the main peptide of the ET-axis.  The ET-axis not only consists of ET-1 
but also the two G protein-coupled receptors (GPCRs) through which the peptide can exert its 
effects; ETAR and ETBR.  The ET-axis also includes the enzyme responsible for the activation of 
ET-1; ECE-1.  ECE-1 is a type II membrane-bound zinc metalloprotease and is a member of the 
neutral endopeptidase family.  It has four distinct isoforms:  ECE-1a, ECE-1b, ECE-1c and ECE-
1d all of which are derived from a single gene through the use of alternative promoter regions.  
Neprilysin (NEP) is another zinc metalloprotease and a member of the neutral endopeptidase 
family.  NEP is important in regulating signal transduction processes throughout the cell and it 
can inactivate mitogenic neuropeptides including ET-1.  NEP is known to be down-regulated in 
cancers, including metastatic human prostate cancer where it has been implicated in the 
transition from the androgen-dependent form of the disease to the more severe androgen-
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independent form (Nelson et al, 2003).  In head and neck squamous cell carcinoma (HNSCC), 
levels of the ET-1 mitogenic peptide are elevated in the saliva of patients suffering with the 
disease (Pickering et al, 2007).  The presence of the peptide correlates with a poor prognosis 
and Awano et al (2006) have shown that HNSCCs produce more ET-1 and have identified that 
treatment of the cell lines with ET-1 results in an increase in their proliferation.  The ET-axis 
has been implicated in HNSCC however the molecular mechanisms underlying its role within 
this environment remain unclear.  The use of therapeutic agents to the ET-axis in the 
treatment of other cancers (Bhalla et al, 2009) raises the possibility that the components of 
the axis could provide new targets in the treatment of HNSCC. 
Treatment of SCC4 cells, a HNSCC cell line isolated from the tongue, with ET-1 resulted in small 
but insignificant increase in cell migration.  Awano et al (2006) identified that ET-1 can 
stimulate the proliferation of HNSCC cells via an autocrine mechanism, suggesting ET-1 may 
contribute to tumour growth.  In this thesis the effect of ET-1 on HNSCC proliferation was not 
examined but the effect on migration, another hallmark associated with cancer progression, 
was.  ET-1 did not significantly stimulate HNSCC migration therefore suggesting that the 
peptide uses different underlying autocrine mechanisms to promote HNSCC proliferation and 
migration.   
Few studies have looked at the molecular mechanism underlying the role that ET-1 plays in the 
promotion of head and neck cancer progression.  There is a need to investigate these 
mechanisms and to determine which cellular processes including, migration and invasion, ET-1 
affects in order to contribute to the process of HNSCC progression.  In the work presented in 
this thesis, qPCR analysis was used to investigate the expression of the components of the ET-
axis within a panel of primary human normal oral keratinocytes (NOKs) and normal oral 
fibroblasts (NOFs) and cell lines derived from oral dysplasias, primary HNSCCs and a local 
metastasis.  This study would determine if critical components of the ET-axis are present 
within the head and neck cancer microenvironment.  Pre-pro ET-1 mRNA was expressed in all 
cell types but no significant trend in differential expression was observed.  ECE-1 transcript 
levels were expressed to a greater extent in NOFs and in cell lines isolated from primary 
HNSCCs, oral dysplasias and a local metastasis in comparison to NOKs.  Protein analysis on the 
same panel of cells also confirmed this increase.  ECE-1 is responsible for the production, 
action or degradation of a number of catalytically active peptides including ET-1, BK, 
neurotensin, atrial natriuretic factor and substance P (Shipp et al, 1991;  Shipp and Look, 
1993).  Its high expression within primary HNSCCs, oral dysplasias and local metastasis in 
comparison to NOKs could therefore result in the production of more catalytically active 
peptides, or potentiate their action, promoting cancer progression.  NEP was highly expressed 
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within the NOFs and a reduction in NEP transcript levels was observed in primary HNSCCs cell 
lines both in comparison to NOKs.  The reduction in NEP expression in primary HNSCC cell lines 
is reminiscent of that observed in prostate cancer (Nelson et al, 2003).  Androgen-dependent 
metastatic prostate cancer cells express NEP and the progression to the androgen-
independent form of the disease coincides with a reduction in the expression levels of the 
enzyme therefore allowing the peptides it normally inactivates, such as ET-1, to stimulate cell 
proliferation.  A loss of NEP expression is associated with a number of malignancies.  These 
include cancers of the lung, stomach, bladder, renal and prostate (Gohring et al, 1998;  Koiso 
et al, 1994;  Sato et al, 1996;  Cohen et al, 1996;  Pekonen et al, 1995;  Papandreou et al, 
1998).  The loss of NEP activity results in the build up of mitogenic peptides at the cell plasma 
membrane which leads to the promotion of cellular proliferation (Papandreou et al, 1998).  
The results obtained here suggest a similar mechanism could be occurring in HNSCC.  The loss 
of NEP expression, combined with the increased expression of ECE-1 observed in cell lines 
isolated from primary HNSCCs, could result in an increase in peptide production or activity at 
the plasma membrane of oral epithelial cells which would normally be controlled by the 
catalytic activity associated with NEP. Further work needs to be conducted in order to fully 
elucidate the role of NEP in head and neck cancer progression.   
ET-1 can exert its effects via one, or both of its receptors, ETAR and ETBR, both of which are 
components of the ET-axis. The predilection of ET-1 for either receptor appears to vary 
depending upon context.  ET-1 promotes ovarian and prostate cancer progression via ETAR 
however in melanoma the interactions between the peptide and ETBR seem to be more 
important (Nelson et al, 2003).  qPCR analysis was used to determine the expression of both 
receptors within the same panel of human primary NOKs and NOFs and cell lines derived from 
primary carcinomas, dysplasias and a local metastasis used previously.  ETAR transcript levels 
were highly expressed in NOFs and were present in all other cell types.  ETBR transcripts were 
also readily detectable in NOFs but were reduced in HNSCC cell lines and the local metastasis, 
B22.  This is in keeping with previous findings that the receptor is reduced in a number of 
HNSCC cell lines (Viet et al, 2011).  The activation of the ETBR has been associated with the 
clearance of ET-1, via its endocytosis and the triggering of cell death and apoptosis (Khodorova 
et al, 2003;  Dupuis et al, 2000;  Peters et al, 2004).  The reduction in its expression, that is 
associated with a number of pathophysiological conditions including cancer, may therefore 
result in an increase in biologically active ET-1 and therefore the promotion of events triggered 
by its activity mediated by ETAR (Khodorova et al, 2003;  Dupuis et al, 2000;  Peters et al, 
2004).  Studies have suggested that the methylation of the ETBR gene is responsible for the 
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silencing of the receptor in cancer (Piovezan et al, 2000;  Jeronimo et al, 2003;  Knight et al, 
2009;  Lo et al, 2002).  
The increase in ECE-1 expression in primary HNSCCs, oral dysplasias and a local metastasis in 
comparison to NOKs raises the question that the enzyme may play a fundamental role in the 
progression of head and neck cancer.  Preliminary work in this thesis was conducted in order 
to begin to further understand the role that the enzyme plays in the progression of head and 
neck cancer and the autocrine mechanisms via which it exerts its effects.  Heterologous over-
expression of ECE-1 in SCC4 cells resulted in an increase in cellular migration. This result could 
suggest that the presence of the enzyme after transient transfection results in an increase in 
the production of biologically active ET-1 that in turn can go on to stimulate the migration of 
HNSCC cells via an autocrine mechanism.  The treatment of SCC4 with exogenous ET-1 in a 
previous experiment however did not stimulate a significant increase in HNSCC migration.  This 
therefore suggests that ECE-1 under these conditions is not exerting its effects via this 
mechanism.   
ECE-1 is a highly glycosylated, type II membrane-associated neutral metalloendopeptidase 
(Shimada et al, 1994) and is involved in a number of complex signalling mechanisms in order to 
maintain its tight regulatory control of peptides (Turner and Tanzawa, 1997).  ECE-1 has a 
specific characteristic in that its different isoforms, which continuously traffic between the 
plasma membrane and endosomes, are pH sensitive and therefore degrade different 
neuropeptides at different locations depending on the particular pH within that location 
(Padilla et al, 2007;  Roosterman et al, 2008;  Johnson et al, 1999).  ECE-1 can hydrolyse big-ET-
1 to produce biologically active ET-1 at a neutral pH within the extracellular fluid (Takahashi et 
al, 1993;  Hoang and Turner, 1997).  The enzyme can also hydrolyse other peptides including 
angiotensin I (Ang I), neurotensin, substance P and BK at an acidic pH which is similar to that 
found within the endosomes (Hoang and Turner, 1997;  Johnson et al, 1999;  Fahnoe et al, 
2000).  The ability of the enzyme to hydrolyse different peptides at different pHs explains why 
ECE-1 preferentially hydrolyses big-ET.  The affinity that ECE-1 also has for ET-1 is greater than 
that that it shows towards other peptides therefore further supporting its favoured activity 
towards big-ET.  These explanations therefore indicate that although ECE-1 can hydrolyse BK 
within the head and neck tumour microenvironment, it is a rare event and therefore the 
peptide can stimulate HNSCC via an autocrine mechanism which results in an increase in 
prostaglandin E2 (PGE2) production (Thomas et al, 2006).   
As mentioned previously ECE-1 can hydrolyse neurotensin.  Levels of the peptide and the 
receptor that it exerts its effects through, the neurotensin receptor 1 (NTSR1), are elevated in 
Discussion  Chapter 7 
148 
 
HNSCC samples and are associated with metastatic spread and HNSCC progression (Shimizu et 
al, 2008).  The increased expression of neurotensin and NTSR1 in HNSCC is associated with an 
increase in interleukin 8 (IL-8) and matrix metalloproteinase-1 (MMP-1) transcripts within the 
samples (Shimizu et al, 2008).  MMPs are a group of enzymes responsible for the remodelling 
and destruction of the extra cellular matrix (ECM), a process which is critical in tumour 
progression (Coussens et al, 2002).  The destruction of the basement membrane by MMPs 
allows tumour cells to invade into the surrounding connective tissue, entry and exit into and 
out of blood vessels and therefore aid metastasis to distant locations (Coussens et al, 2002).  
MMPs are known to be up-regulated in many cancers (Egeblad and Werb, 2002) and have 
therefore been extensively investigated as possible therapeutic targets in the treatment of 
cancer (Coussens et al, 2002).  An increase in MMP-1 transcript production could therefore 
provide evidence for the increase in migration of HNSCC cells observed in this study.  The over 
expression of ECE-1 could increase NTSR1 recycling back to the plasma membrane, resulting in 
the amplification of the intracellular signalling activated by the binding of the neurotensin 
ligand to its receptor.   
A specific example of how ECE-1 regulates the activity of peptides involves the interference of 
the enzyme with the extracellular signal-regulated kinases (ERK) signalling pathway.  ERK 
signalling can promote intracellular processes including cell proliferation and cell growth.  ECE-
1 is responsible for the complex control of ERK signalling associated with the activation of the 
neurokinin-1 receptor (NK1R) by substance P.  NK1R has recently been identified as being over 
expressed in HNSCC which could further implement the activity of ECE-1 in the progression of 
head and neck cancer (Brener et al, 2009).  In physiological conditions substance P binds to 
and activates the NK1R.  NEP is responsible for the degradation of substance P within the 
extracellular fluid resulting in the inhibition of NK1R activation which triggers its 
proinflammatory actions (Okamoto et al, 1994;  Lu et al, 1997;  Sturiale et al, 1999).   This 
process involves GPCR signal transduction which is implicated in autocrine signalling.  GPCR 
signal transduction is controlled by regulating the concentrations of extracellular agonists and 
the coupling of the receptor to heteromeric G proteins (Cottrell et al, 2009).  Although these 
control mechanisms are in place, GPCRs can be internalised and endocytosed.  Within the 
endosomes the receptor can continue to signal via G protein independent mechanisms 
(Cottrell et al, 2009).  Β-Arrestins can mediate the internalisation of GPCR and their trafficking 
to intracellular endosomes where they then facilitate intracellular signalling of the GPCR 
(Cottrell et al, 2009).  The mechanism via which β-Arrestins mediate this process include the 
coupling of the GPCR to clathrin and the clathrin adaptor AP2, which allows the receptor to be 
endocytosed (Ferguson et al, 1996;  Goodman et al, 1996).  This process is enhanced by the 
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phosphorylation of the GPCR kinases which increase the affinity of the GPCR for the β-
Arrestins (Pelayo et al, 2011).  The β-Arrestins translocate from the cytosol to the plasma 
membrane in order to uncouple the GPCR from the heterotrimeric G proteins.  This action 
ultimately desensitises G protein-dependent signalling (Pelayo et al, 2011).  The β-Arrestins 
can act as scaffolds which facilitate the recruitment of mitogen-activated protein kinases 
(MAPKs), Raf-1 and Scr to the GPCR forming a MAPK signalsome.  This process and formation 
of the signalsome determines the location and activation of ERKs (DeFea et al, 2000;  DeFea et 
al, 2000;  Lutterell et al, 1999;  Tohgo et al, 2002).  Cottrell et al (2009) identify that ECE-1 can 
degrade neuropepetides including substance P, found within endosomes and that therefore 
regulate the formation, stability and activation of the signalsome which results in alterations in 
ERK signalling and subsequent activation of transcription factors.   
ECE-1 destabilises the signalsome and therefore inhibits ERK signalling by degrading substance 
P rapidly within the endosome due to the acidic environment found within the cellular 
compartment.  The pH within the extracellular fluid is neutral and at this pH ECE-1 degrades 
substance P more slowly (Cottrell et al, 2009).   The acidic pH conditions found within the 
endosome could promote an increased rate of substance P degradation by increasing ECE-1 
activity (Fahnoe et al, 2000) or the rate at which substance P dissociates from the NK1R (Grady 
et al, 1995;  Roosterman et al, 2007).  The disruption of the signalsome complex results in not 
only the degradation of substance P, but also allows the β-Arrestins to return to the cytosol, 
the NK1R is released from the β-Arrestins and can be recycled and resensitised at the cell 
surface (Roosterman et al, 2007).  The recycling of the NK1R is required for sustained signalling 
and may also be responsible for the control of β-Arrestin-dependent mitogenic signalling of 
endocytosed receptors (Roosterman et al, 2007).  The ECE-1b and ECE-1d isoforms are 
normally colocalised within the endosomes.  Roosterman et al (2007) identified that ECE-1c 
however had the largest effect on substance P degradation and NK1R resensitisation. 
A similar mechanism could be occurring within the experiment in this study as a result of the 
over expression of the ECE-1 enzyme.  Future work needs to be conducted in order to 
investigate the other precursor peptides present within human primary NOKs, NOFs and the 
panel of cell lines in order to determine their expression profiles within the different cell types 
and the effect that ECE-1 has on them.   
There are four different isoforms of ECE-1 and three of the four isoforms, ECE-1b, -1c and -1d 
are constitutively phosphorylated (MacLeod et al, 2002).  This phosphorylation event occurs at 
Ser-18 and Ser-20 and is thought to be conducted by casein kinase I (MacLeod et al, 2002). 
ECE-1a does not contain these residues within its structure (MacLeod et al, 2002).  Smith et al 
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(2006) determined that the activation of protein kinase C (PKC) by phorbol esters significantly 
increased the level of ECE-1c phosphorylation.  This increase in phosphorylation resulted in an 
increase of ECE-1 activity at the external surface of the endothelial plasma membrane (Smith 
et al, 2006).  Smith et al (2006) conclude that this may provide a novel mechanism for the 
rapid trafficking to and/or activation of ECE-1 at the cell surface which results in an increase in 
the rate of peptide production.  A similar mechanism could be responsible for the increase in 
HNSCC migration observed after the cells are transfected with the ECE-1c expression vector in 
this experiment.  The continuous phosphorylation of ECE-1c and therefore increase in its 
activity, could result in the promotion of HNSCC migration.   
The treatment of SCC4 cells with an inhibitor to ECE-1 resulted in a small but insignificant 
decrease in cell migration.  Previous studies have identified that the SM-19712 ECE-1 inhibitor 
can reduce receptor resensitisation triggered by ECE-1 activity (Roosterman et al, 2007).  The 
treatment of SCC4 cells in this experiment with this inhibitor did not result in a significant 
decrease in cell migration.  Further experiments need to be conducted in order validate the 
results.  The inhibitor may not be working (a suitable positive control such as a fluorogenic 
peptide will be required to analyse this; time did not allow this to be tested in this study), or it 
may be being used at an incorrect concentration and therefore further experiments are 
required to determine and confirm its activity.  In order to specifically reduce the expression of 
the enzyme SCC4 cells were transfected with siRNA targeted to ECE-1.  Transient transfection 
of SCC4 cells with siRNA to ECE-1 resulted in a decrease in cellular migration of 0.7-fold; 
however the successful knockdown of the ECE-1 transcript could not be confirmed by qPCR 
analysis.  This result therefore requires further investigation.  
7.3 The role of the RAS in promoting head and neck cancer progression 
via an autocrine mechanism 
Studies have shown that local renin-angiotensin system (RAS) components are elevated in a 
number of diseases including diabetes, cardiovascular disease and diabetic neuropathy (Carey 
and Siragy, 2003;  Goossens et al, 2003; Ruiz-Ortega et al, 2001).  There has been increasing 
evidence in recent years that the RAS plays an important role in tumourigenesis and cancer 
progression (George et al, 2010).  Ang II has mitogenic and angiogenic effects and is the main 
peptide effector of the RAS.  Other components of the RAS include the two GPCRs that Ang II 
can act through, AT1R and AT2R, and the enzymes responsible for the regulatory control of the 
peptide, angiotensin converting enzyme (ACE) and angiotensin converting enzyme 2 (ACE2).  
Components of the RAS have been associated with tumour progression and changes in 
expression levels have been linked to and correlate with tumour grade (Louis et al, 2007;  
Sitzmann et al, 1994).  The changes however are not always consistent and expression levels of 
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individual components can vary between tumour types.  High AT1R expression levels are 
associated with breast hyperplasia however this expression pattern alters as the invasiveness 
of the tumour increases.  Levels of the receptor decrease in this instance (De Paepe et al, 
2002).  In ovarian cancer up-regulation of AT1R is associated with increased invasiveness 
(Suganuma et al, 2005).  The RAS and the ET-axis are both important and potent vasopressor 
systems (Pollock, 2005).  Ang II and ET-1 are both potent vasoconstrictors and for many years 
researchers have investigated the concerted roles played by both systems in the development 
of hypertension and the effect they have on each other (Pollock, 2005).   
Santos et al (2009) identified mRNA for renin, angiotensinogen, ACE, AT1R and AT2R in gingival 
tissue.  Renin, angiotensinogen and AT1R were identified in gingival fibroblasts and renin was 
detected in the vascular endothelium and intensely detected in the epithelial basal layer of 
periodontitis affected gingival tissue.  The identification of a local RAS in rat gingival tissue 
suggests that the production of Ang II and other vasoactive peptides within this tissue is 
possible.  The presence of all the essential components shows that a local RAS is capable of 
generating Ang II in gingival tissue independently of the systemic RAS (Campbell, 1987; Paul et 
al, 2006;  Phillips et al, 1993 and unpublished data generated in the laboratory). 
ACE hydrolyses Ang I at the Phe-8-His-9 bond to generate Ang II.  ACE is a zinc- 
metallopeptidase and is known to be evolutionarily conserved (Macours et al, 2004).  Two 
isoforms of ACE exist; somatic ACE and germinal ACE (Lambert et al, 2010).  Both isoforms of 
ACE are type-I transmembrane glycoproteins.  They consist of an extracellular amino-terminal 
ectodomain and a short intracellular cytoplasmic tail (Lambert et al, 2010).  Their structure 
allows them to hydrolyse peptides, both as a peptidyl dipeptidase (carboxydipeptidase) in the 
case of Ang I or as an endopeptidase in the case of substance P (Skidgel et al, 1984), within the 
extracellular milieu (Lambert et al, 2010).  ACE can also hydrolyse BK and N-acetyl-SDKP 
(Rieger et al, 1993).  The two homologous catalytic domains in ACE which can also be 
described as the N- and C- terminals have different substrate and inhibitor profiles (Lambert et 
al, 2010).   
Work conducted in this thesis has identified that unlike ET-1, Ang II can significantly stimulate 
HNSCC migration and invasion via an autocrine mechanism.  The treatment of both SCC4 and 
H357 cells with Ang II significantly stimulated cellular migration.  This increase in migration 
however was not to the same extent as that observed when SCC4 cells were treated with 
epidermal growth factor (EGF), a potent stimulus for HNSCC migration and invasion. EGF can 
bind to and activate the EGF receptor (EGFR) resulting in an increase in migration and invasion 
of SCC10A cells, a HNSCC cell line.  The binding of EGF to EGFR resulted in the loss of the 
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epithelial phenotype associated with SCC10A cells, coupled with downregulation of E-cadherin 
and the upregulation of both N-cadherin and vimentin.  EGF is thought to promote SCC10A cell 
migration and invasion possibly by an epithelial to mesenchymal transition (EMT)-like 
phenotype change trigged by its binding to the EGFR (Zuo et al, 2011).  Treatment of SCC4 and 
H357 cells with Ang II also resulted in an increase in their ability to invade through Matrigel.  
As mentioned previously Ang II can exert its effects by binding to two GPCRs; AT1R and AT2R.  
Ang II exerts most of its pathophysiological effects through the AT1R.  qPCR analysis 
determined that the AT1R was over expressed in the primary HNSCCs cell lines and was 
robustly expressed by NOFs in comparison to NOKs.  This result coincided with gene expression 
profiling databases that identified AT1R as one of the most prominently over expressed genes 
in pathophysiological processes (Ager et al, 2008).  The over expression of AT1R in primary 
HNSCC cell lines coincides with the cancer cells ability to be overly sensitive to the mitogenic 
effects of Ang II.  The robust expression of the AT1R in NOFs can also explain the cell’s ability to 
stimulate HNSCC paracrine migration and invasion after treatment with Ang II.  The increased 
expression of the AT1R allows the promotion of tumour-stromal interactions between the two 
cell types, a scenario which could also be present within an in vivo environment.  An increase 
in AT1R expression is associated with numerous cancers including breast and ovarian cancer 
(Ager et al, 2008).  The activation of AT1R by Ang II can result in the stimulation of 
phospholipase C (PLC)/inositol 1,4,5-trisphosphate/diacylglycerol cascade promoting cellular 
proliferation, MAPK/ERK tyrosine kinase resulting in stimulation of cell cycle activity and 
promoting irregular cell growth and rho-associated protein kinase (rho/ROCK)  resulting in 
increased cellular migration (Clempus and Griendling, 2006;  Nakashima et al, 2006;  Saito and 
Berk, 2002;  Touyz, 2005).  It can also result in the stimulation of reactive oxygen species (ROS) 
via a nicotinamide adenine dinucleotide phosphate/nicotinamide adenine dinucleotide 
phosphate-oxidase (NADP/NADPH) mechanism.  The production of ROS can influence 
downstream signalling molecules including transcription factors, tyrosine 
kinases/phosphatases, MAPKs and Ca2+ channels which promote cell proliferation and irregular 
cell growth (Clempus and Griendling, 2006;  Touyz, 2005).  The stimulation of the AT1R has 
been implicated in the process of damaged blood vessel revascularization as a result of 
increased vascular endothelial growth factor (VEGF) production and nitric oxide (NO) synthase 
stimulated by the binding of the peptide to the receptor (Tamarat et al, 2002).  This 
mechanism has also been implicated in ovarian cancer (Suganuma et al, 2005). 
The use of an AT1R antagonist confirmed that Ang II was indeed exerting its autocrine effects 
through this receptor.  Telmisartan is commonly used as an anti-hypertensive agent (Ager et al, 
2008).  The use of this receptor antagonist and other AT1R antagonists including losartan and 
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candesartan within the clinic identifies possible therapeutic options in the treatment of head 
and neck cancer.  AT1R therapeutic agents belong to a class of biphenylimidazoles. They can be 
competitive inhibitors (peptide analogues) or insurmountable receptor antagonists (non-
peptide) and exert their effects by restricting the binding of Ang II to the receptor resulting in 
the prevention of signal transduction (Ager et al, 2008). 
qPCR analysis determined that the AT2R was expressed within all primary cells and cell lines 
but transcript levels of AT2R seemed to be lower in primary HNSCCs in comparison to NOKs.  
Evidence has shown that the receptor has been implicated in opposing the effects triggered 
through the AT1R and therefore it may be surmised that reduced levels of the receptor would 
be associated with primary HNSCC cell lines in which an over expression of the AT1R is 
apparent, although further studies are required to confirm this at the level of protein 
expression. 
ACE is responsible for the activation of Ang II from the inactive precursor Ang I.  The expression 
of ACE within the same panel of primary cells including primary human NOKs and NOFs and 
cell lines isolated from primary carcinomas, oral dysplasias and a local metastasis was 
therefore determined.  ACE was expressed within all cell types and was robustly expressed in 
NOFs in comparison to NOKs.  Preliminary work was conducted in order to determine the 
mechanisms involved in regulating Ang II production and therefore the role of ACE in the 
production of Ang II was investigated. The over expression of the ACE in SCC4 cells resulted in 
an increase in HNSCC cellular migration.  This result is in keeping with ACE being responsible 
for the production of Ang II.  Other enzymes have been linked to the production of Ang II.  The 
serine-proteinase, chymase has been identified as being capable of generating Ang II from Ang 
I.  Chymase is of great importance in alternative Ang II-generating pathways in several places, 
including the heart and blood vessels (Cornish et al, 1979;  Trachte and Lefer, 1979;  Schechter 
et al, 1986).  Cathepsin A was identified in human renal extracts as being able to generate Ang 
II from Ang I via the production of an intermediate peptide (Miller et al, 1988). There are few 
reports of expression of either of these enzymes in the oral mucosa, suggesting ACE is likely to 
be the predominant angiotensinase in this setting.  The increase in local Ang II production 
caused by an increase in ACE activation could result in the peptide stimulating HNSCC cell 
migration via an autocrine mechanism in a similar manner to that observed when SCC4 were 
treated directly with Ang II.  The results collected in this study suggest that in HNSCC cells, ACE 
may be responsible for the production of active Ang II, which, coupled with the over-
expression of AT1R identified here, may drive tumour progression Therefore the treatment of 
head and neck cancer with ACE inhibitors may provide a useful therapeutic option in the 
treatment of the disease.  ACE inhibitors are already used within a clinical practice and are 
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commonly used in the treatment for hypertension (Ager et al, 2008).  Studies have also 
indicated that the incidence of fatal cancers was reduced in patients who had been prescribed 
ACE inhibitors as a treatment method for longer than three years (Lever et al, 1999).  
Prolonged treatment with the specific ACE inhibitor captopril has been associated with a 
reduction in the chance of developing prostate cancers (Ronquist et al, 2004).  Although a 
number of studies have identified a protective link between ACE inhibitors and the 
development of cancer, some studies have failed to make this observation and therefore it has 
been deemed necessary to identify the specific role that the population profiles, the types of 
cancer examined, the agents used and the dose and length of administration of those agents 
play in determining the potential benefits associated with ACE inhibitor treatment (Ager et al, 
2008;  Friis et al, 2001;  Meier et al, 2000).   
Previous studies have shown that renin and angiotensinogen transcripts are present within 
gingival tissue (Santos et al, 2009).  Further investigation needs to be conducted to determine 
if both renin and angiotensinogen and therefore Ang I are present within HNSCC cell lines, 
although evidence from other work in the laboratory suggests this is the case.  This would 
further support the fact that ACE over expression within HNSCC cells could result in an increase 
in Ang II produced by the activity of ACE on locally generated Ang I. 
7.4 The role of the ET-axis and the RAS in promoting head and neck 
cancer progression via a paracrine mechanism 
Studies have indicated that ET-1 can stimulate HNSCC proliferation via an autocrine 
mechanism (Awano et al, 2006).  This however is not the case for HNSCC migration.  Previous 
reports have discovered that the presence of prostatic stromal fibroblasts can potentiate the 
effects of ET-1 in prostate cancer (Dawson et al, 2004).  The tumour microenvironment, also 
known as the reactive stroma, is composed of a number of cell types with fibroblasts being the 
most numerous.  Fibroblasts found within the stroma surrounding epithelial tumours 
frequently undergo changes in their phenotype.  These changes can include an increase in 
their migratory nature, increased proliferation and the acquisition of a myofibroblastic and 
more contractile phenotype.  It is thought that these characteristics can be triggered by signals 
released from the epithelial tumour cells, an example of tumour-stromal interactions.  
Determining these tumour-stromal interactions could provide interesting and attractive 
targets for possible future therapeutic strategies and applications.   
The treatment of both SCC4 cells and NOFs with ET-1 stimulated HNSCC migration to a greater 
extent compared to that observed in the absence of NOFs.  The inclusion of NOFs into the 
bottom chamber of the Transwell migration assay created an environment more similar to that 
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observed in vivo.  This observation suggests that ET-1 is working via a paracrine mechanism to 
stimulate the release of soluble factors from the NOFs into the surrounding media which can in 
turn stimulate HNSCC migration. The seeding of NOFs into the bottom chamber of the 
Transwell migration assay did not further enhance the effect of BK on HNSCC migration.  This 
thesis has confirmed work conducted by Thomas et al (2006) have shown that BK can 
stimulate HNSCC migration via an autocrine mechanism.  This has identified that the direct 
treatment of HNSCC cells with Ang II results in an increase in their migration and invasive 
potential.  The results observed in this project identify that the peptide can work via an 
autocrine mechanism similar to that used by BK to also promote HNSCC progression (Thomas 
et al, 2006).  The ability of Ang II to activate paracrine stimulation was also investigated.   
Treatment with filtered conditioned media collected from ET-1 or Ang II-treated NOFs 
stimulated the migration of untreated HNSCC cells in a dose responsive manner. This finding 
suggests that ET-1 and Ang II can both promote the release of factors from NOFs into the 
surrounding media which are involved in the stimulation of HNSCC cell lines.  The presence of 
the mitogenic peptides alone in the Transwell migration chamber did not increase HNSCC 
migration suggesting that the presence of NOFs, or the factors that they release, is required to 
promote HNSCC migration via a paracrine mechanism.  The pre-treatment of NOFs with ET-1 
or Ang II for 4 h before the media was removed, filtered and added to the bottom well of a 
Matrigel invasion assay also resulted in the paracrine stimulation of untreated SCC4 and H357 
cell invasion suggesting that the peptides are working via a similar mechanism to that 
observed for HNSCC cell migration.  Although Ang II can significantly stimulate HNSCC cell 
migration and invasion via an autocrine mechanism, the soluble factors released by the NOFs 
in response to Ang II treatment caused a greater increase in SCC4 and H357 cell migration and 
invasion in comparison to treatment of the HNSCC cells alone.  The ability of ET-1 and Ang II to 
stimulate HNSCC invasion via a paracrine mechanism is an important finding.  The ability of 
cancer cells to invade through the underlying basement membrane and into the surrounding 
connective tissue is a vital step in the process of metastasis.  Invasion into the surrounding 
bone and local metastasis to nearby lymph nodes are both common features associated with 
HNSCC.  The development of both processes complicates the treatment of head and neck 
cancer and ultimately reduces survival rates.  Dawson et al (2004) have identified that levels of 
ECE-1 are elevated in the primary malignant prostatic stromal cells in comparison with benign 
tissue.  The specific inhibition of endogenous ECE-1 activity within these stromal cells 
significantly reduced epithelial cell invasion suggesting that both the enzyme and ET-1 play a 
role in mediating effects on prostate stroma (Dawson et al, 2004).  ET-1 has been implicated in 
the process of bone metastasis that is associated with prostate cancer.  It has been 
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hypothesised that ET-1 can also promote interactions between the prostate metastatic cell 
and the local environment. The increased production of ET-1 by the prostate cancer cells 
located in bone is thought to be stimulated by osteoblast- and endothelial cell-secreted IL-1, 
transforming neurosis factor-α (TNF-α), and tumour growth factor-β (TGF-β).  ET-1 can in 
response stimulate mitotic activity in osteoblasts, decreasing both osteoclastic bone resorption 
and motility (Nelson et al, 1999).  The discovery of the unique interactions between the ET-
axis, the prostate cancer cells and the bone microenvironment including osteoclasts and 
osteoblasts, has led to the development of novel therapeutic treatments in prostate cancer 
(Carducci and Jimeno, 2006).  Discovering the role that the ET-axis plays in promoting the 
invasion of HNSCC and discovering if the axis can contribute to the local metastasis of head 
and neck cancer into the surrounding bone may help to identify new therapeutic targets in the 
treatment of the disease.   
ET-1 can exert its effects via the ETAR and/or ETBR.  qPCR analysis conducted in this thesis has 
identified that the ETAR is highly expressed within the NOFs and is expressed within the 
primary carcinoma cell lines; ETBR transcripts were also present within NOFs suggesting that all 
the cell types tested have the capacity to respond to ET-1.  mRNA levels of the ETBR were 
down regulated in the primary carcinoma-derived cell lines which is in keeping with previous 
reports (Dupuis et al; 2000).  This result however contradicts the findings of Awano et al (2006) 
who observe an increase in ETBR transcript levels in HNSCCs. However, in that study skin 
keratinocytes were used as the ‘normal’ control and this may explain the differences in ETBR 
expression observed. The ability of antagonists to both receptor subtypes, to block the effects 
observed in this thesis suggests that ET-1 uses both receptors in the NOFs to stimulate HNSCC 
cell migration and invasion.  
Ang II can exert its effects through both the AT1R and AT2R.  The peptide exerts most of its 
pathophysiological effects through AT1R.  qPCR analysis conducted within this project 
identified that the highest expression of the AT1R, across the panel of primary cells and cell 
lines tested, was in NOFs, suggesting that it has an important role within these cells.  The 
ability of Ang II to act through this receptor was supported by the finding that telmisartan, a 
specific AT1R antagonist, was able to block the paracrine stimulation of SCC4 cells by NOF 
treatment with Ang II. The extent of AT1R expression in NOFs and HNSCC primary carcinoma 
cell lines may mean that the receptor could be a possible therapeutic target in the treatment 
of HNSCC.  Studies have shown that AT1R can be regulated at a post-transcriptional level 
(Nickenig and Harrison, 2002) via mechanisms including Ang II (Nickenig and Murphy, 1996), 
estrogens (Krishnamurthi et al, 1999) and cyclic adenosine monophosphate (cAMP) stimulating 
agents (Wang et al, 1997) which all decrease rat mRNA levels of the receptor by targeting it for 
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degradation.  Insulin (Nickenig et al, 1998), progesterone (Nickenig et al, 2000) and low density 
lipoproteins (Nickenig et al, 1997) all act in the opposite manner and increase AT1R mRNA 
levels by decreasing the rate at which the mRNA is decayed.  Cytosolic proteins can also 
regulate AT1R expression at a post-transcriptional level by binding to 5’-untranslated region 
(UTR) region of the AT1R mRNA (Krishnamurthi et al, 1999;  Lee et al, 2006;  Ji et al, 2004;  
Zhang et al, 2004;  Wu et al, 2003;  Mok et al, 2003).  The complex regulatory system involved 
in Ang II signalling, which has been identified here, must be taken into account when 
considering the AT1R as a therapeutic target in the treatment of cancers.  The mechanisms 
responsible for its upregulation in HNSCC cells remain to be determined. 
The results presented in this thesis suggest paracrine stimulation of HNSCC migration and 
invasion is the result of the ET-1 or Ang II-stimulated release of bioactive ligands from the 
surface of the NOFs.  The mechanisms involved in this stimulation were further elucidated.  
The ADAMs family of enzymes are known to promote signalling and play a key role in the 
control of the processes that occur and exist between different cells and between cells and 
their microenvironment (Murphy, 2008).  About half of the ADAMs family are known to have 
proteolytic activity and can modulate the activities of membrane growth factors and cytokines 
and their receptors and cell adhesion molecules (Murphy, 2008).  The ability of ADAMs 
enzymes to affect and alter these processes implicates them in the promotion and progression 
of tumourigenesis (Murphy, 2008).  A number of ADAMs enzymes are upregulated or their 
activity increased in different cancers (Rocks et al, 2008; Mochizuki and Okada, 2007).  The 
involvement of ADAMs enzymes in the release of factors from the surface of cells therefore 
warranted further investigation in order to determine if the enzymes were involved in the 
paracrine mechanism stimulated by ET-1 and Ang II treatment of NOFs.  In order to conduct 
this investigation NOFs were pre-treated with a broad range inhibitor to both the ADAMs 
enzymes and MMPs, GM6001.  NOFs were pre-treated with this inhibitor for 30 min before the 
addition of ET-1 or Ang II and this resulted in the inhibition of ET-1 and Ang II stimulated 
HNSCC cellular migration.  This observation suggests that a member of the ADAMs family of 
enzymes or a MMP could be involved in the process.  ADAM17 is the member of the family 
most commonly responsible for the proteolytic release of soluble factors from the surface of 
cells (Murphy, 2008).  siRNA targeted to ADAM17 was used to knock down its expression 
within the NOFs in order to determine its effect HNSCC cell migration.  The successful transient 
transfection of NOFs with siRNA to ADAM17 resulted in the inhibition of ET-1 and Ang II 
stimulated SCC4 migration. qPCR analysis confirmed that the siRNA was only targeting 
ADAM17 and not other members of the family including ADAMs -9, -10 and -15,  suggesting 
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that ADAM17 is at least in part involved in the paracrine mechanism stimulated by ET-1 and 
Ang II.   
EGFR signalling is a pathway commonly deregulated in a number of cancers. The EGFR receptor 
is a receptor tyrosine kinase.  Activation of the receptor via ligand induced 
autophosphorylation, can lead to downstream signalling including that of the mitogenic 
Ras/Raf/ERK 1/2, p38 MAPK and PI3-K/AKT pathways, all of which are involved in regulating 
cell proliferation, growth and differentiation (Cai et al, 2010;  Ciardiello and Tortora, 2008;  
Avraham and Yarden, 2011).  Aberrant activation of the EGFR can also promote an increase in 
cell migration and invasion in HNSCC (Thomas et al, 2006). 
The EGFR can also be transactivated via GPCRs.  A number of GPCR ligands have been 
identified as being able to activate the EGFR, including BK in HNSCC (Thomas et al, 2006). This 
GPCR-mediated EGFR activation has also been apparent in prostate and breast cancer cell lines 
(Filardo et al, 2000;  Prenzel et al, 1999).  Lui et al (2003) discovered that the gastrin-releasing 
peptide (GRP) receptor could activate EGFR resulting in the alteration and promotion of HNSCC 
growth and invasion.  The EGFR has also been activated in HNSCC cases in response to 
lysophosphatidic acid (LPA) and thrombin ligands (Gschwind et al, 2003).  The GPCR-mediated 
EGFR activation results in the triggering of downstream signalling pathways including p44/42 
MAPK (Gschwind et al, 2001;  Santiskulvong et al, 2001).  Depending on the cell type and the 
ligand present the activation of MAPK can be as a result of EGFR-dependent and/or EGFR-
independent mechanisms (Thomas et al, 2006).  BK in vulvar carcinoma A431 cells activated 
MAPK via an EGFR-independent mechanism which involved PI3-K and PKC pathway (Graness et 
al, 2000).  Other intracellular pathways that have been implicated in GPCR-mediated EGFR 
activation include serine/threonine kinase PKC (Slack, 2000), increased Ca2+ levels (Zwick et al, 
1997) and the nonreceptor tyrosines kinases from the Src family (Luttrell et al, 1997).  Prenzel 
et al (1999) have suggested that the extracellular domain of EGFR is involved in the cross talk 
that occurs between the receptor and the GPCR.  In bladder and kidney cancer cells the 
ADAMs -10, -15 and -17 have been implicated in the activation of EGFR proligands (Schafer et 
al, 2004). In HNSCC ADAM17 is in involved in GPCR-mediated EGFR activation and inhibition of 
the enzyme has resulted in a reduction in PGE2-stimulated and BK-stimulated downstream 
signalling events (Gschwind et al, 2003;  Zhang et al, 2006;  Schafer et al, 2004).  In the study 
presented in this thesis it was found that the pre-treatment of HNSCC with an EGFR antagonist 
before their addition to the Transwell migration assay resulted in the inhibition of SCC4 cell 
migration in the presence of ET-1 or Ang II treated NOF conditioned media.  This suggests that 
the release of soluble factors from the surface of the NOFs in response to ET-1 or Ang II 
treatment can act as ligands for the EGFR located on the surface of the SCC4 cells resulting in 
Discussion  Chapter 7 
159 
 
its activation and an increase in the migration and invasion of the epithelial cells.  Pre-treating 
NOFs for 30 min with receptor inhibitors to both ETAR and ETBR before the stimulation with ET-
1 and SCC4 cells with an EGFR receptor antagonist before their addition to the Transwell 
migration assay resulted in the further inhibition of HNSCC migration.  The incubation of 
conditioned media collected from NOFs treated with ET-1 with neutralising antibodies to the 
EGFR ligands transforming growth factor-α (TGF-α), heparin bound (HB)-EGF and amphiregulin 
blocked stimulation of SCC4 migration.  Both results further implicate EGFR transactivation in 
the paracrine mechanism involved in the stimulation of HNSCC cell migration and invasion.  
These findings add weight to the suggestion that the combined inhibition of both GPCR and 
EGFR could lead to enhanced antitumour effects in comparison to the treatment of other the 
GPCR or EGFR independently (Thomas et al, 2006), and give the first indication that this 
approach may be indicated in HNSCC.   
qPCR analysis identified that the activation of the EGFR by ectodomains released from the 
surface of NOFs in response to ET-1 treatment, also stimulated an increase in the expression of 
cyclooxygenase-2 (COX-2).  COX-2 and EGFR are both frequently over-expressed in HNSCC and 
correlate with a poor prognosis (Chan et al, 1999;  Kalyankrishna and Grandis, 2006).  COX-2 is 
known to play an important role in promoting HNSCC migration by increasing the levels of 
PGE2 (Wang et al, 2005).  PGE2 is a pleiotropic factor which can stimulate COX-2 expression and 
promote cancer cell motility (Wang et al, 2005).  PGE2 has also been shown to transactivate 
the EGFR (Kalyankrishna and Grandis, 2006) suggesting that this may form a positive feedback 
loop in response to factors released from the surrounding stroma in the presence of ET-1.  
Segawa et al (2003) discovered that Ang II treatment of human gingival fibroblasts can also 
result in an increase in PGE2 release.  Other mediators of inflammation including BK, histamine, 
IL-1β and TNF-α are also known to increase PGE2 production in human gingival fibroblasts 
(Lerner and Modéer, 1991;  Modéer et al, 1993;  Yokota et al, 1994;  Niisato et al, 1996;  Nakao 
et al, 2000).  An increase in intracellular Ca2+ after treatment was observed, suggesting that 
AT1R activation by Ang II stimulates this increase (Segawa et al, 2003).  This evidence, along 
with that presented in this thesis, suggests a possible paracrine mechanism via which 
mitogenic peptides including ET-1 can promote HNSCC migration and invasion.  It is plausible 
to suggest that the activation of the EGFR via Ang II treatment could result in an increase in 
COX-2 expression, similar to that observed for ET-1 paracrine stimulated SCC4 migration and 
invasion. This remains to be determined but evidence collected from other studies have also 
identified a role that Ang II plays in stimulating COX-2 expression in lung fibroblasts 
(Matsuzuka et al, 2009).  This evidence and that collected in this study using the ET-1 
mitogenic peptide indicates that Ang II stimulation of NOFs may also result in an increase in  
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Figure 7.1  Schematic to illustrate how ET-1, Ang II and other mitogenic peptides may 
promote HNSCC cell migration and invasion either by promoting stromal-tumour 
interactions (ET-1 and Ang II) or by acting directly on tumour epithelial cells (Ang II and BK):  
The mitogenic peptides ET-1 and Ang II bind to their specific GPCRs, ETAR and ETBR for ET-1 
and AT1R for Ang II, which are located on the NOF cells.  This binding event results in the 
activation of the ADAMs proteinase enzyme, ADAM17.  ADAM17 is a member of the ADAMs 
family that is commonly associated with and responsible for triggering the release of soluble 
factors including HB-EGF, TGF-α and amphiregulin from the surface of NOFs which can act as 
ligands for the EGFR located on the surface of the HNSCC epithelial cells.  The binding of these 
ligands to the EGFR results in its activation and an increase in the migration and invasion of the 
epithelial cell on which the receptor is located.  A broad range inhibitor to the ADAMs family of 
enzymes, siRNA to ADAM17 and an antagonist to the EGFR result in the inhibition of HNSCC 
cell migration.  The activation of the EGFR coincides with an increase in COX-2 expression, 
suggesting a possible intracellular mechanism responsible for the increase observed in HNSCC 
migration.  Ang II, like BK, can also stimulate HNSCC migration and invasion via an autocrine 
mechanism in which the mitogenic peptides bind directly to AT1R on the HNSCC epithelial cells. 
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COX-2 expression in the HNSCC microenvironment, possibly contributing to cancer progression 
(Figure 7.1).   
HNSCCs are highly inflammatory and aggressive cancers in nature and express a number of 
growth factors and cytokines which are involved in the inflammatory process (Wang et al, 
2009).  The risk factors associated with head and neck cancer including the consumption of 
both alcohol and tobacco and exposure to the human papillomavirus (HPV) have all been 
linked to increased pro-inflammatory cytokine expression and the induction of inflammatory 
signalling pathways including nuclear factor-kappa B (NF-κB), JAK/STAT and PI3-K/Akt/mTOR 
(Wang et al, 2009), thereby implicating inflammation in head and neck cancer progression.  
Increased NF-κB signalling is associated with an increase in COX-2, a target gene of NF-κB 
(Wang et al, 2009).  As mentioned previously COX-2 is associated with poor prognosis in 
HNSCC and the increase in the expression observed in this thesis suggests that the 
inflammatory response and subsequent signalling activation could be responsible for this 
increase in expression.  Further work needs to be conducted in order to determine the 
signalling mechanisms activated by factors found within the tumour microenvironment. 
ETAR, ETBR and AT1R antagonists and EGFR and COX-2 inhibitors are currently being utilised in 
clinical trials for the treatment of other malignancies (Nelson et al, 2003;  Ager et al, 2008).  
The involvement of these different components of the ET-axis and RAS have been implicated, 
as a result of the work conducted in this thesis, in mechanisms involved in head and neck 
cancer progression.  Therefore the targeting of the different factors and the implementation of 
combined therapy may have considerable significance in the treatment of HNSCC and 
therefore warrants further investigation. 
microRNAs (miRNAs) are small regulatory RNAs recently identified as playing a major role in 
the control of expression of genes that are involved in cancer progression.  It has been 
suggested that they can play an important part in regulating cellular processes including 
migration, invasion and metastasis.  ADAM17 has been identified as being a target of miR-145 
(unpublished data generated in the laboratory), a putative tumour suppressor miRNA down-
regulated in HNSCC.  The over-expression of miR-145 in HNSCC cells reduces their ability to 
migrate in the presence of various stimuli (unpublished data generated in the laboratory).  
These two findings and the identification of the important role ADAM17 plays within the 
paracrine stimulation of HNSCC within this study made it logical to investigate the role of miR-
145 in the paracrine stimulation of HNSCC migration activated by ET-1 and Ang II treatment.  
Heterologous expression of miR-145 in NOFs resulted in the inhibition of conditioned media-
treated SCC4 migration in both the presence and absence of ET-1 and in the presence of Ang II.  
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This suggests that the miRNA can exert its effects by targeting the expression of ADAM17 and 
as a result influencing the activities that are controlled and activated by ADAM17 itself 
(although it is likely to have other contributory targets also).  This includes affecting the release 
of factors from the surface of NOFs both in response to ET-1 treatment and basal ligand 
shedding in its absence.  This finding further suggests that ADAM17 is involved in regulating 
interactions within a microenvironment in a normal cellular situation and that alteration within 
its expression, a characteristic observed in a number of malignancies, could result in the 
uncontrolled behaviour of this microenvironment.  miR-145 is a possible feature within this 
microenvironment that could be responsible for the deregulation of ADAM17 and could 
arguably be considered as a possible drug target for the treatment of HNSCC.  The transfection 
of NOFs with miR-145 resulted in a greater inhibition of SCC4 migration in comparison to NOFs 
transfected with ADAM17 siRNA.  This finding suggests that miR-145 exerts its effects by 
inhibiting more than one factor, whereas transfection of NOFs with siRNA to ADAM17 results 
in the specific targeting of ADAM17 only.  miR-145 has been identified as being down 
regulated in cancer associated fibroblasts (CAFs) isolated from a carcinoma of the bladder 
(Enkelmann et al, 2011), further fuelling this hypothesis.  The other targets of miR-145 and the 
role that they play in the tumour microenvironment need to be investigated in order to 
determine the full potential of the miRNA as a possible treatment of cancers including head 
and neck. 
Other links have been made between miRNAs and fibroblasts found within the tumour 
microenvironment, further supporting the evidence and results collected in this thesis.  
Musumeci et al (2011) identified that miR-15 and miR-16 were both down regulated in 
fibroblasts surrounding prostate tumours.  The down regulation that was observed resulted in 
increased tumour growth and progression (Musumeci et al, 2011).  The group demonstrated 
that this promotion of tumourigenesis was due to the reduced post-transcriptional repression 
of fibroblast growth factor (FGF)-2 and its receptor, FGF receptor (FGFR)-1.  Studies have 
shown that FGF-2 production by both tumour and stromal cells leads to increased proliferation 
and metastasis formation in prostate cancer (Cronauer et al, 1997;  Yang et al, 2008;  Giri et al, 
1999).  Transfection of miR-15 and miR-16 into prostate cells resulted in a decrease in the 
tumour-supportive capability of stromal cells both in vivo and in vitro (Musumeci et al, 2011).  
This observation and the evidence collected in this study identify a role for miRNAs in tumour-
stromal interactions and suggest that miRNAs in the stroma surrounding epithelial tumours 
could provide alternative therapeutic targets in the treatment of cancer. 
Li et al (2010) have also identified that endothelial miR-125a/b-5p can inhibit ET-1 expression 
in vascular endothelial cells therefore suggesting that individual components of the ET-axis 
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could be regulated by miRNAs.  miR-125a/b-5p target the 3'-UTR of pre-pro ET-1 mRNA in 
order to achieve this inhibition.  Additional research has also identified the involvement of 
miR-155 in the control the RAS.  Zheng et al (2010) have identified that AT1R is a target of miR-
155 and have shown that transfection of adventitial fibroblasts with miR-155 resulted in a 
decrease in AT1R protein levels but not mRNA levels.  A reduction in ERK 1/2 signalling and a 
reduction in stimulation of α-SMA) by Ang II treatment was also observed after transfection 
with miR-155 (Zheng et al, 2010).  The results suggest that the miRNA could play a role in 
regulating adventitial fibroblast transdifferentiation via the AT1R (Zheng et al, 2010).  Martin et 
al (2006) show that miR-155 can interact with the 3’-UTR region of AT1R.  Transfection of the 
miRNA into human primary lung fibroblasts led to a reduction in AT1R mRNA and a reduction in 
ERK 1/2 activation triggered by Ang II stimulation (Martin et al, 2006).  When the fibroblasts 
were treated with TGF-β the level of miR-155 was reduced and mRNA levels of AT1R were 
increased (Martin et al, 2006).  This evidence and that collected within this study support the 
fact that miRNAs may play a role in controlling the ET-axis and RAS and may be responsible for 
alterations observed within the systems that are associated with patho-physiological 
scenarios.   
As mentioned previously, ECE-1 is responsible for the biological activation of ET-1.  This study 
has identified that the over expression of the enzyme in HNSCC resulted in an increase in cell 
migration.  The over expression of the enzyme in SCC4 cells and the increase in cellular 
migration that was observed as a result was not thought be have been as a result of increased 
production of biologically active ET-1.  SCC4 cells did not respond to the autocrine activation 
stimulated by ET-1 treatment only therefore it was not logical to suggest that the over 
expression of ECE-1 promoted SCC4 cell migration as a result of the increased production of 
the peptide.  HNSCC cells however did respond to the paracrine stimulation triggered by the 
treatment of NOFs with ET-1.  It is therefore sensible to suggest that expression of the enzyme 
in NOFs may result in the production of biologically active ET-1 which can stimulate an increase 
in SCC4 migration via a similar paracrine mechanism to that observed with direct treatment of 
the NOFs with the mitogenic peptide. ECE-1 is also responsible for the hydrolysis of other 
biologically active peptides including BK, neurotensin and substance P which could result in an 
increase in HNSCC migration via a similar mechanism to that observed for the autocrine 
stimulation of HNSCC cells which may have involved prolonged intracellular signalling triggered 
by the mitogenic peptides in response to the internalisation and recycling of their GPCRs to the 
plasma membrane activated by ECE-1 activity.  Work is currently ongoing to assess any 
changes in ECE-1 expression and ET-1 production in cancer associated fibroblasts from HNSCC 
patients. 
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The treatment of NOFs with a broad range inhibitor to ECE-1 for 30 min before the addition of 
ET-1 resulted in a small decrease in SCC4 cell migration stimulated with condition medium 
from the NOFs.  This was however not to a significant extent suggesting that other factors or 
enzymes aside from ET-1 and ECE-1 are contributing to the paracrine stimulation of HNSCC.  
This is a similar result to that observed when SCC4 cells were treated directly with the ECE-1 
inhibitor.  The small reduction observed in this case may again need further experiments to be 
conducted in order to understand the mechanisms underlying this observation and top 
determine if the inhibitor is working correctly.  The direct targeting and reduction in ECE-1 
activity using siRNA to the enzyme however did result in a significant reduction in SCC4 
migration.  This could not be confirmed however by qPCR analysis and therefore warrants 
further investigation.  The result does suggest that ECE-1 is important in the paracrine 
stimulation of HNSCC migration and invasion and the inactivation of the enzyme may result in 
a reduction in the activity and production of biologically active peptides including ET-1, which 
are responsible for paracrine stimulation of HNSCC migration. 
When HNSCC cells were transiently transfected with a pIRES vector containing the coding 
region for somatic ACE, an increase in cellular migration was observed.  Over expression of ACE 
in SCC4 cells, confirmed by qPCR analysis, is likely to cause an increase in the production of 
biologically active Ang II which in this study has been shown to be able to stimulate the 
migration and invasion of HNSCCs via an autocrine mechanism.  This experiment identified a 
role for ACE in the autocrine signalling mechanism stimulated by Ang II treatment.  A role for 
the enzyme in the paracrine signalling mechanism stimulated by the peptide was investigated 
next.  In order to investigate the effect of over expressing the enzyme in NOFs and determining 
the effect on the paracrine stimulation of HNSCCs, NOFs were transiently transfected with the 
same vector containing the coding region of somatic ACE.  The successful transfection of NOFs 
with ACE, which was confirmed by qPCR analysis, resulted in a significant increase in the 
paracrine stimulation of SCC4 cell migration.  This result suggests that ACE over-expression in 
NOFs could produce biologically active Ang II which can then go on to stimulate the SCC4 cells 
via a paracrine mechanism similar to that observed when NOFs were treated with exogenous 
Ang II.   
7.5 The effect of ET-1 and Ang II of the phenotype of NOFs 
In a number of malignancies it has been shown that cancerous cells can increase the levels of 
numerous factors in the reactive stroma that surrounds them that have the ability to activate 
fibroblasts, resulting in their conversion to a myofibroblast or protomyofibroblast phenotype.  
Myofibroblasts have been identified in the microenvironment that surrounds a number of 
different tumours including invasive breast cancers and HNSCCs (Sappino et al, 1988).  
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Myofibroblasts are characterised by high expression levels of α-SMA and MMP-2 and 
increased cell proliferation, migration and cellular contraction (Allinen et al, 2004).   
Here, the effect of ET-1 on the proliferation of NOFs was determined using an MTS assay.  ET-1 
significantly stimulated NOFs to proliferate after 48 h.  The effect of the peptide was blocked 
using receptor antagonists to ETAR and ETBR further confirming that the peptide is acting 
through both receptors in NOF (as previously shown; Section 4.4) 
Fibroblasts, when activated, can become more migratory.  In order to determine the effect of 
ET-1 and Ang II on NOF migration, a 2D migration assay was used.  The creation of a ‘scratch’ 
within a confluent monolayer of NOFs and their subsequent treatment with ET-1 or Ang II 
resulted in significantly more migration into the ‘scratch’ than that observed when NOFs were 
treated with serum free media.  This effect, stimulated by ET-1 (in the presence of mitomycin C 
to negate the contribution of the increased proliferation), could again be inhibited by the use 
of receptor antagonists to ETAR and ETBR.  ET-1 is known to promote an increase in both 
migration and proliferation of rabbit, guinea pig and rat gingival fibroblasts (Ohsawa et al, 
2005;  Ohuchi et al, 2002;  Ohuchi et al, 2010).  In another instance Yahata et al (2006) showed 
that AT1R knockout mice experience delayed wound healing and identified that the treatment 
of fibroblasts and keratinocytes with Ang II resulted in an increase in their migration (Yahata et 
al, 2006).  The process of wound healing epithelialisation and dermal repair require an 
increase in the migration, proliferation and differentiation of keratinocytes and an increase in 
ECM production by fibroblasts, respectively (Hashimoto, 2000).  Inhibition of AT1R and an 
antagonist to HB-EGF resulted in a decrease in fibroblast and keratinocyte migration 
suggesting that both are involved in the mechanism and the wound healing process triggered 
by Ang II (Yahata et al, 2006).  Haddow (1972) first identified and documented similarities 
between carcinogenesis and wound healing.  In 1986, Dvorak et al described cancer as 
‘wounds that do not heal’.  The molecular mechanisms involved in the wound healing process 
therefore provide valuable evidence and could help to create possible hypotheses that can be 
used in cancer research.  The discovery of the ability of ET-1 and Ang II to promote NOF 
migration, and work conducted previously which has identified that the RAS is involved in the 
wound healing process, further implicate both the ET-axis and RAS in the activation of 
fibroblasts and the creation of a unique tumour microenvironmental niche.   
ET-1 has been shown to exhibit mitogenic activity towards a number of cells types including 
fibroblasts and smooth muscle cells (Levin, 1995) and also promotes fibroblast contraction 
(Guidry and Hook, 1991).  The contraction of fibroblasts is an important action in the processes 
of wound healing and dermis reconstitution (Grinnel, 1994).  ET-1 is also capable of modifying 
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the ECM (Levin, 1995), increasing collagen I and III synthesis, and decreasing the mRNA and 
protein levels of MMP-1 in dermal fibroblasts (Xu et al, 1998; Shi-Wen et al, 2001), all 
processes which are involved in wound healing.  MMPs are a group of enzymes that have been 
implicated in the remodelling and destruction of the ECM, a process which is critical in tumour 
progression (Coussens et al, 2002).  The destruction of the basement membrane by MMPs 
allows tumour cells to invade into the surrounding connective tissue, entry and exit into and 
out of blood vessels and therefore aid metastasis to distant locations (Coussens et al, 2002).  
MMPs are known to be up-regulated in many cancers (Egeblad and Werb, 2002) and have 
therefore been extensively investigated as possible therapeutic targets in the treatment of 
cancer (Coussens et al, 2002).  The treatment of fibroblast:collagen lattices with both ET-1 and 
Ang II resulted in the stimulation of their contraction suggesting that the peptides can promote 
a more contractile phenotype within NOFs.  In this investigation on the influence of the 
peptide on the phenotype of NOFs, the ETBR seems to be predominantly responsible for the 
actions of ET-1 and its ability to stimulate the increased contractile nature of the cells.  A 
similar observation was noted by Knowles et al (2012) who identified that the inhibition of the 
ETAR alone was sufficient to abrogate the effect of ET-1 on the growth and proliferation of 
colonic fibroblasts but that the blocking of ETBR with a specific inhibitor was required in order 
to block the effect of ET-1 on colonic fibroblast contraction.  In this regard ET-1 could be using 
similar mechanisms to that observed in lung fibroblasts; Shi-Wen et al (2004) who observed 
that the treatment of normal lung fibroblasts with ET-1 can result in the cells exhibiting a more 
contractile phenotype and caused by an increase in the expression of α-SMA, paxillin, moesin 
and erzin.  This process was inhibited by blocking the PI3-K/AKT signalling pathway (Shi-Wen et 
al, 2004).  ET-1 exerts its affects by binding to the ETAR on normal lung fibroblasts and can 
increase collagen matrix contraction and the production of α-SMA stress fibres (Shi-Wen et al, 
2004).  Secretion of the peptide is associated with fibroblasts isolated from the scars of 
patients suffering with sclerodema (Shi-Wen et al, 2004).  
The source of myofibroblasts within the tumour environment remains controversial but there 
is strong evidence to support the conversion of normal fibroblast to a more ‘activated’ form; 
the results shown here suggest ET-1 and Ang II may play a role in this.  Studies have identified 
that TGF-β and ET-1 can promote myofibroblast transdifferentiation (Desmouliere et al, 1993;  
Leask, 2008;  Leask, 2010) and Ang II can stimulate myofibroblast transdifferentiation in lung 
fibrosis (Marshal et al, 2004).  Myofibroblasts can also produce more ET-1 in comparison to 
normal fibroblasts suggesting that this may contribute to the higher levels of the mitogenic 
peptide commonly found within the tumour microenvironment. Work is ongoing in the 
laboratory to determine whether activated myofibroblast-derived ET-1 may contribute to 
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HNSCC pathogenesis. Human macrophages (Ehrenreich et al, 1990) and human monocyte-
derived dendritic cells (Spirig et al, 2009), both of which are cell associated with the 
inflammatory cascade, can also produce ET-1.  Alvarez et al (2011) identified that ET-1 was 
produced and released from macrophages activated by Fcγ receptor (FcγR)/toll-like receptor 
(TLR)-7.  The production of increased levels of ET-1 resulted in its ability to act as a profibrotic 
factor in the inflammatory signalling cascade and leading to the resident cardiac fibroblasts 
releasing TGF-β and promoting their transdifferentiation and scarring of the within the local 
area (Alvarez et al, 2011).  It is noteworthy in this context that inflammation is associated with 
poor prognosis in HNSCC (Wang et al, 2010); any contribution of ET-1 to this remains to be 
determined. Alvarez et al (2011) recently showed an increase in collagen synthesis and α-SMA 
was observed in the cardiac fibroblasts treated with ET-1. Antagonists to both ETAR and ETBR 
resulted in a decrease in this activity suggesting that ET-1 is working via both receptors in the 
fibroblasts.  This finding supports work conducted in this study which has identified that ET-1 is 
stimulating paracrine stimulation of HNSCC migration and invasion via both the ETAR and the 
ETBR.  The expression of both receptors varies greatly between tissue and species type and it 
has been suggested that their expression could change depending on developmental stage, 
growth and health conditions (Hafizi et al, 2004). 
TGF-β is a multifunctional cytokine and is a well characterised stimulant of myofibroblast 
transdifferentiation. Treatment of NOFs with TGF-β resulted in a significant increase in both 
MMP-2 and α-SMA mRNA levels and α-SMA protein levels.  MMP-2 and α-SMA are both used 
as markers to determine the existence of myofibroblasts (Sobral et al, 2011). In contrast, 
treatment of the cells with ET-1 resulted in a small but not significant increase in the mRNA of 
MMP-2 and α-SMA and protein levels of α-SMA within the NOFs.  This result suggests that the 
peptide is having some effect on the cells but that they are not fully differentiating into 
myofibroblasts as a result of treatment with ET-1.  A number of different types of activated 
fibroblasts have been found and identified within the tumour microenvironment and these 
fibroblasts have been described as having a broad spectrum of morphological phenotypic 
entities.  These phenotypic characteristics can range from the non-contractile fibroblast to the 
contractile myofibroblast which expresses α-SMA, with a number of intermediate phenotypes 
having been described in between the two extremes (Eyden, 2005) which are often described 
as protomyofibroblasts (Desmouliere et al, 2003).  Although treatment of NOFs with ET-1 does 
not stimulate an increase in α-SMA and MMP-2 expression in comparison to untreated NOFs, 
the mitogenic peptide is altering the phenotypic characteristic of the cells; increasing their 
proliferative and migrational ability and making them more contractile.  This suggests that ET-1 
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treatment of NOFs results in a phenotypic change associated with the intermediate spectrum 
of fibroblast activation. 
The treatment of NOFs with Ang II for 48 h resulted in a significant increase in the mRNA levels 
of both MMP-2 and α-SMA.  This stimulation however was not to the same extent as that 
observed with TGF-β treatment further implementing the broad spectrum of phenotypic 
characteristics associated with activated fibroblasts found within the reactive stroma.  The 
increase in α-SMA transcript levels activated by Ang II treatment could be reduced by the pre-
treatment of NOFs with telmisartan suggesting that Ang II is stimulating the 
transdifferentiation of the NOFs into myofibroblasts via the AT1R.   
Previous work demonstrates that ET-1, Ang II and TGF-β can interact with each other to alter 
the behaviour of cells and the regulatory systems responsible for the control of the individual 
peptides (Lagares et al, 2010;  Shi-Wen et al, 2007;  Shephard et al, 2004;  Alvarez et al, 2011).  
A TGF-β-ET-1 axis has been suggested in the fibrotic process.  TGF-β can induce ET-1 
expression in human dermal fibroblasts.  Within this scenario the TGF-β1 induced expression 
of profibrotic genes was dependent on ET-1 (Lagares et al, 2010).  This finding suggests that 
the activity and control of ET-1 and TGF-β is dependent on each other in this example.  ET-1 
can mediate the induction of profibrotic genes including CCN2, type I collagen and fibronectin 
in human lung fibroblasts in the presence of TGF-β (Shi-Wen et al, 2007). Shephard et al (2004) 
suggest that TGF-β can act in an autocrine manner to amplify the production of ET-1.  This 
evidence supports work conducted by Alvarez et al (2011) who suggested that fetal cardiac 
fibroblasts may secret TGF-β in response to ET-1 which is secreted by macrophages infiltrating 
the area which could lead to further production of ET-1.   
It was therefore deemed necessary to begin to investigate the role that TGF-β might play in the 
mechanisms triggered by ET-1 and Ang II stimulation. Previous studies conducted have helped 
to support the rational for this next series of experiments and have also identified that both 
the ET-axis and RAS can affect the expression and function of the cytokine itself.  Ang II 
treatment of human lung fibroblasts resulted in an increase in TGF-β1 synthesis (Marshall et al, 
2004;  Marshall et al, 2006).  Martin et al (2007) identified that TGF-β1 stimulation results in 
the activation of PI3-K, p38K and JNK signalling pathways and phosphorylation of Smad 
proteins at additional serine threonine sites resulting in their translocation to the nucleus with 
Smad4 and an increase in AT1R expression, an example of a TGF-β responsive gene. The 
crosstalk between the pathways and Smad complex are crucial in the ability of TGF-β to 
modulate AT1R expression (Martin et al, 2007).  TGF-β1 phosphorylates Smad2 and -3 within 
their conserved COOH-terminal SSXS motif (Derynk and Zhang, 2003;  Shi and Massague, 
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2003).  The activation of these signalling pathways could also result in direct and indirect 
phosphorylation of transcription factors which in turn translocate to the nucleus and merge 
their signal with the activated Smad complex again resulting in an increase in AT1R expression 
(Martin et al, 2007).  The results suggest that a self-potentiating loop may exist between TGF-β 
and Ang II and both may be involved in pulmonary fibrosis (Martin et al, 2007).   
Altered TGF-β signalling has been associated with a number of diseases (Konigshoff et al, 
2009).  In chronic obstructive pulmonary disease, increased TGF-β signalling is associated with 
increased ECM within patient’s distal airways (Neptune et al, 2003).  Reduced TGF-β signalling 
is also a factor present within the disease and can be associated with suboptimal matrix 
deposition which may result in reduced repair of the airspace compartment within the lung 
which can lead to histologic emphysema (Habashi et al, 2006).  Within the kidney and the 
myocardium, enhanced renin-angiotensin-aldosterone signalling is associated with fibrosis 
(Kagami et al, 1994;  Zhou et al, 2006).  Within these examples angiotensin promotes increased 
TGF-β expression and signalling which can promote EMT transition and epithelial cell apoptosis 
within the lung resulting in its injury (Kagami et al, 1994;  Zhou et al, 2006).  Angiotensin 
receptor inhibitors can attenuate this effect (Li et al, 2003;  Marshall et al, 2004).  Podowski et 
al (2012) identified that the use of losartan, an AT1R inhibitor used clinically to antagonise TGF-
β signalling resulted in improved oxidative stress, elastin remodelling, metalloprotease 
activation and inflammation within the lungs of mice suffering with chronic obstructive 
pulmonary disease. 
Burns et al (2010) identified that Ang II can stimulate TGF-β1 synthesis and EMT.  Zhou et al 
(2010) showed that the activation of the AT1R was associated with glucose stimulated EMT.  
The effects triggered through the receptor could be reduced but not completely blocked using 
antagonists to the receptor.  In 2012, Zhou et al showed that high glucose concentration within 
renal epithelial cell lines resulted in decreased mRNA levels of the Mas receptor and ACE2.  
This was coupled with an increase in α-SMA and vimentin mRNA levels, an increase in TGF-β1 
and fibronectin synthesis and production and a decrease in E-cadherin which is normally 
associated with EMT.  Treatment with Ang 1-7 resulted in a decrease in levels of α-SMA, 
vimentin, TGF-β1 and fibronectin and increased levels of E-cadherin.  Ang 1-7 treatment also 
resulted in a decrease in ERK and p38 phosphorylation which had previously been stimulated 
by the high glucose treatment.  The peptide however did not alter the increased stimulation of 
JNK phosphorylation stimulated by high glucose (Zhou et al, 2012).    
In light of all this evidence, the synergistic effect of combining ET-1, Ang II and/or TGF-β on 
NOFs and on the paracrine stimulation of HNSCC migration was investigated using a Transwell 
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migration assay.  The synergistic effect of all three peptides has been implicated in the process 
of myofibroblasts transdifferentiation in cardiac fibroblasts.  The combined treatment of NOFs 
with ET-1 and Ang II and ET-1 and TGF-β resulted in the further increase in SCC4 migration in 
comparison to that observed when the NOFs were treated with the peptides individually.  
These effects however were not significant.  The treatment of NOFs with Ang II and TGF-β and 
ET-1, Ang II and TGF-β however did result in a significant further increase in SCC4 migration in 
comparison to that observed when NOFs were treated with each peptide alone.  The 
combined treatment of NOFs with ET-1, Ang II and/or TGF-β resulted in further paracrine 
stimulation of SCC4 cells in comparison to treatment of NOFs with the peptides individually.  
Although these results were not always significant there was a definite increase in the overall 
trend.  Further experiments are required to form a conclusive result however it is clear that 
the paracrine stimulation of SCC4 migration is enhanced by the synergistic effects of the 
mitogenic peptides on NOFs. 
The effect of combining treatment of ET-1, Ang II and/or TGF-β on the phenotype of NOFs was 
investigated using a wound healing model.  The combined treatment of NOFs with ET-1 and 
Ang II and Ang II and TGF-β resulted in a significant increase in their migration in comparison to 
their treatment with the peptides individually.  The treatment of NOFs with ET-1 and TGF-β 
and all three peptides combined resulted in a small increase in their migration but not 
significantly more than that observed when the cells were treated with the peptides 
individually.  This result was similar to that observed in the determination of the synergistic 
effects of the peptides on the stimulation of SCC4 migration via a paracrine mechanism.  Some 
combined treatments resulted in an increase in NOF migration but not significantly more 
compared to treatment of the cells with the individual peptides.  There was also an increase in 
α-SMA transcript levels for all combined in comparison to treatment of NOFs with each 
peptide individually.  A similar pattern was observed when cells were subject to protein 
analysis.   
These findings suggest that the effects of ET-1 and Ang II on NOFs can be enhanced when 
combined with other factors including peptides and cytokines. Porter and Turner (2009) 
identified that a similar synergism exists in lung tissue where ET-1 can act with TGF-β and Ang 
II to promote myofibroblast transdifferentiation.   
These results again highlight the synergistic effect that the peptides have and their ability to 
further influence the behaviour of NOFs and promote their transdifferentiation into 
myofibroblasts.  This result further complicates and highlights the importance of determining 
the factors present within the tumour microenvironment and the roles that individual and 
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combined components play in initiating and promoting tumour-stromal interactions.  The 
results also suggest that the treatment of HNSCC may be more successful if numerous 
components were considered and targeted with combined drug therapies in order to 
counteract the synergistic and enhanced effects that the components including mitogenic 
peptides and cytokines promote as a combined unit.  
7.6 Ang 1-7 can inhibit the autocrine and paracrine effects stimulated 
by mitogenic peptides  
Angiotensin 1-7 (Ang 1-7), the major product formed by the catalytic degradation of Ang II, 
appears to have the ability to antagonise the effects triggered by Ang II stimulation (Herath et 
al, 2007).  Ang 1-7 is produced from Ang II by angiotensin converting enzyme 2 (ACE2) at the 
Pro-7-Phe-8 bond.  Ang 1-7 can also be hydrolysed from Ang I by NEP at the same bond 
(Chappell et al, 2000).  The ability of NEP to hydrolyse Ang I tend to be masked by the activity 
of ACE2 (Herath et al, 2009).  Ang 1-7 can also be generated from Ang I via the generation of 
Ang 1-9, a pathway which involves both ACE and ACE2 (Donoghue et al, 2000;  Herath et al, 
2007).  ACE2 was originally cloned from a human heart ventricular cDNA library (Tipnis et al, 
2000).  ACE2 knockout mice show a reduction in cardiac contractility which is an indicator of 
heart dysfunction (Crackower et al, 2002).  This phenotype was rescued in the same study by 
the ablation of the ACE gene, highlighting a critical balance between the two enzymes (Guy et 
al, 2008).  Further studies that involved disruption of the ACE2 gene resulted in mice that gave 
viable, fertile progeny that did not express gross structural or anatomical abnormalities and 
showed moderately elevated systolic blood pressure (Gurley et al, 2006).  Treatment of these 
animals with Ang II resulted in an increase in blood pressure and decreased heart rate in 
comparison to control animals.  Gurley et al (2006) concluded that the absence of ACE2 
resulted in mice being more susceptible to hypertension triggered by Ang II.  qPCR analysis 
determined that ACE2 mRNA was expressed in primary human NOKs and cell lines derived 
from HNSCC primary carcinomas, dysplasias and a local metastasis.  ACE2 was not detectable 
within primary human NOFs.  As mentioned before ACE was over expressed in NOFs in 
comparison to NOKs.  Transcripts of the enzyme were present in all cell lines deriving from 
primary HNSCCs, oral dysplasias and a local metastasis.  The distinct patterns of ACE and ACE2 
observed in this study and work previously conducted highlights the possible importance in the 
balance of the two enzymes and the role that a change in their expression profiles may play in 
the progression of HNSCC.  The balance of the two enzymes is critical in maintaining a correct 
and functioning local tissue RAS, in particular the production and hydrolysis of Ang II within 
physiological conditions (Lambert et al, 2010).   
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Ang 1-7 exerts its effects through the Mas receptor (MasR) (Santos et al, 2008;  Santos et al, 
2003).  MasR mRNA was detectable in human primary NOKs and NOFs and cell lines derived 
from oral dysplasias and a local metastasis as identified by qPCR.  The receptor was greatly 
over expressed in cell lines isolated from HNSCC primary carcinomas.  This result is in keeping 
with the original identification of the MasR as an oncogene (Santos et al, 2003:  Santos et al, 
2008).  The MasR is a seven transmembrane GPCR and was identified as having tumourigenic 
properties which originated from the rearrangement of its 5’ flanking region (Young et al, 
1986;  Rabin et al, 1987).  Studies conducted by Jackson et al (1988) identified that the 
tumourigenic properties exhibited by the MasR were negligible and their work using 
transfection procedures concluded that the Mas gene could encode for an Ang II receptor.  
This theory was not upheld and Ambroz et al (1991) identified that Ang II only induced 
intracellular Ca2+ responses in cells transfected with Mas if they already expressed endogenous 
levels of the AT1R.  Santos et al (2003) identified that the MasR binds Ang 1-7.  They did this 
using radioligand binding, cell-specific binding and functional studies as well as creating an in 
vivo mouse model that was deficient in Mas.  Although the MasR is known to bind Ang 1-7, 
some researchers have suggested that an indirect link and interaction between Ang 1-7 and 
the Ang II peptide and AT1R cannot be excluded (Santos et al, 2003).  Its overexpression in 
HNSCC cell lines suggests that it may play a ligand independent role in the progression of 
HNSCC progression. 
Work conducted on vascular smooth muscle cells first identified that Ang 1-7 could oppose the 
mitogenic effects triggered by Ang II.  Studies conducted in vivo and in vitro showed that Ang -
1-7 could inhibit vascular smooth muscle cell proliferation, could reduce neointimal formation 
in the carotid artery after vascular injury and in the abdominal aorta after stent implantation 
(Freeman et al, 1996;  Strawn et al, 1999;  Langeveld et al, 2005).   The ability of Ang 1-7 to 
inhibit the effects triggered by Ang II in cancer was also determined.  The use of inhibitors to 
ACE which result in an increase in Ang 1-7 reduce the risk of cancer, particularly within the 
breast and lung (Lever et al, 1998).  Ang 1-7 can reduce lung cancer cell migration (Gallagher 
and Tallant, 2004) and lung tumour growth which coincides with a reduction in COX-2 
expression (Menon et al, 2007).   In lung and breast cancer the peptide has also been shown to 
be able to inhibit microvessel density as a result of decreased levels of VEGF (Soto-Pantoja et 
al, 2009;  Soto-Pantoja et al, 2008).  Cook et al (2011) identified that Ang 1-7 can inhibit the 
growth of myofibroblasts and can reduce fibrosis within the breast tumour microenvironment.  
The peptide achieves this by reducing collagen 1 deposition and perivascular fibrosis.  In this 
study Ang 1-7 reduced TGF-β signalling, fibronectin production and ERK 1/2 activity (Cook et al, 
2011).  Ang 1-7 also reduced MAPK signalling and Cook et al (2011) suggest that this is as a 
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result of the heptapeptide inducing an increase in dual specificity protein phosphatase 1 
(DUSP1), a MAPK phosphatase.  
Given the documented ability Ang 1-7 to oppose the pathophysiological effects of Ang II in 
other physiological settings, it was deemed appropriate to investigate the effect of Ang 1-7 on 
the migration and invasion of HNSCCs triggered by both aurocrine and paracrine stimulation by 
Ang II. The presence of Ang 1-7 inhibited Ang II stimulated migration and invasion of SCC4 cells 
suggesting that the peptide can antagonise the effects of Ang II in HNSCC.  Ang 1-7 only 
inhibited HNSCC migration in the presence of Ang II.  This is in contrast to the effect observed 
in breast and lung cancer, in which Ang 1-7 had a tumour suppressive effect in the absence of 
stimuli; these effects were observed within in vivo models (which may be constitutively 
stimulated by serum components and other factors) which may explain the difference 
between them and the result within this study.  Within an in vivo scenario there may be 
increased levels of endogenous Ang II on which Ang 1-7 may be able to act and inhibit the 
effects of the mitogenic peptide.  The pre-treatment of SCC4 cells with an inhibitor to the 
MasR resulted in the abrogation of Ang 1-7 inhibition of Ang II stimulation migration, 
suggesting that the peptide is exerting its effect through this receptor.   
This is an intriguing paradox as Ang 1-7 appears to mediate its tumour suppressor activities 
through a receptor over-expressed on cancer cells.  It is possible that the MasR has other, 
ligand independent, roles or unidentified ligands that can bind to and activate it.  The MasR 
was initially identified as an orphan GPCR.  It has been suggested that the control of non-
orphan GPCRs may be controlled by positive and negative regulation by orphan GPCRs (Levoye 
et al, 2006).  The Mas-related gene (Mrg) family is comprised of orphan and non-orphan GPCRs 
(Levoye et al, 2006).  Mrg-D subtype is a non-orphan GPCR that is activated by β-alanine.  Mrg-
E is an orphan GPCR.  Both GPCRs have been found as a heterodimer within human embryonic 
kidney (HEK) 293 cells.   The presence of the heterodimer results in increased potency of β-
alanine-stimulation of the Mrg-D subtype which leads to the phosphorylation downstream of 
ERK 1 and 2 and the maintenance of elevated levels of intracellular Ca2+ (Levoye et al, 2006).  
Levoye et al (2006) have also suggested that orphan GPCRs may also be able to recruit 
additional intracellular regulators to the heterodimer complex.  Orphan GPCRs have also been 
identified as being constitutively activated and are therefore described as being ligand 
independent (Rosenkilde et al, 2006;  Vischer et al, 2006).  Constitutively activated orphan 
GPCRs can cause patho-physiological consequences due to their stimulation of constitutively 
downstream signalling (Schoneberg et al, 2004).  In general the activity of orphan GPCRs is 
controlled not by ligand stimulation but maybe by regulating the actual protein levels of the 
receptor (Levoye et al, 2006).  This control of protein levels may be achieved by the induction 
Discussion  Chapter 7 
174 
 
of target-cell genome-encoded receptors (Levoye et al, 2006).  Levoye et al (2006) also suggest 
that aside from controlling the level of orphan GPCR, the relative expression of the orphan 
GPCR compared with the paired non-orphan GPCR may also be another important mode of 
regulation.  The orphan GPCR could also be controlled by post-translational modifications that 
are associated with GPCR desensitization (Levoye et al, 2006). 
Although the MasR is no longer classified as an orphan GPCR, the characteristics that led 
researchers to first identify it as an oncogene and it’s over expression in HNSCC cell lines and 
NOFs in comparison to NOKs requires further investigation to fully explain its role.  The 
mechanisms via which the MasR functions are not fully elucidated and further work is required 
in order to discover if it can still function as an orphan-like receptor alongside its role as a 
receptor for Ang 1-7.   
In order to investigate the ability of the peptide to antagonise the paracrine effects triggered 
by the treatment of NOFs with Ang II, the cells were pre-treated with the peptide before 
treatment with Ang II.  Treatment of NOFs with Ang 1-7 only resulted in a slight increase in 
migration of the SCC4 cells.  When NOFs were pre-treated with Ang 1-7 before the addition of 
Ang II there was a reduction in SCC4 migration, similar to that observed when the HNSCC cells 
were treated directly. A similar inhibition was observed for Ang II stimulated SCC4 cell 
invasion.  These observations support the theory that Ang 1-7 can antagonise the paracrine 
stimulated mitogenic effects of Ang II.   
The pre-treatment of NOFs with an antagonist to the MasR before the combined treatment 
with Ang 1-7 and Ang II resulted in the loss of the inhibition of Ang II stimulated migration by 
Ang 1-7.  This finding suggests that Ang 1-7 is exerting its inhibitory effects through the MasR 
which is a similar result to that observed for the autocrine mechanism that was described 
previously within this thesis.  The method by which Ang 1-7 inhibits the effect of Ang II is 
unclear.  A number of studies have identified signalling pathways which Ang 1-7 can interfere 
with.  In studies on the kidney, treatment with Ang 1-7 resulted in reduced levels of p38, ERK 1 
and 2 and JNK phosphorylation and reduced TGF-β1 production caused by Ang II (Su et al, 
2006).  Ang 1-7 is also known to alter the levels of arachidonic acid metabolites including PGE2 
and the enzymes that regulate their production (Tallent et al, 1999;  Tallant and Clark, 2003).  
Within this thesis mitogenic peptide paracrine stimulation of HNSCC migration coincides with 
an increase in COX-2 expression therefore highlighting a possible control point at which Ang 1-
7 can act on and inhibit the activities triggered by mitogenic peptides.  These all contribute to 
tumour progression if their control becomes unregulated.  Diabetic patients experience 
enhanced EGFR phosphorylation at specific tyrosine residues and therefore an increase in ERK 
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1 and 2 and p38 MAPK downstream signalling (Akhtar et al, 2012).  Rats treated with Ang 1-7 
resulted in an inhibition of EGFR transactivation stimulated by both Ang II and glucose.  The 
attenuated effects were inhibited upon treatment with a selective MasR antagonist.  This 
evidence links Ang 1-7 with components that are important in the paracrine mechanism and 
stimulation of HNSCC by Ang II.  This highlights the possibility of numerous control points 
within HNSCC and the tumour microenvironment.   
Reports have identified that Ang 1-7 can reduce DNA, collagen and protein synthesis in cardiac 
fibroblasts after their stimulation with ET-1 or serum (McCollum et al, 2012). The effects 
triggered by Ang 1-7 can be inhibited when a receptor antagonist to the MasR is used 
(McCollum et al, 2012).  The treatment of cardiac fibroblasts with Ang 1-7 after ET-1 or Ang II 
stimulation resulted in a decrease in phospho –ERK 1 and 2 stimulated by the mitogenic 
peptides (McCollum et al, 2012).  Ang 1-7 also caused a decrease in COX-2 and prostaglandin 
synthase transcript levels which were induced and stimulated after treatment of the cardiac 
fibroblasts with ET-1 (McCollum et al, 2012).  The effect of Ang 1-7 on the paracrine 
stimulation of HNSCC migration by other mitogenic peptides was investigated.  NOFs were pre-
treated with Ang 1-7 for 30 min before the addition of Ang II, ET-1, BK or EGF.  NOFs treated 
with both Ang 1-7 and ET-1 or BK resulted in a decrease in SCC4 migration in comparison to 
that observed when NOFs were treated with the mitogenic peptides alone.  This reduction in 
migration was significant but was not to the same extent as that observed when NOFs were 
treated with both Ang 1-7 and Ang II.  The combined treatment of NOFs with Ang 1-7 and EGF 
did not result in a change in SCC4 migration.  This result suggests that Ang 1-7 is not exerting 
its effects by inhibiting the ability of EGF to bind to the EGFR.  EGF is known to bind directly to 
the EGFR, causing its activation (Carpenter and Cohen, 1990).  ET-1, BK and Ang II are known to 
exert their effects by binding to GPCRs.  This binding event can trigger the activation of 
members of the ADAMs family of cell surface proteinases including ADAM17, resulting in the 
release of soluble factors from the cell surface which has been observed in this study.  The 
release of these stimulatory factors allows them to act as ligands for the EGFR.  The reduction 
in SCC4 cell migration observed when Ang 1-7 is combined with ET-1 or BK suggests that the 
peptide could be interfering in the activation of members of the ADAMs family that would 
normally be triggered by the binding of ET-1 and BK to their specific GPCRs.  Ang 1-7 could 
inhibit the activation of GPCRs therefore resulting in a decrease in the soluble factors being 
released from the surface of the NOFs.  This event would result in a reduction in the number of 
potential ligands for the EGFR resulting in reduced activation of the receptor and a decrease in 
the stimulation of SCC4 cellular migration.  The effect of combining Ang 1-7 with Ang II showed 
the greatest inhibition of SCC4 migration.  It is known that Ang II can trigger the activation of 
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members of the ADAMs family in the same way that ET-1 and BK can but the greater effect on 
inhibition could also suggest that Ang 1-7 is targeting the effects triggered by Ang II at another 
specific location, perhaps interfering directly with the activation of AT1R.  Ang 1-7 could be 
exerting its inhibitory effects through the specific GPCRs to ET-1, BK and Ang II but the peptide 
may have a great affinity for AT1R therefore explaining the increased inhibition observed when 
cells are treated with both Ang 1-7 and Ang II.  This work will be the subject of further 
investigation.   
Ang 1-7 is currently in Phase I clinical trials.  Petty et al (2009) have conducted a study in order 
to determine its toxicity and pharmacokinetics in cancer patients.  Their study concluded that 
treatment with Ang 1-7 is well-tolerated and a number of patients showed some clinical 
benefit.  Their work concludes that the RAS is a potential and beneficial target in the 
development of drug therapies for the treatment of cancer.  Work conducted in this thesis 
highlights that the system could be targeted in the treatment of head and neck cancer.  Petty 
et al (2009) also stated the potential of the RAS as an important target for cancer 
chemoprevention. A number of large, clinical studies have concluded that ACE inhibitors can 
increase levels of the Ang 1-7 and have apparent chemopreventive activity (Luque et al, 1996;  
Pahor et al, 1996;  Jick et al, 1997;  Lever et al, 1998;  van der Knaap et al, 2008).  This study 
identifies and supports the potential benefits associated with the treatment of cancers with 
Ang 1-7.  The peptide not only has the ability to target epithelial cancer cells but also 
components within the surrounding tumour microenvironment further expanding the 
opportunities of the peptide as a possible therapeutic treatment in cancer. 
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8.1 Conclusion  
The results obtained in this thesis provide compelling evidence for a role for mitogenic 
peptides in promoting head and neck cancer progression. 
Endothelin-1 (ET-1) and angiotensin II (Ang II) are both examples of mitogenic peptides and are 
both regulated via a complex system of enzymes and specific receptors.  The expression levels 
of ET-1 are controlled by the ET-axis which consists of the enzymes endothelin converting 
enzyme-1 (ECE-1) and neprilysin (NEP) and its two specific cell surface receptors ETAR and 
ETBR.  Ang II is similar to ET-1 in that two enzymes also control its expression, angiotensin 
converting enzyme (ACE) and angiotensin converting enzyme 2 (ACE2), and the peptide can 
bind to two specific G protein-coupled receptors (GPCRs); AT1R and AT2R.  These controlling 
components are known collectively as the renin angiotensin system (RAS).  The RAS also 
contains an additional peptide angiotensin 1-7 (Ang 1-7), derived from Ang II, which is thought 
to have antagonise the effects triggered by the binding of Ang II to AT1R.   
The data collected within this study suggests that mitogenic peptides can promote HNSCC 
migration and invasion via distinct mechanisms.  ET-1 and Ang II both work via a paracrine 
mechanism that involves the binding of the peptides to their specific GPCRs on neighbouring 
cells.  The activation of their GPCRs on the surface of normal oral fibroblasts (NOFs) allows the 
activation of ADAM17 which results in the release of soluble factors including tumour growth 
factor-α (TGF-α), amphiregulin and heparin bound-epidermal growth factor (HB-EGF).  These 
factors are released from the NOFs and can act as ligands for the EFR receptor (EGFR) located 
on the cancer cells.  The activation of the EGFR ultimately results in the triggering of 
intracellular signalling pathways stimulating signalling pathways resulting in the upregulation 
of cyclooxygenase-2 (COX-2) and promoting an increase in HNSCC cellular migration and 
invasion.  Ang II can also stimulate head and neck squamous cell carcinoma (HNSCC) via an 
autocrine mechanism similar to that observed for bradykinin (BK) in the promotion of head 
and neck cancer (Thomas et al, 2006).  The ability of ET-1 and Ang II to stimulate head and 
neck cancer progression proves the hypothesis first set out at the beginning of this thesis.  The 
peptides promote HNSCC progression via the stimulation of epithelial cancer migration and 
invasion; two characteristic hallmarks associated with the progression of cancer.   
In addition, experiments conducted within this thesis have implicated microRNAs (miRNAs) in 
modulating peptide-stimulated stromal-epithelial interactions and the findings have 
highlighted the important and complex role that miRNAs can play in the regulation of factors 
including ADAM17 that are known directly and indirectly to promote cancer progression.  It is 
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necessary to fully determine the characteristics that are changed upon the activation of 
fibroblasts and how these changes alter the cells ability to promote cancer progression. 
The final aim of this thesis was to investigate the role of the tumour microenvironment in head 
and neck cancer progression.  The results of this study have highlighted the importance of the 
tumour microenvironment which surrounds cancer cells in modulating the pro-migratory and 
pro-invasive effects of mitogenic peptides.  This project has begun to elucidate the molecular 
mechanisms underlying tumour-stromal interactions between fibroblasts cells, the most 
numerous cell type found within the reactive stroma, and epithelial HNSCC cells.  This work 
has, to date, mainly utilised fibroblasts isolated from non-cancerous specimens. In vivo, 
fibroblasts in proximity to cancer cells acquire an activated, myofibroblast phenotype. This 
project has also begun to address the ability of the mitogenic peptides to influence the 
phenotype of NOFs.  The mechanism by which ET-1 stimulates phenotypic changes in NOFs 
remains unclear. In this study, unlike TGF-β, a well characterized stimulant of myofibroblast 
transdifferentiation, and Ang II, ET-1 did not significantly alter the expression of α-smooth 
muscle actin (α-SMA) and matrix metalloproteinase (MMP)-2, two ‘markers’ of myofibroblasts.  
This is the first report of Ang II-mediated fibroblast remodelling influencing cancer cell 
behaviour. The ability of ETAR and ETBR antagonists and an AT1R antagonist to block the 
fibroblast phenotypic changes induced by ET-1 and Ang II, at least in vitro, raises the possibility 
of utilising such antagonists in the clinic to inhibit metastasis and to reduce fibrosis to improve 
penetration of existing chemotherapeutic agents. 
This study has identified that Ang- 1-7 can inhibit the autocrine and paracrine stimulation of 
HNSCC migration and invasion triggered by Ang II, ET-1 and BK.  This novel finding and studies 
which have indicated that in clinical trials Ang 1-7 is well-tolerated and shows some clinical 
benefit highlight the potential use of the peptide as a therapeutic agent in the treatment of 
head and neck cancer. 
The survival rate of HNSCC patients has increased only slightly over the past three decades.  
The work conducted in this thesis has identified novel mechanisms that contribute to HNSCC 
progression and has therefore highlighted possible new therapeutic targets and clinical 
applications that could be used in the diagnosis and treatment of the disease. 
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8.2 Future work 
The work carried out in this thesis and the results collected have raised a number of questions.  
The carrying out of future experiments which would focus on answering these questions would 
allow further conviction and validation of the results already collected and would allow further 
progress to be made in determining the role mitogenic peptides play in HNSCC progression.   
Analysis of tissue from patients 
Staining of tissue collected from HNSCC tumours and normal tissue would allow further 
evaluation and confirmation of the components involved in HNSCC cancer progression.  The 
enzymes involved in the regulation of ET-1 and Ang II could be stained for in order to establish 
their localization and any changes that occur in their expression levels during the different 
stages of cancer development.  Staining for the expression of the specific GPCRs for ET-1 and 
Ang II needs to be conducted to further analyse the methods by which the mitogenic peptides 
are contributing to the promotion of HNSCC cancer progression.  By performing staining on a 
number of different patient samples a true representation of altered receptor expression can 
be concluded.  RNA could also be extracted from tissue from the same patient cohort.  This 
would allow qPCR analysis to be conducted on a number of patient samples thereby providing 
information on receptor and enzyme expression ex vivo. 
Tumour microenvironment 
From the work conducted in this thesis the importance of the tumour microenvironment is 
apparent.  The involvement of NOFs in cancer progression triggered by mitogenic peptides is 
imperative.  Further work is needed to fully understand the extent to which the fibroblasts are 
involved in HNSCC progression.   
Construction of a 3D organotypic model would allow better representation of a system more 
in keeping with that observed in vivo.  The model could combine NOFs and HNSCC cells, 
recreating a microenvironment.  The incorporation of other cell types would further improve 
the in vitro scenario making it more similar to that observed in vivo.  The inclusion of immune 
cells or the involvement of endothelial cells would allow this improvement in comparisons 
between in vitro and in vivo scenarios.  The results collected from the conduction of a 3D 
organotypic model would also allow the commencement of in vivo models in which coinjection 
of cancer cells and NOFs/cancer associated fibroblasts (CAFs) into immunocompromised mice 
would allow the assessment of the effects of GPCR antagonists and/or Ang 1-7.  
Further analysis needs to be conducted in order to determine the importance of 
myofibroblasts within the tumour microenvironment and their ability to promote HNSCC 
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progression. The isolation and characterisation of CAFs from head and neck tumours would be 
invaluable. The use of fibroblasts isolated form HNSCCs which show an increase in α-SMA 
expression in future experiments instead of treating NOFs with TGF-β could help in the 
investigation of the importance of the tumour microenvironment and would allow the creation 
of an environment more similar to that observed in vivo.  The isolated myofibroblasts could 
then be incorporated into experiments similar to those that have previously been conducted 
and any differences in HNSCC cell migration or invasion could be analysed.  It is possible that 
the treatment of myofibroblasts with mitogenic peptides may promote the migration ability of 
HNSCC cells even further in comparison to that observed with NOFs.   
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